EP4216934A1 - Lipid compositions comprising polynucleotide antigens - Google Patents
Lipid compositions comprising polynucleotide antigensInfo
- Publication number
- EP4216934A1 EP4216934A1 EP21871737.9A EP21871737A EP4216934A1 EP 4216934 A1 EP4216934 A1 EP 4216934A1 EP 21871737 A EP21871737 A EP 21871737A EP 4216934 A1 EP4216934 A1 EP 4216934A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- chitosan
- oil
- negatively charged
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 389
- 150000002632 lipids Chemical class 0.000 title claims abstract description 275
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 162
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 162
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 162
- 239000000427 antigen Substances 0.000 title description 83
- 108091007433 antigens Proteins 0.000 title description 83
- 102000036639 antigens Human genes 0.000 title description 83
- 229920001661 Chitosan Polymers 0.000 claims abstract description 130
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 76
- 229940126575 aminoglycoside Drugs 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 38
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 29
- 230000028996 humoral immune response Effects 0.000 claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 claims abstract description 12
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 9
- 230000024932 T cell mediated immunity Effects 0.000 claims abstract description 6
- 230000001668 ameliorated effect Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 184
- 108020004999 messenger RNA Proteins 0.000 claims description 122
- 239000002245 particle Substances 0.000 claims description 118
- 239000000243 solution Substances 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 67
- 239000003921 oil Substances 0.000 claims description 66
- 229920002477 rna polymer Polymers 0.000 claims description 66
- 235000019198 oils Nutrition 0.000 claims description 65
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 57
- 230000002209 hydrophobic effect Effects 0.000 claims description 57
- 102000053602 DNA Human genes 0.000 claims description 55
- 108020004414 DNA Proteins 0.000 claims description 55
- 239000000126 substance Substances 0.000 claims description 55
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- -1 phosphoinositol Chemical compound 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 31
- 239000003960 organic solvent Substances 0.000 claims description 30
- 125000002091 cationic group Chemical group 0.000 claims description 29
- 239000002480 mineral oil Substances 0.000 claims description 23
- 235000010446 mineral oil Nutrition 0.000 claims description 22
- 108090000994 Catalytic RNA Proteins 0.000 claims description 20
- 102000053642 Catalytic RNA Human genes 0.000 claims description 20
- 239000003125 aqueous solvent Substances 0.000 claims description 20
- 108091092562 ribozyme Proteins 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- ZLJJDBSDZSZVTF-LXOQPCSCSA-N Trehalose-6,6'-dibehenate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)O1 ZLJJDBSDZSZVTF-LXOQPCSCSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 230000006196 deacetylation Effects 0.000 claims description 15
- 238000003381 deacetylation reaction Methods 0.000 claims description 15
- 238000004108 freeze drying Methods 0.000 claims description 15
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 14
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 11
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims description 11
- 239000000787 lecithin Substances 0.000 claims description 11
- 235000010445 lecithin Nutrition 0.000 claims description 11
- 229940067606 lecithin Drugs 0.000 claims description 11
- 239000007762 w/o emulsion Substances 0.000 claims description 11
- 108020005544 Antisense RNA Proteins 0.000 claims description 9
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 9
- 150000001841 cholesterols Chemical class 0.000 claims description 9
- 239000003184 complementary RNA Substances 0.000 claims description 9
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- GNENAKXIVCYCIZ-PGUFJCEWSA-N 4-[(2r)-2,3-di(hexadecanoyloxy)propoxy]-4-oxobutanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCC(O)=O)OC(=O)CCCCCCCCCCCCCCC GNENAKXIVCYCIZ-PGUFJCEWSA-N 0.000 claims description 8
- CBOJBBMQJBVCMW-UHFFFAOYSA-N D-(+)-Galactosamine Chemical compound Cl.O=CC(N)C(O)C(O)C(O)CO CBOJBBMQJBVCMW-UHFFFAOYSA-N 0.000 claims description 8
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 claims description 8
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- ILRKKHJEINIICQ-UHFFFAOYSA-N azanium;6-[(11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl)oxy]-5-(6-carboxy-3,4,5-trihydroxyoxan-2-yl)oxy-3,4-dihydroxyoxane-2-carboxylate Chemical compound N.CC1(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C(O)=O)CC5C4=CC(=O)C3C2(C)CCC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O ILRKKHJEINIICQ-UHFFFAOYSA-N 0.000 claims description 8
- 230000002452 interceptive effect Effects 0.000 claims description 8
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 8
- 229940049964 oleate Drugs 0.000 claims description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 8
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 7
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 7
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 7
- 235000019483 Peanut oil Nutrition 0.000 claims description 7
- 229940072056 alginate Drugs 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 229950006137 dexfosfoserine Drugs 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 7
- 239000010466 nut oil Substances 0.000 claims description 7
- 235000019488 nut oil Nutrition 0.000 claims description 7
- 239000000312 peanut oil Substances 0.000 claims description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 7
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 7
- 235000012424 soybean oil Nutrition 0.000 claims description 7
- 239000003549 soybean oil Substances 0.000 claims description 7
- 150000003445 sucroses Chemical class 0.000 claims description 7
- 150000003625 trehaloses Chemical class 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000008158 vegetable oil Substances 0.000 claims description 7
- 239000001116 FEMA 4028 Substances 0.000 claims description 6
- 229960004853 betadex Drugs 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims description 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 61
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 52
- 229920001184 polypeptide Polymers 0.000 abstract description 45
- 102000039446 nucleic acids Human genes 0.000 abstract description 24
- 108020004707 nucleic acids Proteins 0.000 abstract description 24
- 150000007523 nucleic acids Chemical class 0.000 abstract description 24
- 238000011282 treatment Methods 0.000 abstract description 23
- 230000002265 prevention Effects 0.000 abstract description 15
- 238000009472 formulation Methods 0.000 description 112
- 239000002671 adjuvant Substances 0.000 description 76
- 108090000623 proteins and genes Proteins 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 54
- 230000014509 gene expression Effects 0.000 description 39
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 32
- 239000001632 sodium acetate Substances 0.000 description 32
- 235000017281 sodium acetate Nutrition 0.000 description 32
- 229940107161 cholesterol Drugs 0.000 description 31
- 239000012071 phase Substances 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 26
- 229920000642 polymer Polymers 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 210000003719 b-lymphocyte Anatomy 0.000 description 23
- 239000002679 microRNA Substances 0.000 description 23
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 108700011259 MicroRNAs Proteins 0.000 description 21
- 239000002502 liposome Substances 0.000 description 21
- 239000003085 diluting agent Substances 0.000 description 19
- 239000012528 membrane Substances 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- 239000013566 allergen Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000028993 immune response Effects 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 16
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 15
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 239000005090 green fluorescent protein Substances 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 230000009368 gene silencing by RNA Effects 0.000 description 14
- 239000003053 toxin Substances 0.000 description 13
- 231100000765 toxin Toxicity 0.000 description 13
- 108700012359 toxins Proteins 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 108091027757 Deoxyribozyme Proteins 0.000 description 11
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 11
- 229960004784 allergens Drugs 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 108010083644 Ribonucleases Proteins 0.000 description 10
- 102000006382 Ribonucleases Human genes 0.000 description 10
- 102000002689 Toll-like receptor Human genes 0.000 description 10
- 108020000411 Toll-like receptor Proteins 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 210000004443 dendritic cell Anatomy 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 102000019034 Chemokines Human genes 0.000 description 9
- 108010012236 Chemokines Proteins 0.000 description 9
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 8
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 8
- 230000018044 dehydration Effects 0.000 description 8
- 238000006297 dehydration reaction Methods 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000002105 nanoparticle Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical group [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 7
- 102000008076 Angiogenic Proteins Human genes 0.000 description 7
- 108010074415 Angiogenic Proteins Proteins 0.000 description 7
- 102000004550 Angiostatic Proteins Human genes 0.000 description 7
- 108010017551 Angiostatic Proteins Proteins 0.000 description 7
- 102000009410 Chemokine receptor Human genes 0.000 description 7
- 108050000299 Chemokine receptor Proteins 0.000 description 7
- 108091054729 IRF family Proteins 0.000 description 7
- 102000009490 IgG Receptors Human genes 0.000 description 7
- 108010073807 IgG Receptors Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 102000007999 Nuclear Proteins Human genes 0.000 description 7
- 108010089610 Nuclear Proteins Proteins 0.000 description 7
- 101710172711 Structural protein Proteins 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 7
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 7
- 108010067390 Viral Proteins Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000000964 angiostatic effect Effects 0.000 description 7
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 7
- 102000003675 cytokine receptors Human genes 0.000 description 7
- 108010057085 cytokine receptors Proteins 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002296 dynamic light scattering Methods 0.000 description 7
- 102000034356 gene-regulatory proteins Human genes 0.000 description 7
- 108091006104 gene-regulatory proteins Proteins 0.000 description 7
- 230000003394 haemopoietic effect Effects 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- NYZTVPYNKWYMIW-WRBBJXAJSA-N 4-[[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-dimethylazaniumyl]methyl]benzoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)CC1=CC=C(C=C1)C([O-])=O)OC(=O)CCCCCCC\C=C/CCCCCCCC NYZTVPYNKWYMIW-WRBBJXAJSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 6
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 6
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000693 micelle Substances 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 150000004804 polysaccharides Chemical class 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 238000003260 vortexing Methods 0.000 description 6
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 5
- 108010028921 Lipopeptides Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 150000004665 fatty acids Chemical group 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960003677 chloroquine Drugs 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000013020 final formulation Substances 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 229940048914 protamine Drugs 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 101150084233 ago2 gene Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 101150028842 ctxA gene Proteins 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000713826 Avian leukosis virus Species 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 229930183912 Cytidylic acid Natural products 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 102100026965 RISC-loading complex subunit TARBP2 Human genes 0.000 description 2
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MYWIQTOLPLOSAL-UHFFFAOYSA-N chloroform;2-methylpropan-2-ol Chemical compound ClC(Cl)Cl.CC(C)(C)O MYWIQTOLPLOSAL-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UAKOZKUVZRMOFN-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CCCCCCCC\C=C/CCCCCCCC UAKOZKUVZRMOFN-JDVCJPALSA-M 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- CKFAFJGSVBYGIM-UHFFFAOYSA-N ethanol;2-methylpropan-2-ol Chemical compound CCO.CC(C)(C)O CKFAFJGSVBYGIM-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 229940028843 inosinic acid Drugs 0.000 description 2
- 239000004245 inosinic acid Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 230000010468 interferon response Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013573 pollen allergen Substances 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- AKIIJJAKZRNOLW-HTIIIDOHSA-N (2r)-2-[di(hexadecanoyl)amino]-3-(2,3-dihydroxypropylsulfanyl)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N([C@@H](CSCC(O)CO)C(O)=O)C(=O)CCCCCCCCCCCCCCC AKIIJJAKZRNOLW-HTIIIDOHSA-N 0.000 description 1
- PZFZLRNAOHUQPH-DJBVYZKNSA-N (2r)-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-2-(hexadecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CSC[C@H](OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PZFZLRNAOHUQPH-DJBVYZKNSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- GMOJQZRQEJVUSE-AWLASTDMSA-N 2-[3-(2-hydroxyethyl)-2-[(Z)-octadec-9-enyl]imidazolidin-1-ium-1-yl]ethyl (Z)-octadec-9-enoate chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCC1N(CCO)CC[NH+]1CCOC(=O)CCCCCCC\C=C/CCCCCCCC GMOJQZRQEJVUSE-AWLASTDMSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 241001493160 California encephalitis virus Species 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 description 1
- 102000011591 Cleavage And Polyadenylation Specificity Factor Human genes 0.000 description 1
- 108010076130 Cleavage And Polyadenylation Specificity Factor Proteins 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
- 101710127030 Dermatan-sulfate epimerase Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101710192245 Endoribonuclease Dicer Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 108010055191 EphA3 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000974349 Homo sapiens Nuclear receptor coactivator 6 Proteins 0.000 description 1
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 description 1
- 101001109419 Homo sapiens RNA-binding protein NOB1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 description 1
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 102100040442 Kidney-associated antigen 1 Human genes 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241000579048 Merkel cell polyomavirus Species 0.000 description 1
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001049378 Mus musculus Ephrin-B2 Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- GOWLTLODGKPXMN-MEKRSRHXSA-N OM-174 Chemical compound O1[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 GOWLTLODGKPXMN-MEKRSRHXSA-N 0.000 description 1
- 101000967612 Onchocerca volvulus Major sperm protein 2 Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- ZJDGBYLDGRDQFC-JZBGLOBFSA-N P(=O)(O)(O)O.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(O)=NC=NC12.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(O)=NC=NC12 Chemical compound P(=O)(O)(O)O.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(O)=NC=NC12.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(O)=NC=NC12 ZJDGBYLDGRDQFC-JZBGLOBFSA-N 0.000 description 1
- 108700038250 PAM2-CSK4 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000392928 Parachromis friedrichsthalii Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 102000017794 Perilipin-2 Human genes 0.000 description 1
- 108010067163 Perilipin-2 Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 102100037419 Pituitary tumor-transforming gene 1 protein-interacting protein Human genes 0.000 description 1
- 101710199379 Pituitary tumor-transforming gene 1 protein-interacting protein Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102100030616 Protein-cysteine N-palmitoyltransferase HHAT Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000621172 Pseudocowpox virus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 108091077788 STING family Proteins 0.000 description 1
- 102000042336 STING family Human genes 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101100206155 Schizosaccharomyces pombe (strain 972 / ATCC 24843) tbp1 gene Proteins 0.000 description 1
- 102100038689 Scm-like with four MBT domains protein 1 Human genes 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000517830 Solenopsis geminata Species 0.000 description 1
- 240000002439 Sorghum halepense Species 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- RZBMBMLIIRIAMH-LDLOPFEMSA-N [(2R)-2,3-dihydroxypropyl] 2-[di(octadecanoyl)amino]ethyl hydrogen phosphate Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCCCCCCCCCCCC)=O RZBMBMLIIRIAMH-LDLOPFEMSA-N 0.000 description 1
- PVNJLUVGTFULAE-UHFFFAOYSA-N [NH4+].[Cl-].[K] Chemical compound [NH4+].[Cl-].[K] PVNJLUVGTFULAE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical compound N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 101150078331 ama-1 gene Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000013570 bacterial allergen Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 108010031071 cholera toxoid Proteins 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical class [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 125000001901 erucoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 239000013574 grass pollen allergen Substances 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 101150027374 irgA gene Proteins 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- LMPVQXVJTZWENW-KPNWGBFJSA-M sodium;[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] sulfate Chemical compound [Na+].C1C=C2C[C@@H](OS([O-])(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 LMPVQXVJTZWENW-KPNWGBFJSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to lipids compositions for delivery of negatively charged molecules such as a polynucleotide.
- the present invention also relates to use of such compositions for delivering a negatively charged molecule (e.g., polynucleotide) to a subject.
- a negatively charged molecule e.g., polynucleotide
- nucleic acids may be, for example, sequences encoding a gene product or instead short sequences of nucleotides that correspond to the sense or antisense sequence of specific genes or their products and hence have a direct effect on the expression of these genes and/or their products.
- Nucleic acid delivery presents unique challenges due to their molecular size, electric charge, and significant susceptibility to enzymatic degradation.
- problems in delivering nucleic acids to the correct target site and to a sufficient number of target cells A wide variety of delivery methods have been proposed, including microinjection, scrape loading, and receptor-mediated endocytosis.
- Lipid-based delivery systems including those involving the use of liposomes, are frequently used to package therapeutic nucleic acids.
- the use of lipids alone may pose problems such as poor encapsulation efficacy and rapid clearance from circulation.
- the present disclosure provides, among other things, lipid compositions suitable for the delivery of negatively charged molecules (e.g., polynucleotides). Methods of using such lipid compositions for delivering a negatively charged molecule to a target cell or a subject, or for treatment of a disorder or a disease are also provided. Further provided are methods of preparing the lipid compositions and kits comprising the lipid compositions.
- negatively charged molecules e.g., polynucleotides
- composition comprising: a) one or more lipids, b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, and d) an ionizable aminoglycoside.
- the lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof.
- the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin.
- the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3- phosphocholine (DPPC), dioleoyl phosphatidylethanolamine (DOPE), 1 ,2-dipalmitoyl-sn- glycero-3-succinate (DGS), or a combination thereof.
- DOPC dioleoyl phosphatidylcholine
- DPPC 1,2-dipalmitoyl-sn-glycero-3- phosphocholine
- DOPE dioleoyl phosphatidylethanolamine
- DVS 1 ,2-dipalmitoyl-sn- glycero-3-succinate
- the one or more lipids comprise DOPC and cholesterol.
- the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, DEAE-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose-6,6-dibehenate (TDB) with Dimethyldioctadecylammonium bromide (DDA), heptakis(6-deoxy-6-amino)- ⁇ -cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof.
- the ionizable aminoglycoside is chitosan.
- the chitosan has a molecular weight of about 60 kDa to 150 kDa (e.g., about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, or about 150 kDa).
- the chitosan has a molecular weight of about 100 kDa to 120 kDa.
- the chitosan has a molecular weight of about 100 kDa.
- the chitosan has a degree of deacetylation (DD) of about 15 - 95%. In one embodiment, the chitosan has a degree of deacetylation (DD) of about 25%.
- the chitosan is added in a concentration of about 0.5 mg/mL to about 3 mg/mL (e.g., about 0.5 mg/mL, about 0.75 mg/mL, about 1 mg/mL, about 1.25 mg/mL, about 1.5 mg/mL, about 1.75 mg/mL, about 2 mg/mL, about 2.25 mg/mL, about 2.5 mg/mL, about 2.75 mg/mL or about 3 mg/mL). In some embodiments, the chitosan is added in a concentration of about 1 mg/mL to about 2 mg/mL.
- composition described above further comprises an adjuvant.
- compositions comprising: a) one or more positively charged lipids, b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, d) an ionizable aminoglycoside, and e) optionally, an adjuvant.
- the one or more positively charged lipids comprise 1,2- dioleoyl-3-trimethylammonium-propane (DOTAP), 3 ⁇ -[N-(N',N'-dimethylaminoethane)- carbamoyl] cholesterol (DC-cholesterol), 1,2-distearoyl-3-dimethylammonium-propane (DAP), N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-l-aminium (DOBAQ), N-palmitoyl homocysteine (PHC), DC-cholesterol, or a combination thereof.
- DOTAP 1,2- dioleoyl-3-trimethylammonium-propane
- DC-cholesterol 3 ⁇ -[N-(N',N'-dimethylaminoethane)- carbamoyl] cholesterol
- DC-cholesterol 1,2-distearoyl-3-dimethylammonium
- the negatively charged molecule is a polynucleotide.
- the negatively charged molecule is a ribonucleic acid (RNA), or RNA derivative.
- the negatively charged molecule is a deoxyribonucleic acid (DNA), or DNA derivative.
- the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme.
- the polynucleotide comprises an mRNA.
- the polynucleotide encodes a polypeptide.
- the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
- the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen, a toxin, or an allergen.
- the concentration ratio of the lipids and the negatively charged molecule is between about 33000:1 to about 3300:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 30800:1 to about 4400:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 28600:1 to about 5500:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 26400:1 to about 6600:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 24200:1 to about 7700:1.
- the concentration ratio of the lipids and the negatively charged molecule is between about 22000:1 to about 8800:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 19800:1 to about 9900:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 17600:1 to about 11000: 1.
- the concentration ratio of the lipids and the negatively charged molecule may be about 4400:1, 5500:1, 6600:1, 7700:1, 8800:1, 9900:1, 11000:1, 12100:1, 13200:1, 14300:1, 15400:1, 16500:1, 17600:1, 18700:1, 19800:1, 22000:1, 23100:1, 24200:1, 25300:1, 26400:1, 27500:1, 28600:1, 29700:1, 30800:1, 31900:1, or 33000:1.
- the concentration ratio of the lipids and the negatively charged molecule is about 13200:1.
- the carrier comprises an oil or a water-in-oil emulsion.
- a) the one or more lipids comprise DOPC and cholesterol
- b) the negatively charged molecule is a polynucleotide
- c) the carrier comprises an oil or a water-in-oil emulsion
- d) the ionizable aminoglycoside is chitosan.
- the oil comprises a natural oil or a synthetic oil.
- the oil comprises a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, or combinations thereof.
- the carrier comprises a mannide oleate in mineral oil solution.
- the carrier comprises Montanide® ISA 51.
- the carrier comprises MS80 oil (mixture of mineral oil and Span 80).
- the adjuvant is a polymer, a protein, a polysaccharide, or a combination thereof.
- the composition further comprises a buffer and/or surfactant. [0023] In some embodiments, the composition is an injectable composition.
- a method for delivering a negatively charged molecule to a target cell comprising administering the composition of any one of the embodiments above to said target cell.
- the target cell is an antigen- presenting cell (APC).
- APC antigen- presenting cell
- a method for delivering a negatively charged molecule to a subject comprising administering the composition of any one of the embodiments above to said subject.
- the negatively charged molecule is a polynucleotide.
- the polynucleotide comprises an mRNA.
- the polynucleotide encodes a polypeptide.
- the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
- the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen or a toxin.
- the composition is administered via subcutaneous, intramuscular or intradermal injection.
- a method for preparing a composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside, comprising: a) dissolving the one or more lipids in one or more organic solvents and optionally an aqueous solvent to create a lipid solution, b) adding the negatively charged molecule to the lipid solution formed in step a) and mixing; c) adding the ionizable aminoglycoside to the mixture formed in step b) and mixing; d) optionally, adding additional amount of the organic solvent(s) or aqueous solvent to the mixture formed in step c) thereby the overall Wt/Wt or V/V percentage ratio of organic: aqueous solvent or aqueous: organic solvent in the mixture is between 20-50%; e) drying the mixture formed in step c) or d) to generate a dried preparation; and f)
- the one or more organic solvents is present in an amount sufficient to prevent the one or more lipids from forming lipid vesicle particles in the lipid solution.
- the organic solvent is tert-butanol, ethanol, methanol, chloroform, or a mixture thereof.
- the organic solvent is tert-butanol, tert-butanol-ethanol mixture or tert-butanol-chloroform mixture.
- the lipid solution comprises about 30% tert-butanol.
- the aqueous solvent is water or a buffer solution.
- drying is performed by freeze-drying, spray freeze-drying, spray drying, or rotary evaporation.
- the lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof.
- the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin.
- the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), dioleoyl phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof.
- DOPC dioleoyl phosphatidylcholine
- DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
- DOPE dioleoyl phosphatidylethanolamine
- DVS 1,2-dipalmitoyl-sn-glycero-3-succinate
- the one or more lipids comprise DOPC and cholesterol.
- the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, DEAE-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose- 6,6-dibehenate (TDB) with Dimethyldioctadecylammonium (DDA), heptakis(6-deoxy-6- amino)- ⁇ -cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof.
- chitosan cationic alginate, cationic gelatin, cationic dextran, DEAE-dextran hydrochloride
- aminated cellulose aminated sucrose, aminated trehalose, N-ace
- the ionizable aminoglycoside is chitosan.
- the chitosan has a molecular weight of about 60 kDa to 150 kDa (e.g., about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, or about 150 kDa).
- the chitosan has a molecular weight of about 100 kDa to 120 kDa.
- the chitosan has a molecular weight of about 100 kDa. In some embodiments, the chitosan has a degree of deacetylation (DD) of about 15 - 95%. In one embodiment, the chitosan has a degree of deacetylation (DD) of about 25%.
- the chitosan is added in a concentration of about 0.5 mg/mL to about 3 mg/mL (e.g., about 0.5 mg/mL, about 0.75 mg/mL, about 1 mg/mL, about 1.25 mg/mL, about 1.5 mg/mL, about 1.75 mg/mL, about 2 mg/mL, about 2.25 mg/mL, about 2.5 mg/mL, about 2.75 mg/mL or about 3 mg/mL).
- the chitosan is added in a concentration of about 1 mg/mL to about 2 mg/mL.
- the negatively charged molecule is a polynucleotide.
- the negatively charged molecule is a ribonucleic acid (RNA), or RNA derivative.
- the negatively charged molecule is a deoxyribonucleic acid (DNA), or DNA derivative.
- the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme.
- the polynucleotide comprises an mRNA.
- the polynucleotide encodes a polypeptide.
- the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
- the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen, a toxin, or an allergen.
- the concentration ratio of the lipids and the negatively charged molecule is between about 33000:1 to about 3300:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 30800: 1 to about 4400: 1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 28600:1 to about 5500:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 26400:1 to about 6600:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 24200:1 to about 7700:1.
- the concentration ratio of the lipids and the negatively charged molecule is between about 22000:1 to about 8800:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 19800:1 to about 9900:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 17600:1 to about 11000:1.
- the concentration ratio of the lipids and the negatively charged molecule may be about 4400:1, 5500:1, 6600:1, 7700:1, 8800:1, 9900:1, 11000:1, 12100:1, 13200:1, 14300:1, 15400:1, 16500:1, 17600:1, 18700:1, 19800:1, 22000:1, 23100:1, 24200:1, 25300:1, 26400:1, 27500:1, 28600:1, 29700:1, 30800:1, 31900:1, or 33000: 1.
- the concentration ratio of the lipids and the negatively charged molecule is about 13200:1.
- the carrier comprises an oil or a water-in-oil emulsion.
- the one or more lipids comprise DOPC and cholesterol
- the negatively charged molecule is a polynucleotide
- the carrier comprises an oil or a water-in-oil emulsion
- the ionizable aminoglycoside is chitosan.
- the oil comprises a natural oil or a synthetic oil.
- the oil comprises a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, or combinations thereof.
- the carrier comprises a mannide oleate in mineral oil solution.
- the carrier comprises Montanide® ISA 51.
- the carrier comprises MS80 oil (mixture of mineral oil and Span 80).
- the composition further comprises an adjuvant.
- the adjuvant is a polymer, a protein, a polysaccharide, or a combination thereof.
- the composition further comprises a buffer and/or surfactant.
- the composition is an injectable composition.
- kits comprising a composition of any one of the embodiments above, and instructions for using said composition to deliver a negatively charged molecule to a subject.
- the subject is a mammal. In some embodiments, the subject is a human.
- Figure 1 depicts a schematic of the nucleic acid delivery using an exemplary lipid vesicle particle of the present disclosure.
- FIG. 2 shows green fluorescent protein (GFP) expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing different polymers and transfection agents.
- Sample 1 formulation method A (standard) without addition of different polymers and transfection agents.
- Figure 3 shows GFP expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing 1,2-dioleoyl-3-trimethylammonium- propane (DOTAP).
- Sample 1 formulation method A (standard) without addition of 1,2- dioleoyl-3-trimethylammonium-propane (DOTAP).
- Figure 4 shows GFP expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing DC-Cholesterol.
- Sample 1 formulation method A (standard) without addition of DC-Cholesterol.
- Figure 5 shows GFP expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing DOTAP.
- Sample 1 formulation method A (standard) without addition of DOTAP.
- Figure 6 shows GFP expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing chitosan.
- Sample 1 formulation method A (standard) without addition of chitosan.
- Figure 7A-7B show antigen-specific interferon-gamma (IFN- ⁇ ) response in the spleens ( Figure 7A) and lymph nodes ( Figure 7B) collected from mice receiving the indicated lipid formulations.
- IFN- ⁇ interferon-gamma
- Figure 7A-7B show antigen-specific interferon-gamma (IFN- ⁇ ) response in the spleens ( Figure 7A) and lymph nodes ( Figure 7B) collected from mice receiving the indicated lipid formulations.
- the IFN-y response was determined using an enzyme-linked immunospot (ELISpot) assay.
- ELISpot enzyme-linked immunospot
- Figure 8A-8B show immune profiles of site of injections (SOIs) collected from mice receiving the indicated lipid formulations.
- Figure 9 shows the study design of an in vitro stability study of lipid-nucleic acid formulations.
- Figure 10A-10B show mRNA ( Figure 10A) and DNA ( Figure 10B) quantities in the investigated lipid-nucleic acid formulations as measured by UV spectroscopy.
- Figure 11A-11B show gel electrophoresis analyses of mRNA (Figure 11A) and DNA ( Figure 11B) in the investigated lipid-nucleic acid formulations.
- Figures 12A-12B show quantification of RNA or DNA expression efficiency (Figure 12A) evaluated in transient transfection experiments as well as representative fluorescence microscopy images ( Figure 12B).
- Figure 13 shows the study design of an in vivo stability study of lipid-mRNA formulations.
- Figures 14A-14B show that mRNA formulated in the investigated lipid-mRNA formulation is stable for up to 14 days in vivo.
- Figure 14A shows evaluation of E7 mRNA integrity by detection of E7 transcripts using RT-PCR and gel electrophoresis. Complete sequence of the E7 transcript was amplified via RT-PCR from total RNA extracted from SOIs.
- Figure 14B shows quantification of GFP expression in cells transfected with total RNA extracted from SOIs.
- the present disclosure provides, among other things, lipid vesicle particles that facilitate delivery of molecules (e.g., polynucleotides) into a biological system, for example into cells such as mammalian cells.
- molecules e.g., polynucleotides
- lipid vesicle particle may be used interchangeably with “lipid vesicle”.
- a lipid vesicle particle refers to a complex or structure having an internal environment separated from the external environment by a continuous layer of enveloping lipids.
- the expression "layer of enveloping lipids” can mean a single layer lipid membrane (e.g., as found on a micelle or reverse micelle), a bilayer lipid membrane (e.g., as found on a liposome) or any multilayer membrane formed from single and/or bilayer lipid membranes.
- the layer of enveloping lipids is typically a single layer, bilayer or multilayer throughout its circumference, but it is contemplated that other conformations may be possible such that the layer has different configurations over its circumference.
- the lipid vesicle particle may contain, within its internal environment, other vesicle structures (i.e., it may be multivesicular).
- lipid vesicle particle encompasses many different types of structures, including without limitation micelles, reverse micelles, unilamellar liposomes, multilamellar liposomes and multivesicular liposomes.
- the lipid vesicle particles may take on various different shapes, and the shape may change at any given time (e.g., upon sizing, mixing with the second therapeutic agent, and/or drying).
- lipid vesicle particles are spherical or substantially spherical structures.
- substantially spherical it is meant that the lipid vesicle particles are close to spherical, but may not be a perfect sphere.
- lipid vesicle particles include, without limitation, oval, oblong, square, rectangular, triangular, cuboid, crescent, diamond, cylinder or hemisphere shapes. Any regular or irregular shape may be formed. Further, a single lipid vesicle particle may comprise different shapes if it is multivesicular. For example, the outer vesicle shape may be oblong or rectangular while an inner vesicle may be spherical.
- the lipid vesicle particles may be formed from single layer lipid membranes, bilayer lipid membranes and/or multilayer lipid membranes.
- the lipid membranes are predominantly comprised of and formed by lipids, but may also comprise additional components.
- the lipid membrane may include stabilizing molecules to aid in maintaining the size and/or shape of the lipid vesicle particle. Any stabilizing molecule known in the art may be used so long as it does not negatively affect the ability of the lipid vesicle particles to be used in the disclosed methods.
- lipid vesicle particles of the present disclosure may be synonymous with lipid nanoparticles.
- lipid nanoparticles there are contrasting views in the art on the meaning of the term “lipid nanoparticle”.
- a lipid nanoparticle refers to any nano-sized particle (i.e. , having a diameter of between 1 nanometer and 1000 nanometers) formed by a lipid membrane.
- the size threshold for a nanoparticle material is limited to between 1 nanometer and 100 nanometers.
- lipid vesicle sizes that are encompassed by the present disclosure (e.g., lipid vesicle particles >100 nm in size), and to this extent is inconsistent with the term “lipid vesicle particles” as used in the present disclosure.
- lipid has its common meaning in the art in that it is any organic substance or compound that is soluble in nonpolar solvents, but generally insoluble in polar solvents (e.g., water).
- Lipids are a diverse group of compounds including, without limitation, fats, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides and phospholipids.
- any lipid may be used so long as it is a membrane-forming lipid.
- the lipid vesicle particles may comprise a single type of lipid or two or more different types of lipids.
- negatively charged molecule includes molecules such as naturally occurring and chemically modified nucleic acid molecules (e.g., RNA, DNA, polynucleotides, oligonucleotides, mixed polymers, peptide nucleic acid, and the like), peptides (e.g., polyaminoacids, polypeptides, proteins and the like), nucleotides, pharmaceutical and biological compositions, that have negatively charged groups.
- nucleic acid molecules e.g., RNA, DNA, polynucleotides, oligonucleotides, mixed polymers, peptide nucleic acid, and the like
- peptides e.g., polyaminoacids, polypeptides, proteins and the like
- nucleotides e.g., nucleotides, pharmaceutical and biological compositions, that have negatively charged groups.
- polynucleotide encompasses a chain of nucleotides of any length (e.g., 9, 12, 18, 24, 30, 60, 150, 300, 600, 1500, 2000, 2500, 3000, 4000, 5000, 6000, 7000, 8000 or more nucleotides) or number of strands (e.g., single-stranded or doublestranded).
- Polynucleotides may be DNA (e.g., genomic DNA or cDNA) or RNA (e.g., mRNA, siRNA, miRNA, shRNA, self-amplifying RNA) or combinations thereof. They may be naturally occurring or synthetic (e.g., chemically synthesized).
- polynucleotide may contain modifications of one or more nitrogenous bases, pentose sugars or phosphate groups in the nucleotide chain. Such modifications are well-known in the art and may be for the purpose of e.g., improving stability of the polynucleotide.
- polypeptide or “protein” means any chain of amino acids, regardless of length (e.g., 4, 6, 8, 10, 20, 50, 100, 200, 500 or more amino acids) or post- translational modification (e.g., glycosylation or phosphorylation). Both terms are used interchangeably.
- ionizable aminoglycoside refers to any poly amino sugar having the ability to bind with a negatively charged molecule (e.g., polynucleotide such as RNA) through electrostatic interactions.
- the polyamino sugar may be naturally occurring, semi-synthetic, or fully synthetic.
- the ionizable aminoglycoside may protect the polynucleotide (e.g., RNA) from nuclease attack.
- adjuvant refers to a compound or mixture that enhances the immune response to an antigen.
- the term "antigen” refers to any substance or molecule that can bind specifically to components of the immune system.
- suitable antigens are those that are capable of inducing or generating an immune response in a subject.
- An antigen that is capable of inducing an immune response is said to be immunogenic, and may also be called an immunogen.
- the term “antigen” includes immunogens and the terms may be used interchangeably unless specifically stated otherwise.
- a “toxin”, as used herein, refers to any substance produced by living cells or organisms (e.g., plants, animals, microorganisms, etc.) that is capable of causing a disease or ailment, or an infectious substance, or a recombinant or synthesized molecule capable of adverse effect.
- Toxins may be for example small molecules (e.g., cocaine), peptides, or proteins.
- An “allergen”, as used herein, refers to any substance that can cause an allergy.
- an “antibody” is a protein comprising one or more polypeptides substantially or partially encoded by immunoglobulin genes or fragments of immunoglobulin genes.
- the recognized immunoglobulin genes include the ⁇ , ⁇ . ⁇ , ⁇ , ⁇ and ⁇ constant region genes, as well as myriad immunoglobulin variable region genes.
- Light chains are classified as either K or X.
- Heavy chains are classified as ⁇ , ⁇ . ⁇ , ⁇ , or ⁇ , which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
- a typical immunoglobulin (antibody) structural unit comprises a protein containing four polypeptides.
- Each antibody structural unit is composed of two identical pairs of polypeptide chains, each having one “light” and one “heavy” chain.
- the N-terminus of each chain defines a variable region primarily responsible for antigen recognition.
- Antibody structural units e.g., of the IgA and IgM classes
- cancer refers to cells that exhibit abnormal growth, characterized by a significant loss of control of cell proliferation or cells that have been immortalized.
- cancer or “tumor” includes metastatic as well as non-metastatic cancer or tumors.
- a cancer may be diagnosed using criteria generally accepted in the art, including the presence of a malignant tumor.
- Treating” or “treatment of”, or “preventing” or “prevention of”, as referred to herein refers to an approach for obtaining beneficial or desired results, including clinical results.
- Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilization of the state of disease, prevention of development of disease, prevention of spread of disease, delay or slowing of disease progression, delay or slowing of disease onset, conferring protective immunity against a disease-causing agent and amelioration or palliation of the disease state.
- Treating” or “preventing” can also mean prolonging survival of a patient beyond that expected in the absence of treatment and can also mean inhibiting the progression of disease temporarily, although more preferably, it involves preventing the occurrence of disease such as by preventing infection in a subject.
- effective amount means an amount effective, at dosages and for periods of time necessary, to achieve the desired result.
- an immune response is to elicit and/or potentiate an immune response. Inducing an immune response encompasses instances where the immune response is enhanced, elevated, improved or strengthened to the benefit of the host relative to the prior immune response status, for example, before the administration of a composition of the disclosure.
- antibody response refers to an increase in the amount of antigen-specific antibodies in the body of a subject in response to introduction of the antigen into the body of the subject.
- Human immune response as referred to herein relates to antibody production and the accessory processes that accompany it, such as for example T-helper 2 (Th2) cell activation and cytokine production, isotype switching, affinity maturation and memory cell activation. It also refers to the effector functions of an antibody, such as for example toxin neutralization, classical complement activation, and promotion of phagocytosis and pathogen elimination.
- the humoral immune response is aided by CD4+Th2 cells and therefore the activation or generation of this cell type is also indicative of a humoral immune response as referred to herein.
- a “humoral immune response” as referred to herein may also encompass the generation and/or activation of T-helper 17 (Thl7) cells.
- Thl7 cells are a subset of helpereffector T-lymphocytes characterized by the secretion of host defense cytokines such as IL-17, IL-17F, IL-21, and IL-22.
- Th 17 cells are considered developmentally distinct from Thl and Th2 cells, and have been postulated to facilitate the humoral immune response, such as for example, providing an important function in anti-microbial immunity and protecting against infections.
- Their production of IL-22 is thought to stimulate epithelial cells to produce antimicrobial proteins and production of IL-17 may be involved in the recruitment, activation and migration of neutrophils to protect against host infection by various bacterial and fungal species.
- the term “about” means reasonably close.
- “about” can mean within an acceptable standard deviation and/or an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend on how the particular value is measured. Further, when whole numbers are represented, about can refer to decimal values on either side of the whole number.
- the term “about” encompasses all of the exemplary values between the one particular value at one end of the range and the other particular value at the other end of the range, as well as reasonably close values beyond each end.
- composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside.
- composition comprising one or more positively charged lipids (or cationic lipids), a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and optionally an adjuvant.
- Negatively charged molecules that can be delivered using the composition of the present disclosure include, but are not limited to, naturally occurring and chemically modified nucleic acid molecules (e.g., RNA, DNA, polynucleotides, oligonucleotides, mixed polymers, peptide nucleic acid, and the like), peptides (e.g., polyaminoacids, polypeptides, proteins and the like), nucleotides, pharmaceutical and biological compositions, that have negatively charged groups. While not wishing to be bound by theory, the negatively charged groups may ion-pair with the positively charged groups of any positively charged molecules (e.g., lipids, adjuvant) in the lipid vesicle particles of the disclosure.
- nucleic acid molecules e.g., DNA, polynucleotides, oligonucleotides, mixed polymers, peptide nucleic acid, and the like
- peptides e.g., polyaminoacids, polypeptide
- the negatively charged molecule in the composition of the present disclosure is a polynucleotide.
- polynucleotides as described herein refers specifically to polynucleotides that contain sequences that correspond largely to the sense or antisense sequence of specific genes or their products, and hence have a direct effect on the expression of these genes and/or their products.
- polynucleotides that contain gene coding sequences affects the transcription and/or translation of the genes of interest in cells that uptake such polynucleotides.
- RNA interference polynucleotides affects the expression of specific genes of interest by directly affecting the levels of mRNA in cells that uptake such nucleotides.
- polynucleotide-based molecules such as CpG and polylC adjuvants, which do not act through the presence of gene specific sequences.
- polynucleotide-based adjuvants are believed to modulate an immune response in a non-specific manner, and their actions start at the site of vaccination where they interact with extracellular receptors to enhance the activity of immune cells in a non-specific manner.
- polynucleotide-based adjuvants are internalized whereby they exert their effects by interacting with intracellular receptors, similarly leading to the activation of downstream pathways, and resulting collectively in the enhancement of immune cell activity to aid in the generation of an immune response.
- Such adjuvants do not directly affect the expression of specific genes that are being targeted by polynucleotide constructs as contemplated herein. Such adjuvants do not directly interact with the expression products of targeted genes, nor do they contain sequences that correspond to the sense or antisense sequence of targeted genes.
- the composition is useful for enhancing the expression of a polypeptide-encoding polynucleotide in vivo.
- the polynucleotide encode a polypeptide that is deficient in the subject.
- the polynucleotide may not encode a polypeptide, but may instead be e.g., a polynucleotide comprising or encoding an antisense RNA or other molecule that is not a polypeptide.
- compositions comprise a polynucleotide of interest, optionally operably linked to regulatory sequences suitable for directing protein expression from the polynucleotide (e.g., a promoter), lipids, and a carrier comprising a continuous phase of a hydrophobic substance.
- regulatory sequences suitable for directing protein expression from the polynucleotide e.g., a promoter
- lipids e.g., lipids
- a carrier comprising a continuous phase of a hydrophobic substance.
- compositions of the disclosure are useful for delivering polynucleotides of all kinds to a subject in vivo.
- the polynucleotide is not expressed as a protein in the subject, but rather encodes e.g., an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme.
- the polynucleotide encodes a polypeptide to be expressed in vivo in a subject.
- the polynucleotide is a messenger RNA (mRNA). The disclosure is not limited to the expression of any particular type of polypeptide.
- the polypeptide may be, merely by way of illustrative examples, an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
- the polynucleotides delivered with the compositions of the present disclosure may encode an antigen such as, but not limited to: those derived from Cholera toxoid, tetanus toxoid, diphtheria toxoid, hepatitis B surface antigen, hemagglutinin, neuraminidase, influenza M protein, PfHRP2, pLDH, aldolase, MSP1, MSP2, AMA1, Der-p- 1, Der-f-1, Adipophilin, AFP, AIM-2, ART-4, BAGE, alpha-fetoprotein, BCL-2, Bcr-Abl, BING-4, CEA, CPSF, CT, cyclin DIEp-CAM, EphA2, EphA3, ELF-2, FGF-5, G250, Gonadotropin Releasing Hormone, HER-2, intestinal carboxyl esterase (iCE), IL13Ralpha2, MAGE-1, MAGE-1, MAGE
- Pertussis Pneumonia, Salmonella, Shigella, Staphylococcus, Streptococcus pneumoniae and Yersinia enterocolitica,' or those derived from a protozoa, e.g., of the genus Plasmodium (Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale or Plasmodium knowlesif
- the antigen may be an allergen derived from, without limitation, cells, cell extracts, proteins, polypeptides, peptides, peptide mimics of polysaccharides and other molecules, such as small molecules, lipids, glycolipids, and carbohydrates of plants, animals, fungi, insects, food, drugs, dust, and mites.
- Allergens include but are not limited to environmental aeroallergens; plant pollens (e.g., ragweed/hayfever); weed pollen allergens; grass pollen allergens; Johnson grass; tree pollen allergens; ryegrass; arachnid allergens (e.g., house dust mite allergens); storage mite allergens; Japanese cedar pollen/hay fever; mold/fungal spore allergens; animal allergens (e.g., dog, guinea pig, hamster, gerbil, rat, mouse, etc., allergens); food allergens (e.g., crustaceans; nuts; citrus fruits; flour; coffee); insect allergens (e.g., fleas, cockroach); venoms: (Hymenoptera, yellow jacket, honey bee, wasp, hornet, fire ant); bacterial allergens (e.g., streptococcal antigens; parasite allergens such as As
- a hapten is used in a composition of the disclosure, it may be attached to a carrier to form a hapten-carrier adduct.
- the hapten-carrier adduct is capable of initiating a humoral immune response, whereas the hapten itself would not elicit antibody production.
- Non-limiting examples of haptens are aniline, urushiol (a toxin in poison ivy), hydralazine, fluorescein, biotin, digoxigenin and dinitrophenol.
- the antigen may be an antigen associated with a disease where it is desirable to sequester the antigen in circulation, such as for example an amyloid protein (e.g., Alzheimer's disease).
- an amyloid protein e.g., Alzheimer's disease
- the polynucleotide may encode a T-helper epitope.
- T helper epitope is a sequence of amino acids (natural or non-natural amino acids) that have T helper activity.
- T helper epitopes are recognized by T helper lymphocytes, which play an important role in establishing and maximizing the capabilities of the immune system, and are involved in activating and directing other immune cells, such as for example B cell antibody class switching.
- a T-helper epitope can consist of a continuous or discontinuous epitope. Hence not every amino acid of a T-helper is necessarily part of the epitope. Accordingly, T-helper epitopes, including analogs and segments of T-helper epitopes, are capable of enhancing or stimulating an immune response. Immunodominant T-helper epitopes are broadly reactive in animal and human populations with widely divergent MHC types (Celis et al. (1988) J. Immunol. 140:1808-1815; Demotz et al. (1989) J. Immunol. 142:394-402; Chong et al. (1992) Infect. Immun. 60:4640-4647).
- the T-helper domain of the subject peptides has from about 10 to about 50 amino acids and preferably from about 10 to about 30 amino acids. When multiple T-helper epitopes are present, then each T-helper epitope acts independently.
- the T-helper epitope may be encoded in a polynucleotide as part of an antigen described herein.
- the antigen if it is of sufficient size, it may contain an epitope that functions as a T-helper epitope.
- the T-helper epitope is encoded in a polynucleotide as a separate molecule from the antigen.
- the T helper epitope is encoded in a polynucleotide with at least one antigen (i.e., a peptide), or a mixture of antigens, to make a fusion peptide.
- T-helper epitope analogs may include substitutions, deletions and insertions of from one to about 10 amino acid residues in the T-helper epitope.
- T-helper segments are contiguous portions of a T-helper epitope that are sufficient to enhance or stimulate an immune response.
- An example of T-helper segments is a series of overlapping peptides that are derived from a single longer peptide.
- RNA interference is a sequence specific post-transcriptional gene silencing mechanism, which is triggered by double-stranded RNA such as small (or short) interference RNA (siRNA) and single stranded intracellular RNA such as microRNA (miRNA), both of which can cause degradation of mRNAs homologous in sequence to siRNA or miRNA (Fire et al, 1998, Nature, 391:806-811; Montgomery et al, 1998, PNAS, 95: 15502-15507; Elbashir et al, 2001, Nature, 411:494-498).
- siRNA small interference RNA
- miRNA microRNA
- RNAi is a conserved pathway common to plants and mammals that suppress expression of genes with complementary sequences (Hannon and Rossi, 2004, Nature, 431:371-378; Meister and Tuschl, 2004, Nature, 431, 343-349). RNAi was first observed in lower organisms, such as plants or nematodes. In these systems, long dsRNAs serve as effective triggers of RNAi. Long dsRNAs are not the actual triggers but are degraded by the endoribonuclease Dicer into small effector molecules called siRNAs. In mammals, Dicer processing occurs as a complex with the RNA-binding protein TRBP.
- RISC RNA-Induced Silencing Complex
- RNAi can be performed in mammalian cells using short RNAs, which generally do not induce IFN responses.
- Many researchers today employ synthetic 21-mer RNA duplexes as their RNAi reagents, which mimic the natural siRNAs that result from Dicer processing of long substrate RNAs.
- An alternative approach is to use synthetic RNA duplexes that are greater than 21-mer in length, which are substrates for Dicer (Tuschl, T. 2002, Nature Biotechnology, 20:446).
- DsiRNAs Dicer-substrate RNAs
- Dicer-substrate RNAs are chemically synthesized RNA duplexes that have increased potency in RNA interference (Kim et al, 2005, Nat Biotechnol, 23:222-226).
- DsiRNAs are processed by Dicer into 21-mer siRNAs and designed so that cleavage results in a single, desired product. This is achieved through use of a novel asymmetric design where the RNA duplex has a single 2-base 3 '-overhang on the AS strand and is blunt on the other end; the blunt end is modified with DNA bases.
- This design provides Dicer with a single favorable PAZ binding site that helps direct the cleavage reaction.
- miRNAs are encoded by genes that are transcribed from DNA but not translated into protein (non-coding RNA); instead they are processed from primary transcripts known as pri-miRNA to short stem-loop structures called pre-miRNA and finally to functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to downregulate gene expression. Although miRNA is generated within the cell and is highly conserved, it rarely has perfect complementarity with mRNA sequences. However, miRNA can affect protein translation and mRNA decay by binding to its imperfectly matched target sites on 3' UTR region of mRNA, which also requires Ago protein (not necessarily Ago2 as in seen in siRNA).
- mRNA messenger RNA
- siRNA Comparing and contrasting siRNA with miRNA shows that if siRNA hits an imperfect complementary target on 3 UTR, it behaves similar to microRNA, and if a miRNA hits a perfectly matched target on a mRNA, it can behave like an siRNA.
- siRNA and miRNA might possess similar biological functions in the cells of host animal, with some differences in the mechanism of action.
- RNAi molecules provide a powerful tool for inhibiting endogenous gene expression and thereby could provide a means to effectively modulate biological responses.
- RNAi can be induced in antigen presenting dendritic cells (DC) to polarize immune responses.
- DC dendritic cells
- siRNA specific for cytokine IL-12 p35 sub-unit
- bioactive IL-12 which subsequently led to Th2 polarization
- modification of professional antigen presenting cells with siRNA in vivo has been used to enhance cancer vaccine potency (Kim et al, Cancer Research, 2005, 65:309-316).
- siRNA may be a naturally occurring or synthetic double stranded nucleotide (RNA) chain of varying length.
- siRNA can be duplexes, usually but not always limited to, 20 to 25-nt long that have 19 base pair central double stranded domain with terminal 2-base 3' overhangs.
- siRNA can be further modified chemically to enhance its in vivo efficacy, induce nuclease- resistance to prevent degradation and enhance stability.
- the anti-sense strand may have either a free 5'-OH or 5 '-phosphate terminus, the latter results in natural Dicer processing and represents the active form of the molecule.
- siRNA may have phosphorothioate or boranohosphate modification of the intemucleoside linkage to improve nuclease stability and prolong life of the duplex when exposed to serum or other nuclease sources.
- siRNA may have modifications at 2' position, for example, 2'-O-methyl RNA residue incorporation to retain full potency compared with unmodified RNA, retaining stability in serum and significantly reducing the risk of potential IFN responses in the cell.
- siRNA may also have 2'- fluoro modification, which is usually incorporated selectively at pyrimidine bases, to improve stability and potency.
- siRNA and miRNA used as mediators of RNAi may be used as targets in, but not limited to, various infectious diseases, autoimmune/allergic diseases, heart diseases, metabolic disorders, solid tumors/cancers, hematological disorders/cancers.
- the polynucleotide in the composition may be a polynucleotide for use in RNAi, including, without limitation, an siRNA, an miRNA, small hairpin RNA (shRNA), a long dsRNA for cleavage by Dicer, or a DsiRNA, all as described above.
- RNAi including, without limitation, an siRNA, an miRNA, small hairpin RNA (shRNA), a long dsRNA for cleavage by Dicer, or a DsiRNA, all as described above.
- the negatively charged molecule may be an antagomir.
- Antagomirs also known as anti-miRs or blockmirs
- Antagomirs are synthetically engineered oligonucleotides that silence endogenous miRNA. It is unclear how antagomirization (the process by which an antagomir inhibits miRNA activity) operates, but it is believed to inhibit by irreversibly binding the miRNA. Because of the promiscuity of microRNAs, antagomirs could affect the regulation of many different mRNA molecules.
- Antagomirs are designed to have a sequence that is complementary to an mRNA sequence that serves as a binding site for microRNA.
- the negatively charged molecule may be a catalytic DNA (deoxyribozyme) or a catalytic RNA (ribozyme).
- catalytic DNA refers to any DNA molecule with enzymatic activity.
- the catalytic DNA is a single-stranded DNA molecule.
- the catalytic DNA is synthetically produced as opposed to naturally occurring.
- the catalytic DNA may perform one or more chemical reactions.
- the catalytic DNA is a ribonuclease, whereby the catalytic DNA catalyzes the cleavage of ribonucleotide phosphodiester bonds.
- the catalytic DNA is a DNA ligase, whereby the catalytic DNA catalyzes the joining of two polynucleotide molecules by forming a new bond.
- the catalytic DNA can catalyze DNA phosphorylation, DNA adenylation, DNA deglycosylation, porphyrin metalation, thymine dimer photoreversion, or DNA cleavage.
- catalytic RNA refers to any RNA molecule with enzymatic activity. Catalytic RNAs are involved in a number of biological processes, including RNA processing and protein synthesis. In an embodiment, the catalytic RNA is a naturally occurring RNA. In an embodiment, the catalytic RNA is synthetically produced.
- the subject may be any subject to which it is desired to deliver a polynucleotide.
- the subject is preferably a vertebrate, such as a bird, fish or mammal, preferably a human.
- the polynucleotide may delivered in various forms.
- a naked polynucleotide may be used, either in linear form, or inserted into a plasmid, such as an expression plasmid.
- a live vector such as a viral or bacterial vector may be used.
- one or more regulatory sequences that aid in transcription of DNA into RNA and/or translation of RNA into a polypeptide may be present.
- such regulatory sequences may be absent.
- regulatory sequences relating to the transcription process e.g., a promoter
- protein expression may be effected in the absence of a promoter.
- suitable regulatory sequences as the circumstances require.
- the polynucleotide is present in an expression cassette, in which it is operably linked to regulatory sequences that will permit the polynucleotide to be expressed in the subject to which the composition of the disclosure is administered.
- the choice of expression cassette depends on the subject to which the composition is administered as well as the features desired for the expressed polypeptide.
- an expression cassette typically includes a promoter that is functional in the subject and can be constitutive or inducible; a ribosome binding site; a start codon (ATG) if necessary; the polynucleotide encoding the polypeptide of interest; a stop codon; and optionally a 3' terminal region (translation and/or transcription terminator). Additional sequences such as a region encoding a signal peptide may be included.
- the polynucleotide encoding the polypeptide of interest may be homologous or heterologous to any of the other regulatory sequences in the expression cassette.
- Sequences to be expressed together with the polypeptide of interest are typically located adjacent to the polynucleotide encoding the protein to be expressed and placed in proper reading frame.
- the open reading frame constituted by the polynucleotide encoding the protein to be expressed solely or together with any other sequence to be expressed e.g., the signal peptide
- Promoters suitable for expression of polynucleotides in a wide range of host systems are well-known in the art. Promoters suitable for expression of polynucleotides in mammals include those that function constitutively, ubiquitously or tissue-specifically. Examples of nontissue specific promoters include promoters of viral origin.
- viral promoters examples include Mouse Mammary Tumor Virus (MMTV) promoter, Human Immunodeficiency Virus Long Terminal Repeat (HIV LTR) promoter, Moloney virus, avian leukosis virus (ALV), Cytomegalovirus (CMV) immediate early promoter/enhancer, Rous Sarcoma Virus (RSV), adeno-associated virus (AAV) promoters; adenoviral promoters, and Epstein Barr Virus (EBV) promoters.
- MMTV Mouse Mammary Tumor Virus
- HBV LTR Human Immunodeficiency Virus Long Terminal Repeat
- AAV avian leukosis virus
- CMV Cytomegalovirus
- RSV Rous Sarcoma Virus
- AAV adeno-associated virus
- ESV Epstein Barr Virus
- tissue-specific promoter is the desmin promoter which drives expression in muscle cells (Li et al. 1989, Gene 78:243; Li & Paulin 1991, J. Biol. Chem. 266:6562 and Li & Paulin 1993, J. Biol. Chem. 268:10403, which are hereby incorporated by reference in their entireties).
- Other examples include artificial promoters such as a synthetic muscle specific promoter and a chimeric muscle-specific/CMV promoter (Li et al. 1999, Nat. Biotechnol. 17:241-245; Hagstrom et al. 2000, Blood 95:2536-2542, which are hereby incorporated by reference in their entireties).
- the polynucleotide of interest may be delivered naked, e.g., either alone or as part of a plasmid, or may be delivered in a viral or bacterial or bacterial vector.
- plasmid-type vector or a bacterial or viral vector
- the vector may be desirable that the vector be unable to replicate or integrate substantially in the subject.
- Such vectors include those whose sequences are free of regions of substantial identity to the genome of the subject, as to minimize the risk of host-vector recombination.
- One way to do this is to use promoters not derived from the recipient genome to drive expression of the polypeptide of interest.
- the promoter is preferably non-mammalian derived though it should be able to function in mammalian cells, e.g., a viral promoter.
- Viral vectors that may be used to deliver the polynucleotide include e.g., adenoviruses, lentiviruses and poxviruses.
- Useful bacterial vectors include e.g., Shigella, Salmonella, Vibrio cholerae, Lactobacillus, Bacille bilie de Calmette-Guerin (BCG), and Streptococcus.
- adenovirus vector As well as a method for constructing an adenovirus vector capable of expressing a polynucleotide, is described in U.S. Pat. No. 4,920,209, which is hereby incorporated by reference in its entirety.
- Poxvirus vectors include vaccinia and canary pox virus, described in U.S. Pat. No. 4,722,848 and U.S. Pat. No. 5,364,773 (which are hereby incorporated by reference in their entireties), respectively. Also see, e.g., Tartaglia et al.
- Poxvirus vectors capable of expressing a polynucleotide of interest may be obtained by homologous recombination as described in Kieny et al. 1984, Nature 312:163 (which is hereby incorporated by reference in its entirety), so that the polynucleotide is inserted in the viral genome under appropriate conditions for expression in mammalian cells.
- non-toxicogenic Vibrio cholerae mutant strains that are useful for expressing a foreign polynucleotide in a host are known.
- Mekalanos et al. 1983, Nature 306:551 and U.S. Pat. No. 4,882,278 (which are hereby incorporated by reference in their entireties) describe strains which have a substantial amount of the coding sequence of each of the two ctxA alleles deleted so that no functional cholerae toxin is produced.
- WO 92/11354 (which is hereby incorporated by reference in its entirety) describes a strain in which the irgA locus is inactivated by mutation; this mutation can be combined in a single strain with ctxA mutations.
- WO 94/01533 (which is hereby incorporated by reference in its entirety) describes a deletion mutant lacking functional ctxA and attRSl DNA sequences. These mutant strains are genetically engineered to express heterologous proteins, as described in WO 94/19482 (which is hereby incorporated by reference in its entirety).
- Attenuated Salmonella typhimurium strains genetically engineered for recombinant expression of heterologous proteins are described in Nakayama et al. 1988, Bio/Technology 6:693 and WO 92/11361, which are hereby incorporated by reference in their entireties.
- the polynucleotide of interest may be inserted into the bacterial genome or remain in a free state as part of a plasmid.
- the negatively charged molecule may be present in the composition of the present disclosure at about 0.01-2 mg/mL. In some embodiments, the negatively charged molecule (e.g., polynucleotide) may be present in the composition of the present disclosure at about 0.01 mg/mL, 0.02 mg/mL, 0.03 mg/mL, 0.04 mg/mL 0.05 mg/mL, 0.06 mg/mL, 0.07 mg/mL, 0.08 mg/mL, 0.09 mg/mL, 0.1 mg/mL, 0.11 mg/mL, 0.12 mg/mL, 0.13 mg/mL, 0.14 mg/mL 0.15 mg/mL, 0.16 mg/mL, 0.17 mg/mL, 0.18 mg/mL, 0.19 mg/mL, 0.2 mg/ml, 0.25 mg/mL, 0.3 mg/mL, 0.35 mg/mL, 0.4 mg/mL, 0.45 mg/m
- the negatively charged molecule (e.g., polynucleotide) may be present in the composition of the present disclosure at about 0.01-0.1 mg/mL, 0.05-0.2 mg/mL, 0.1-0.3 mg/mL, 0.2-0.4 mg/mL, 0.3-0.6 mg/mL, 0.4-0.8 mg/mL, 0.5- 1 mg/mL, 0.8-1.2 mg/mL, 1-1.5 mg/mL, or 1-2 mg/mL. In one embodiment, the negatively charged molecule (e.g., polynucleotide) may be present in the composition of the present disclosure at about 0.1 mg/mL.
- the composition disclosed herein comprise a single type of negatively charged molecule in a composition.
- the composition disclosed herein comprise a mixture of multiple different negatively charged molecules in a single composition.
- the composition disclosed herein comprise a mixture of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more different negatively charged molecules in a single composition.
- Any lipid may be used in the composition described herein so long as it is a membrane-forming lipid.
- any lipid as defined above may be used, particularly suitable lipids may include those with at least one fatty acid chain containing at least 4 carbons, and typically about 4 to 28 carbons.
- the fatty acid chain may contain any number of saturated and/or unsaturated bonds.
- the lipid may be a natural lipid or a synthetic lipid.
- Non-limiting examples of lipids may include phospholipids, sphingolipids, sphingomyelin, cerobrocides, gangliosides, ether lipids, sterols, cardiolipin, cationic lipids and lipids modified with poly (ethylene glycol) and other polymers.
- Synthetic lipids may include, without limitation, the following fatty acid constituents: lauroyl, myristoyl, palmitoyl, stearoyl, arachidoyl, oleoyl, linoleoyl, erucoyl, or combinations of these fatty acids.
- the lipid or lipids of the lipid vesicle particle are amphiphilic lipids, meaning that they possess both hydrophilic and hydrophobic (lipophilic) properties.
- Lipids suitable for use in the composition of the present disclosure include, but are not limited to phospholipids, cationic lipids, cholesterol and/or cholesterol derivatives, or a combination thereof. It is to be understood that the terms “phospholipids”, “cationic lipids” or “cholesterol derivatives”, are not necessarily mutually exclusive of each other.
- a "phospholipid” is a member of a group of lipid compounds that yield on hydrolysis phosphoric acid, an alcohol, fatty acid, and nitrogenous base.
- Phospholipids that are preferably used in the preparation of the composition of the present disclosure are those with at least one head group selected from the group consisting of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine and phosphoinositol. More preferred are lipids which are about 94-100% phosphatidylcholine. Such lipids are available commercially in the lecithin Phospholipon® 90 G (Phospholipid GmBH, Germany) or lecithin S100 (Lipoid GmBH, Germany).
- the phospholipid used in the preparation of the composition of the present disclosure is dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), Dioleoyl Phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof.
- the phospholipid used in the preparation of the composition of the present disclosure is dioleoyl phosphatidylcholine (DOPC).
- DOPC dioleoyl phosphatidylcholine
- a mixture of DOPC and unesterified cholesterol may be used.
- a mixture of Lipoid S 100 lecithin and unesterified cholesterol may be used.
- the lipid vesicle particles comprise a synthetic lipid.
- the lipid vesicle particles comprise synthetic DOPC.
- the lipid vesicle particles comprise synthetic DOPC and cholesterol.
- Sphingomyelin contains sphingosine, an amino alcohol with a long unsaturated hydrocarbon chain. A fatty acyl side chain is linked to the amino group of sphingosine by an amide bond, to form ceramide. The hydroxyl group of sphingosine is esterified to phosphocholine. Like phosphoglycerides, sphingomyelin is amphipathic.
- Lecithin which also may be used, is a natural mixture of phospholipids typically derived from chicken eggs, sheep's wool, soybean and other vegetable sources.
- Phospholipids can be purchased, for example, from Av anti lipids (Alabastar, AL, USA), Lipoid LLC (Newark, NJ, USA) and Lipoid GmbH (Germany), among various other suppliers.
- Cholesterol and/or cholesterol derivatives may be used in the composition of the present disclosure.
- unesterified cholesterol is used in the composition, the cholesterol is usually used in an amount equivalent to about 10% of the amount of phospholipid. If a compound other than cholesterol is used to stabilize the composition, one skilled in the art can readily determine the amount needed in the composition.
- Cholesterol derivatives suitable for use in the present disclosure include cholesterol [3-D-glucoside, cholesterol 3-sulfate sodium salt, positively charged cholesterol such as DC-cholesterol and other cholesterol like molecules such as Campesterol, Ergosterol, Betulin, Lupeol, [3-Sitosterol, a, [3-Amyrin and bile acids.
- the lipid vesicle particles comprise DOPC and cholesterol at a DOPC: Cholesterol ratio of about 10:1 (w/w). In some embodiments, the lipid vesicle particles comprise DOPC and cholesterol at a DOPC: cholesterol ratio of about 8:1 (w/w), about 9:1 (w/w), about 11:1 (w/w), or about 12:1 (w/w).
- the compositions disclosed herein comprise about 66 mg/ml of DOPC and cholesterol. In other embodiments, the compositions disclosed herein comprise about 55 mg/ml, 56 mg/ml, 57 mg/ml, 58 mg/ml, 59 mg/ml, 60 mg/ml, 61 mg/ml, 62 mg/ml, 63 mg/ml, 64 mg/ml, 65 mg/ml, 67 mg/ml, 68 mg/ml, 69 mg/ml, 70 mg/ml, 71 mg/ml, 72 mg/ml, 73 mg/ml, 74 mg/ml, or 75 mg/ml of DOPC and cholesterol.
- compositions disclosed herein comprise about 60 mg/ml of DOPC and about 6 mg/ml of cholesterol.
- positively charged lipids are used in the composition of the present disclosure.
- exemplary cationic lipids suitable for use in the compositions of the present disclosure include but are not limited to, 1,2-dioleoyl-3- trimethylammonium-propane (DOTAP), 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2- hydroxyethyl)imidazolinium chloride (DOTIM), N-[1-(2,3-dioleyloxy)propyl]-N,N,N- trimethylammonium chloride (DOTMA), dioctadecylamidoglycylspermine-4trifluoroacetic acid (DOGS), dioleyldimethylammonium chloride (DODAC), dimethyldioctadecylammonium bromide (DDAB), 1,2-distearoyl-3-dimethylammonium-propane (DAP),
- DOTAP 1,2-dioleoyl-3
- DODMA Dimethyldioctadecylammonium Bromide Salt
- EPC 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine chloride salt
- N4-Cholesteryl-Spermine HC1 Salt GL67
- GAP-DLRIE 2,3dioleyloxy-N- [2[sperminecarboxaminino]ethyl]-N,N-dimethyl-1-propanaminium trifluroacetate
- DOSPA 2,3dioleyloxy-N- [2[sperminecarboxaminino]ethyl]-N,N-dimethyl-1-propanaminium trifluroacetate
- cationic lipids include those described in, for example, Audouy and Hoekstra, Mol Membr Biol, Apr- Jun 2001;18(2):129-43; Shim et al., Asian Journal of Pharmaceutical Sciences 8(2):72-80, April 2013; and Faneca et al (2013) Cationic Liposome-Based Systems for Nucleic Acid Delivery: From the Formulation Development to Therapeutic Applications.
- eds Drug Delivery Systems: Advanced Technologies Potentially Applicable in Personalised Treatment. Advances in Predictive, Preventive and Personalised Medicine, vol 4. Springer, Dordrecht, which are incorporated herein by reference in their entireties.
- the lipid vesicle particles may have closed vesicular structures. They are typically spherical in shape, but other shapes and conformations may be formed and are not excluded. Exemplary embodiments of lipid vesicle particles include, without limitation, single layer vesicular structures (e.g., micelles) and bilayer vesicular structures (e.g., unilamellar or multilamellar vesicles), or various combinations thereof. [00144] By “single layer” it is meant that the lipids do not form a bilayer, but rather remain in a layer with the hydrophobic part oriented on one side and the hydrophilic part oriented on the opposite side.
- bilayer it is meant that the lipids form a two-layered sheet, typically with the hydrophobic part of each layer internally oriented toward the center of the bilayer with the hydrophilic part externally oriented.
- multilayer is meant to encompass any combination of single and bilayer structures. The form adopted may depend upon the specific lipid that is used. .
- the lipid vesicle particle is a bilayer vesicular structure, such as for example, a liposome.
- Liposomes are completely closed lipid bilayer membranes. Liposomes may be unilamellar vesicles (possessing a single bilayer membrane), multilamellar vesicles (characterized by multimembrane bilayers whereby each bilayer may or may not be separated from the next by an aqueous layer) or multivesicular vesicles (possessing one or more vesicles within a vesicle).
- a general discussion of liposomes can be found in Gregoriadis 1990; and Frezard 1999, which are incorporated herein by reference in their entirety.
- the lipid vesicle particles are liposomes.
- the liposomes are unilamellar, multilamellar, multivesicular or a mixture thereof.
- the carrier of the composition comprises a continuous phase of a hydrophobic substance, preferably a liquid hydrophobic substance.
- the continuous phase may be an essentially pure hydrophobic substance or a mixture of hydrophobic substances.
- the carrier may be an emulsion of water in a hydrophobic substance or an emulsion of water in a mixture of hydrophobic substances, provided the hydrophobic substance constitutes the continuous phase.
- the carrier may function as an adjuvant.
- Hydrophobic substances that are useful in the compositions as described herein are those that are pharmaceutically and/or immunologically acceptable.
- the carrier is preferably a liquid but certain hydrophobic substances that are not liquids at atmospheric temperature may be liquefied, for example by warming, and are also useful in this disclosure.
- the hydrophobic carrier may be a PBS/FIA emulsion.
- Oil or water-in-oil emulsions are particularly suitable carriers for use in the present disclosure.
- Oils should be pharmaceutically and/or immunologically acceptable.
- suitable oils include, for example, mineral oils (especially light or low viscosity mineral oil such as Drakeo® 6VR), vegetable oils (e.g., soybean oil), nut oils (e.g., peanut oil), or mixtures thereof.
- the oil is a mannide oleate in mineral oil solution, commercially available as Montanide® ISA 51.
- the oil is MS80 oil (mixture of mineral oil and Span 80).
- Animal fats and artificial hydrophobic polymeric materials particularly those that are liquid at atmospheric temperature or that can be liquefied relatively easily, may also be used. Mixtures of different hydrophobic substances, such as mixtures that include one or more different oils, animal fats or artificial hydrophobic polymeric materials, may be used.
- composition of the present disclosure contains an ionizable aminoglycoside.
- Ionizable aminoglycosides useful in the compositions of the present disclosure include, but are not limited to, chitosan, cationic alginate, cationic gelatin, cationic dextran, DEAE-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, glycyrrhizic acid ammonium salt, or derivatives thereof.
- the ionizable aminoglycoside is a polymer.
- the ionizable aminoglycoside is chitosan, chitosan derivative, or a chitosan like molecule.
- Chitosan derivatives suitable for use in the present disclosure include, but are not limited to N- trimethyl chitosan, mono-N-carboxymethyl chitosan (MCC), N-palmitoyl chitosan (NPCS), EDTA-chitosan, low molecular weight chitosan, galactosylated chitosan, N-dodecylated chitosan, thiolated chitosan or combinations thereof.
- the chitosan like molecules include, but are not limited to, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, galactosamine, N-acetylgalactosamine, cellulose acetate, mannosamine, N-acetylneuraminic acid, alginic acid, Trehalose-6,6-dibehenate (TDB) with Dimethyldioctadecylammonium bromide (DDA), heptakis(6-deoxy-6-amino)- ⁇ -cyclodextrin heptahydrochloride, DEAE-dextran hydrochloride, and glycyrrhizic acid ammonium salt. It is contemplated that the chitosan, chitosan derivative, or a chitosan like molecule may also function as a carrier (e.g., a structural carrier).
- a carrier e.g., a
- the chitosan or chitosan derivative used in the composition has a molecular weight of about 10 kDa to 200 kDa. In some embodiments, the chitosan or chitosan derivative used in the composition has a molecular weight of about 60 kDa to 150 kDa, about 80 kDa to 150 kDa, about 90 kDa to 110 kDa, about 100 kDa to 120 kDa, about 100 kDa, or about 120 kDa.
- the chitosan or chitosan derivative used in the composition has a molecular weight of about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, or about 150 kDa. In one embodiment, the chitosan or chitosan derivative used in the composition has a molecular weight of about 100 kDa.
- Degree of deacetylation is another main parameter characterizing chitosan.
- the degree of deacetylation (DD, %) is defined as the molar fraction of D-glusoamine units in the copolymers (chitosan) composed of N-acetylglucosamine units and D-glusoamine units (Shigemasa Y et al., Int. J. Biol. Macromol. 1996;18:237-242, which is incorporated hereby by reference in its entirety).
- the chitosan or chitosan derivative used in the composition has a degree of deacetylation (DD) of about 15% to 95%.
- the chitosan or chitosan derivative used in the composition has a degree of deacetylation (DD) of about 15% to 30%, about 20% to 30%, about 20% to 40%, about 25% to 50%, about 30% to 60%, about 40% to 70%, about 50% to 80%, about 60% to 90%, about 70% to 95%.
- the chitosan or chitosan derivative used in the composition has a degree of deacetylation (DD) of about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- the chitosan or chitosan derivative has a DD% of about 25%.
- the chitosan or chitosan derivative is added in a concentration of about 0.1 mg/mL to about 5 mg/mL. In some embodiments, the chitosan or chitosan derivative is added in a concentration of about 0.25 mg/mL to about 4 mg/mL, about 0.5 mg/mL to about 3 mg/mL, about 0.75 mg/mL to about 2.5 mg/mL, about 1 mg/mL to about 2 mg/mL. In some embodiments, the chitosan or chitosan derivative is added in a concentration of about 0.5 mg/mL to about 3 mg/mL or about 1 mg/mL to about 2 mg/mL.
- the chitosan or chitosan derivative is added in a concentration of about 0.1 mg/ml, about 0.25 mg/ml, about 0.5 mg/ml, about 0.75 mg/ml, about 1 mg/mL, about 1.25 mg/ml, about 1.5 mg/mL, about 1.75 mg/ml, about 2 mg/mL, about 2.25 mg/ml, about 2.5 mg/ml, about 2.75 mg/ml, about 3 mg/ml, about 3.25 mg/ml, about 3.5 mg/ml, about 3.75 mg/ml, about 4 mg/ml, about 4.25 mg/ml, about 4.5 mg/ml, about 4.75 mg/ml, about 5 mg/ml. In some embodiments, the chitosan or chitosan derivative is added in a concentration of about 0.1 mg/ml, about 1.5 mg/mL, about 2 mg/mL, about 2.5 mg/mL, or about 3 mg/mL.
- the composition may comprise one or more adjuvants.
- an adjuvant may be present.
- An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non- specifically enhances the immune response (Hood et al, Immunology, 2d ed., Benjamin/Cummings: Menlo Park, C.A., 1984; see Wood and Williams, In: Nicholson, Webster and May (eds.), Textbook of Influenza, Chapter 23, pp. 317-323, which are incorporated hereby by reference in their entireties).
- polynucleotide of interest to be delivered to the subject may itself function as an adjuvant, or may encode a polypeptide that constitutes an adjuvant (e.g., IL-12, IFN-gamma, or Granulocyte-Macrophage Colony Stimulating Factor (“GMCSF”)).
- an adjuvant e.g., IL-12, IFN-gamma, or Granulocyte-Macrophage Colony Stimulating Factor (“GMCSF”)
- the adjuvant is a protein, a polymer, a polysaccharide, or a combination thereof.
- the adjuvant may be a natural or synthetic substance.
- the amount of adjuvant used depends on the amount of antigen expressed by the polynucleotide and on the type of adjuvant. One skilled in the art can readily determine the amount of adjuvant needed in a particular application.
- Suitable adjuvants include, but are not limited to, alum, other compounds of aluminum, Bacillus of Calmette and Guerin (BCG), TiterMax®, incomplete Freund's adjuvant (IF A), saponin, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, Corynebacteriumparvum, QS-21, and Freund's Complete Adjuvant (FCA), adjuvants of the STING family Bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP), Bis-(3'- 5')-cyclic dimeric adenosine monophosphate (c-di-AMP) and cyclic di-inosine monophosphate (c-di-IMP), adjuvants of the TLR agonist family such as CpG-containing oligodeoxynucleotides (CpG ODN), polyLC, falgellin, lipopeptides
- Suitable adjuvants also include cytokines or chemokines in their polypeptide or DNA coding forms such as, but not limited to, GM-CSF, TNF-alpha, IFN- gamma, IL-2, IL-12, IL-15, IL-21.
- Suitable adjuvants that activate or increases the activity of TLR2 include those described in U.S. Patent Nos. 10,105,435 and 10,022,441, which are hereby incorporated by reference in their entirety.
- the adjuvant is a CpG ODN.
- CpG ODNs are DNA molecules that contain one or more unmethylated CpG motifs (consisting of a central unmethylated CG dinucleotide plus flanking regions).
- An exemplary CpG ODN is 5'- TCCATGACGTTCCTGACGTT-3' (SEQ ID NO: 1). The skilled person can readily select other appropriate CpG ODNs on the basis of the target species and efficacy.
- the adjuvant may be a polyLC polynucleotide.
- PolyLC polynucleotides are polynucleotide molecules (either RNA or DNA or a combination of DNA and RNA) containing inosinic acid residues (I) and cytidylic acid residues (C), and which induce the production of inflammatory cytokines, such as interferon.
- the polyI:C polynucleotide is double-stranded.
- they may be composed of one strand consisting entirely of cytosine-containing nucleotides and one strand consisting entirely of inosine-containing nucleotides, although other configurations are possible.
- each strand may contain both cytosine-containing and inosine-containing nucleotides.
- either or both strands may additionally contain one or more non-cytosine or non-inosine nucleotides.
- polyI:C can be segmented every 16 residues without an effect on its interferon activating potential (Bobst 1981). Furthermore, the interferon inducing potential of a polyI:C molecule mismatched by introducing a uridine residue every 12 repeating cytidylic acid residues (Hendrix 1993), suggests that a minimal double stranded polyI:C molecule of 12 residues is sufficient to promote interferon production. Others have also suggested that regions as small as 6-12 residues, which correspond to 0.5-1 helical turn of the double stranded polynucleotide, are capable of triggering the induction process (Greene 1978).
- polyI:C polynucleotides are typically about 20 or more residues in length (commonly 22, 24, 26, 28 or 30 residues in length). If semi-synthetically made (e.g. using an enzyme), the length of the strand may be 500, 1000 or more residues.
- a “polI:C”, “ polyI:C polynucleotide” or “ polyI:C polynucleotide adjuvant” is a double- or single-stranded polynucleotide molecule (RNA or DNA or a combination of DNA and RNA), each strand of which contains at least 6 contiguous inosinic or cytidylic acid residues, or 6 contiguous residues selected from inosinic acid and cytidylic acid in any order (e.g., IICIIC or ICICIC), and which is capable of inducing or enhancing the production of at least one inflammatory cytokine, such as interferon, in a mammalian subject.
- RNA or DNA or a combination of DNA and RNA each strand of which contains at least 6 contiguous inosinic or cytidylic acid residues, or 6 contiguous residues selected from inosinic acid and cytidylic acid
- PolyI:C polynucleotides will typically have a length of about 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, 26, 28, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 500, 1000 or more residues.
- Preferred polyI:C polynucleotides may have a minimum length of about 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30 nucleotides and a maximum length of about 1000, 500, 300, 200, 100, 90, 80, 70, 60, 50, 45 or 40 nucleotides.
- Each strand of a double-stranded polyI:C polynucleotide may be a homopolymer of inosinic or cytidylic acid residues, or each strand may be a heteropolymer containing both inosinic and cytidylic acid residues.
- the polymer may be interrupted by one or more non-inosinic or non-cytidylic acid residues (e.g. uridine), provided there is at least one contiguous region of 6 I, 6 C or 6 I/C residues as described above.
- each strand of a polyI:C polynucleotide will contain no more than 1 non-I/C residue per 6 1/C residues, more preferably, no more than 1 non-I/C residue per every 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 or 30 I/C residues.
- the inosinic acid or cytidylic acid (or other) residues in the polyI:C polynucleotide may be derivatized or modified as is known in the art, provided the ability of the polyI:C polynucleotide to promote the production of an inflammatory cytokine, such as interferon, is retained.
- Non-limiting examples of derivatives or modifications include e.g. azido modifications, fluoro modifications, or the use of thioester (or similar) linkages instead of natural phosphodiester linkages to enhance stability in vivo.
- the polyI:C polynucleotide may also be modified to e.g. enhance its resistance to degradation in vivo by e.g. complexing the molecule with positively charged poly-lysine and carboxymethylcellulose, or with a positively charged synthetic peptide.
- the polyI:C polynucleotide may be a single-stranded molecule containing inosinic acid residues (I) and cytidylic acid residues (C).
- the single-stranded polyI:C may be a sequence of repeating dldC.
- the sequence of the single-stranded polyI:C may be a 26-mer sequence of (IC) 13 , i.e. ICICICICICICICICICICIC (SEQ ID NO: 2).
- ICICICICICICICICICICICICIC SEQ ID NO: 2
- the polyI:C polynucleotide adjuvant is a traditional form of polyI:C with an approximate molecular weight of 989,486 Daltons, containing a mixture of varying strand lengths of polyl and polyC of several hundred base pairs (Thermo Scientific; USA).
- the adjuvant may be one that activates or increases the activity of TLR2.
- an adjuvant which “activates” or “increases the activity” of a TLR2 includes any adjuvant, in some embodiments a lipid-based adjuvant, which acts as a TLR2 agonist. Further, activating or increasing the activity of TLR2 encompasses its activation in any monomeric, homodimeric or heterodimeric form, and particularly includes the activation of TLR2 as a heterodimer with TLR1 or TLR6 (i.e. TLR1/2 or TLR2/6).
- an adjuvant that activates or increases the activity of TLR2 include lipid-based adjuvants, such as those described in WO2013/049941, which is hereby incorporated by reference in its entirety.
- the adjuvant may be a lipid-based adjuvant, such as disclosed for example in WO2013/049941, which is hereby incorporated by reference in its entirety.
- the lipid-based adjuvant is one that comprises a palmitic acid moiety such as dipalmitoyl-S-glyceryl-cysteine (PAM2Cys) or tripalmitoyl-S-glyceryl-cysteine (PAM3Cys).
- the adjuvant is a lipopeptide.
- exemplary lipopeptides include, without limitation, PAM2Cys-Ser-(Lys)4 (SEQ ID NO: 3) or PAM3Cys-Ser-(Lys)4 (SEQ ID NO: 4).
- the adjuvant is PAM3Cys-SKKKK (EMC Microcollections, Germany; SEQ ID NO: 5) or a variant, homolog and analog thereof.
- the PAM2 family of lipopeptides has been shown to be an effective alternative to the PAM3 family of lipopeptides.
- the adjuvant may be a lipid A mimic or analog adjuvant, such as for example those disclosed in WO2016/109880 and the references cited therein, which are hereby incorporated by reference in their entireties.
- the adjuvant may be JL-265 or JL-266 as disclosed in W02016/109880, which is hereby incorporated by reference in its entirety.
- a combination of a polyI:C polynucleotide adjuvant and a lipid- based adjuvant may be used, such as described in the adjuvanting system disclosed in WO2017/083963, which is hereby incorporated by reference in its entirety.
- compatible adjuvants may include, without limitation, chemokines, Toll like receptor agonists, colony stimulating factors, cytokines, 1018 ISS, aluminum salts, Amplivax, AS04, AS 15, ABM2, Adjumer, Algammulin, AS01B, AS02 (SBASA).
- the composition may further comprise one or more additional components that may facilitate the delivery of the negatively charged molecule (e.g., polynucleotide) to the subject.
- the additional components may enhance the stability of the composition, or complement or enhance the function of the negatively charged molecule (e.g., polynucleotide) to be delivered to the subject.
- the composition further comprises a buffer.
- a buffer works to maintain the pH of solution to prevent a sharp pH change in the liquid formulation for stabilizing the composition.
- the buffer may include an alkaline salt (sodium or potassium phosphate or hydrogen or dihydrogen salts thereof), sodium citrate/citric acid, sodium acetate/acetic acid, and any other pharmaceutically acceptable pH buffer known in the art, and a combination thereof.
- the preferred example of such buffer includes an acetate buffer, citrate buffer, and phosphate buffer.
- the buffer may also include zwitterionic salts such THAM tris(hydroxymethyl)aminomethane, HEPES (4-(2-hydroxy ethyl)- 1 -piperazineethanesulfonic acid), MOPS (3-(N-Morpholino) propanesulfonic acid) and MES (2-(N- morpholino)ethanesulfonic acid).
- zwitterionic salts such THAM tris(hydroxymethyl)aminomethane, HEPES (4-(2-hydroxy ethyl)- 1 -piperazineethanesulfonic acid), MOPS (3-(N-Morpholino) propanesulfonic acid) and MES (2-(N- morpholino)ethanesulfonic acid).
- the buffer is sodium acetate. In some embodiments, the concentration of the sodium acetate buffer is about 25-250 mM. In some embodiments, the concentration of the sodium acetate buffer is about 100 mM. In some embodiments, the sodium acetate buffer has a pH of 6.0-10.5. In some embodiments, the sodium acetate buffer has a pH of about 7.
- the composition further comprises a surfactant.
- exemplary surfactants may include, but are not limited to sorbitan monooleate, Cremophor, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamers, polyethylene glycol, transcutol, Capmul®, labrasol, isopropyl myristate, and/or Span 80.
- an additional component in the composition is a polypeptide
- a polynucleotide encoding the additional polypeptide may instead be provided, in the same manner as for the polynucleotide encoding the polypeptide of primary interest.
- Such polypeptides could be expressed from the same or separate expression vectors, or could be expressed in the form of a fusion protein.
- the lipid vesicle particles of the present disclosure may be prepared by methods known in the art, and/or described herein, e.g., in the Examples section below. [00180] In some embodiments, the lipid vesicle particles of the present disclosure are prepared using the methods described in International PCT Application WO/2019/090411, U.S. Patent No. 9,498,493, which are incorporated herein by reference in their entirety.
- the lipid vesicle particles may form structures such as liposomes.
- Methods for making liposomes are well known in the art: see, for example, Gregoriadis (1990) and Frezard (1999), both cited previously. Any suitable method for making liposomes may be used in the practice of the disclosure.
- Liposomes are typically prepared by hydrating the liposome components that will form the lipid bilayer (e.g., phospholipids and cholesterol) with an aqueous solution, which may be pure water or any other physiologically compatible solution such as saline, e.g., phosphate-buffered saline (PBS).
- PBS phosphate-buffered saline
- the present disclosure provides a method for preparing a composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside.
- the method can comprise one or more of the following steps: a) dissolving the one or more lipids in one or more organic solvents and optionally an aqueous solvent to create a lipid solution, b) adding the negatively charged molecule to the lipid solution formed in step a) and mixing; c) adding the ionizable aminoglycoside to the mixture formed in step b) and mixing; d) optionally, adding additional amount of the organic solvent(s) or aqueous solvent to the mixture formed in step c) thereby the overall Wt/Wt or V/V percentage ratio of organic: aqueous solvent or aqueous: organic solvent in the mixture is between 20-50%; e) drying the mixture formed in step c) or d) to generate a dried preparation; and
- a lipid component or mixture of lipid components such as a phospholipid (e.g., DOPC) and cholesterol
- a lipid component or mixture of lipid components may be solubilized in one or more organic solvent, such as tert-butanol, ethanol, methanol, chloroform, or a mixture of chloroform and methanol, tert-butanol, a mixture of tert-butanol and ethanol, a mixture of tert-butanol and chloroform, or mixture of tert-butanol and water followed by filtering (e.g., a PTFE 0.2 pm filter) and drying, e.g., by rotary evaporation, freeze-drying to remove the solvents.
- organic solvent such as tert-butanol, ethanol, methanol, chloroform, or a mixture of chloroform and methanol, tert-butanol, a mixture of tert-butanol and
- the organic solvent(s) is present in an amount sufficient to prevent the one or more lipids from forming lipid vesicle particles in the lipid solution.
- the organic solvent(s) and the aqueous solvent are present in a percentage ratio of organic: aqueous solvent or aqueous: organic solvent ratio between 20- 50%.
- the organic solvent(s) and the aqueous solvent are present in a percentage ratio of organic: aqueous solvent or aqueous: organic solvent ratio of about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50%.
- the organic solvent is tert-butanol.
- the lipid solution comprises about 20%-50% tert-butanol. In some embodiments, the lipid solution comprises about 20% tert-butanol, about 25% tert-butanol, about 30% tert-butanol, about 35% tert-butanol, about 40% tert-butanol, about 45% tert-butanol, or about 50% tertbutanol. In one embodiment, the lipid solution comprises about 30% tert-butanol.
- Hydration of the resulting lipid mixture may be effected by e.g., injecting the lipid mixture into an aqueous solution or sonicating the lipid mixture and an aqueous solution.
- the lipid components form single bilayers (unilamellar) or multiple bilayers (multilamellar) surrounding a volume of the aqueous solution with which the lipid components are hydrated.
- the lipid vesicle particles are then dehydrated, such as by freeze-drying or lyophilization, spray freeze-drying, spray drying, or rotary evaporation, and subsequently reconstituted with an aqueous solution.
- the lipid vesicle particles are combined with the carrier comprising a continuous hydrophobic phase.
- the hydrophobic phase is essentially water-free. This can be done in a variety of ways.
- the carrier is essentially water-free, and is composed solely of a hydrophobic substance or a mixture of hydrophobic substances (e.g., use of a 100% mineral oil carrier), lipid vesicle particles may simply be mixed with the hydrophobic substance, or if there are multiple hydrophobic substances, mixed with any one or a combination of them.
- An exemplary preparation method is further described below and in the Examples section (see Formulation Method A (standard). In this method, any negatively charged molecules (e.g., polynucleotide) presented in an aqueous solution (e.g., sterile RNase free water) is added to a suitable buffer solution.
- lipid vesicle particles in sterile RNase free water e.g., particle size ⁇ 120 nm, poly dispersity index (PDI) ⁇ 0.1
- formulation method A is prepared with different polymers and transfection agents by adding the respective stock solutions to the polynucleotide loaded lipid vesicle particles obtained from the above step, mixed well gently by e.g., hand or vortexing for 30 seconds.
- the final formulation (with and without different polymers and transfection agents) is then dehydrated by freeze-drying or lyophilization or spray-drying; and subsequently reconstituted with an aqueous solution or with a hydrophobic substance or amixture of hydrophobic substances (e.g., use of a 100% mineral oil carrier) prior to administration.
- a hydrophobic substance or amixture of hydrophobic substances e.g., use of a 100% mineral oil carrier
- the carrier comprising a continuous phase of a hydrophobic substance contains a discontinuous aqueous phase
- the carrier will typically take the form of an emulsion of the aqueous phase in the hydrophobic phase, such as a water-in-oil emulsion.
- Such compositions may contain an emulsifier to stabilize the emulsion and to promote an even distribution of the lipid vesicle particles (e.g., liposomes).
- emulsifiers may be useful even if water-free carrier is used, for the purpose of promoting an even distribution of the lipid vesicle particles (e.g., liposomes) in the carrier.
- Typical emulsifiers include mannide oleate (ArlacelTM A), lecithin, TweenTM 80, and SpansTM 20, 80, 83 and 85.
- the weight to volume ratio (w/v) of hydrophobic substance to emulsifier is in the range of about 5:1 to about 15:1 with a ratio of about 10:1 being preferred.
- the lipid vesicle particles may be added to the finished emulsion, or they may be present in either the aqueous phase or the hydrophobic phase prior to emulsification.
- polynucleotide includes the polynucleotide in naked form including, for example, in an mRNA or a plasmid such as an expression plasmid, or in a live vector such as a bacteria or virus.
- lipid or lipid-mixture is dissolved in 20- 50% or 100% tert-butanol or ethanol by, e.g., simple vortexing or by shaking at 150-300 RPM in an incubator shaker at room temperature or at 37°C until dissolved.
- any negatively charged molecules e.g., polynucleotide
- aqueous solution e.g., sterile RNase free water
- suitable buffer solution ed with another positively charged molecule/ adjuvant with known cryoprotectants
- the overall Wt/Wt or V/V percentage ratio of organic: aqueous solvent mixture aqueous: organic solvent mixture in the final formulation prior to dehydration is maintained between 20-50%.
- the one or more lipids when dissolved in the organic solvent(s) are presented in clear solution form.
- the aqueous solution(s) containing the negatively charged molecule (e.g., polynucleotide) and/or ionizable aminoglycoside the one or more lipids form lipid vesicle particles.
- the formed lipid vesicle particles are then dehydrated, such as by freeze-drying or lyophilization or spray-drying; and subsequently reconstituted with an aqueous solution or with a hydrophobic substance or a mixture of hydrophobic substances (e.g., use of a 100% mineral oil carrier) prior to administration.
- this method has several advantages over the conventional lipid nanoparticles method including increased solubility and encapsulation of hydrophobic molecules, decreased freeze- drying time, and better oil reconstitution characteristics for hydrophobic or complex compounds.
- More than one polynucleotide may be incorporated into the composition.
- two or more polynucleotides encoding different proteins may be incorporated into the composition, or a polynucleotide encoding a protein may be present as well as a polynucleotide encoding an antisense RNA or interfering RNA. Proteins may be expressed as the fusion product of two different polynucleotides.
- More than one polynucleotide may be under the control of the same regulatory elements, e.g., two or more polynucleotides under transcriptional control of a single promoter.
- the polynucleotide is present in the aqueous solution used to hydrate the components that are used to form the lipid bilayers of the lipid vesicle particles (e.g., liposomes).
- the polynucleotide will be encapsulated in the lipid vesicle particles , present in its aqueous interior. If the resulting liposomes are not washed or dried, such that there is residual aqueous solution present that is ultimately mixed with the carrier comprising a continuous phase of a hydrophobic substance, it is possible that additional polynucleotide may be present outside the lipid vesicle particles in the final product.
- the polynucleotide may be mixed directly with the lipid vesicle particles or with the components used to form the lipid bilayers of the lipid vesicle particles, prior to hydration with the aqueous solution.
- the polynucleotide may instead be mixed with the carrier comprising a continuous phase of a hydrophobic substance, before, during, or after the carrier is combined with the lipid vesicle particles.
- the carrier is an emulsion
- the polynucleotide may be mixed with either or both of the aqueous phase or hydrophobic phase prior to emulsification.
- the polynucleotide may be mixed with the carrier after emulsification.
- the technique of combining the polynucleotide with the carrier may be used together with encapsulation of the polynucleotide in the lipid vesicle particles as described above, such that polynucleotide is present both within the lipid vesicle particles and in the carrier comprising a continuous phase of a hydrophobic substance.
- the composition may comprise about 0.1 to 5 mg polynucleotide per ml of the composition and about 1 mg to 300 mg lipid vesicle particles per ml of the composition.
- the particle size of the lipid vesicle particles prepared according the methods described herein prior to dehydration is about 100-5000 nm (0.1 to 5 microns).
- the particle size of the lipid vesicle particles may vary depending upon the ratio of organic: aqueous or aqueous: organic solvent composition in the final formulation prior to dehydration and also on the choice of organic solvent.
- the particle size of the lipid vesicle particles prepared according the methods described herein prior to dehydration is about 100-200 nm, about 100-300 nm, about 100-400 nm, about 100-500 nm, about 100-1000 nm, about 100-1500 nm, about 110-1500 nm, about 110-1800 nm, about 120- 1500 nm, about 120-2000 nm, about 130-2000 nm, about 130-2500 nm, about 150-3000 nm, about 150-4000 nm, about 200-4000 nm, or about 200-5000 nm.
- the mean particle size of the lipid vesicle particles prepared according the methods described herein prior to dehydration is about 100-1000 nm (0.1 to 1 microns). In some embodiments, the mean particle size of the lipid vesicle particles prepared according the methods described herein prior to dehydration is about 100 nm, about 115 nm, about 120 nm, about 125 nm, about 130 nm, about 135 nm, about 140 nm, about 145 nm, about 150 nm, about 160 nm, about 170 nm, about 180 nm, about 190 nm, about 200 nm, about 300 nm, about 400 nm, about 500 nm, about 600 nm, about 700 nm, about 800 nm, about 900 nm, or about 1000 nm.
- the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance form reverse micelles.
- the particle size of the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance is about 1-50 nm. In some embodiments, the particle size of the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance is about 1-10 nm, 2-8 nm, 4-9 nm, 5-10 nm, 6-12 nm, 7-15 nm, 8-20 nm, 10-30 nm, 15-40 nm, 20-45 nm, or 30-50 nm.
- the mean particle size of the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance is about 1-20 nm. In some embodiments, the mean particle size of the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance is about 1 nm, about 2 nm, about 3 nm, about 4 nm, about 5 nm, about 6 nm, about 7 nm, about 8 nm, about 9 nm, about 10 nm, about 11 nm, about 12 nm, about 13 nm, about 14 nm, about 15 nm, about 16 nm, about 17 nm, about 18 nm, about 19 nm, or about 20 nm.
- lipid vesicle particles there are several techniques, instruments and services that are available to measure the mean particle size of lipid vesicle particles, such as electron microscopy (transmission, TEM, or scanning, SEM), atomic force microscopy (AFM), Fourier-transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), powder X-ray diffraction (XRD), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI- TOF-MS), nuclear magnetic resonance (NMR) and dynamic light scattering (DLS).
- DLS is a well-established technique for measuring the particle size in the submicron size range, with available technology to measure particle sizes of less than 1 nm (LS Instruments, CH; Malvern Instruments, UK).
- Polydispersity index is a measure of the size distribution of the lipid vesicle particles. It is known in the art that the term “poly dispersity” may be used interchangeably with “dispersity”.
- the PDI can be calculated by determining the mean particle size of the lipid vesicle particles and the standard deviation from that size.
- DLS is a well- established technique for measuring the particle size and size distribution of particles in the submicron size range, with available technology to measure particle sizes of less than 1 nm (LS Instruments, CH; Malvern Instruments, UK). For a perfectly uniform sample, the PDI would be 0.0.
- PDI of a lipid vesicle particle prepared according the methods described herein prior to dehydration is between about 0.1 to about 0.7. In some embodiments, PDI of a lipid vesicle particle prepared according the methods described herein prior to dehydration is about 0.1 to about 0.4, about 0.2 to about 0.5, about 0.3 to about 0.6, about 0.4 to about 0.7, or about 0.5 to 0.7. In some embodiments, PDI of a lipid vesicle particle described herein is about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, or about 0.7.
- the PDI is measured by any instrument and/or machine suitable for measuring the PDI of lipid vesicle particles.
- the PDI size distribution is determined by DLS (Malvern Instruments, UK).
- the PDI is measured by DLS using a Malvern Zetasizer series instrument, such as for example the Zetasizer Nano S, Zetasizer APS, Zetasizer pV or Zetasizer AT machines (Malvern Instruments, UK).
- the PDI is measured by DLS using a Malvern Zetasizer Nano S machine. Exemplary conditions and system settings are described above in respect of determining mean particle size.
- the adjuvant(s) and/or additional component(s) can be incorporated in the composition together with the polynucleotide at the same processing step, or separately, at a different processing step.
- the polynucleotide and the adjuvant(s) and/or additional component(s) may both be present in the aqueous solution used to hydrate the lipid bilayer-forming components, such that both the polynucleotide and adjuvant(s) and/or additional component(s) become encapsulated in the lipid vesicle particles.
- the polynucleotide may be encapsulated in the lipid vesicle particles, and the adjuvant(s) and/or additional component(s) mixed with the carrier comprising a continuous phase of a hydrophobic substance. It will be appreciated that many such combinations are possible.
- the polynucleotide and the adjuvant(s) and/or additional component(s) may be in the form of a complex, in which they are in intimate contact at least prior to incorporation into the composition.
- Complexing may but need not necessarily involve a chemical linkage, such as covalent bonding.
- compositions as described herein may be formulated in a form that is suitable for any administration routes, such as oral, nasal, aerosol, rectal or parenteral administration.
- Parenteral administration includes intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular, transepithelial, intrapulmonary, intrathecal, and topical modes of administration.
- the compositions may be formulated for systemic or localized distribution in the body of the subject.
- the preferred routes are intramuscular, subcutaneous and intradermal to achieve a depot effect. In practice, a depot effect is achieved when the therapeutic agent remains at the site of injection for more than about one hour.
- the injection site may be anywhere close to, or directly into a lymph node, for example. Alternatively, the injection site may be directly into a spleen, a tumor or other diseased tissue.
- the volume that may be injected is within the professional judgment of the clinician. The volume depends on the injecting device used and the site of injection. When the injection is intramuscularly or subcutaneous, the injection volume may be about 1 mL. When needleless injection is used, the volume may be as low as 0.01 mL. The volume may be increased by injecting multiple sites.
- Suitable injection volumes may be about 0.01 mL, about 0.02 mL, about 0.05 mL, about 0.1 mL, about 0.2 mL, about 0.3 mL, about 0.4 mL, about 0.5 mL, about 0.6 mL, about 0.7 mL, about 0.8 mL, about 0.9 mL, about 1 mL, about 1.5 mL, about 2 mL, about 0.01-0.05 mL, about 0.05-0.1 mL, about 0.1-0.2 mL, about 0.2-0.4 mL, about 0.1-0.5 mL, about 0.4-0.8 mL, about 0.5-1 mL, about 0.8-1.2 mL, or about 1-1.5 mL.
- formulations of the present disclosure may create stable depot at the site of delivery that protects active ingredient (e.g., a polynucleotide) from degradation by nucleases or by renal or hepatic clearance for an extended period of time (e.g., up to one week or two weeks).
- active ingredient e.g., a polynucleotide
- formulations of the present disclosure may also provide controlled and prolonged exposure of active ingredients (e.g., a polynucleotide) to the cells at the delivery site allowing a direct delivery of treatment into target and limits drug distribution specifically to its target site, thus avoiding systemic effects.
- kits of the disclosure contains one or more of the compositions of the disclosure.
- the kit can further comprise one or more additional reagents, packaging material, containers for holding the components of the kit, and an instruction set or user manual detailing preferred methods of using the kit components for a desired purpose.
- the invention finds application in any instance in which it is desired to deliver a negatively charged molecule (e.g., polynucleotide) to a target cell or a subject.
- a negatively charged molecule e.g., polynucleotide
- a method for delivering a negatively charged molecule to a target cell comprising administering a composition of the present disclosure to the target cell.
- the target cell is an antigen-presenting cell (APC).
- a method for delivering a negatively charged molecule to a subject comprising administering the composition of the present disclosure to the subject.
- compositions of the present disclosure may have applications in the treatment or prevention of a disease.
- Representative applications of the disclosure include cancer treatment and prevention, gene therapy, adjuvant therapy, infectious disease treatment and prevention, allergy treatment and prevention, autoimmune disease treatment and prevention, neuron- degenerative disease treatment, and arteriosclerosis treatment.
- Prevention or treatment of disease includes obtaining beneficial or desired results, including clinical results.
- beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilization of the state of disease, prevention of development of disease, prevention of spread of disease, delay or slowing of disease progression, delay or slowing of disease onset, conferring protective immunity against a disease-causing agent and amelioration or palliation of the disease state.
- Prevention or treatment can also mean prolonging survival of a patient beyond that expected in the absence of treatment and can also mean inhibiting the progression of disease temporarily, although more preferably, it involves preventing the occurrence of disease such as by preventing infection in a subject.
- the antigen encoded by a polynucleotide in the composition of the disclosure may be a cancer or tumor-associated protein, such as for example, a membrane surface-bound cancer antigen which is capable of being recognized by an antibody.
- Cancers that may be treated and/or prevented by the use or administration of a composition of the disclosure include, without limitation, carcinoma, adenocarcinoma, lymphoma, leukemia, sarcoma, blastoma, myeloma, and germ cell tumors.
- the cancer may be caused by a pathogen, such as a virus.
- Viruses linked to the development of cancer are known to the skilled person and include, but are not limited to, human papillomaviruses (HPV), John Cunningham virus (JCV), Human herpes virus 8, Epstein Barr Virus (EBV), Merkel cell polyomavirus, Hepatitis C Virus and Human T cell leukemia virus- 1.
- a composition of the disclosure may be used for either the treatment or prophylaxis of cancer, for example, in the reduction of the severity of cancer or the prevention of cancer recurrences.
- Cancers that may benefit from the compositions of the disclosure include any malignant cell that expresses one or more tumor specific antigens.
- the antigen may be a toxin or an allergen that is capable of being neutralized by an antibody.
- the antigen may be an antigen associated with a disease where it is desirable to sequester the antigen in circulation, such as for example an amyloid protein (e.g., Alzheimer's disease).
- a composition of the disclosure may be suitable for use in the treatment and/or prevention of a neurodegenerative disease in a subject in need thereof, wherein the neurodegenerative disease is associated with the expression of an antigen.
- the subject may have a neurodegenerative disease or may be at risk of developing a neurodegenerative disease.
- Neurodegenerative diseases that may be treated and/or prevented by the use or administration of a composition of the disclosure include, without limitation, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).
- Alzheimer's disease is characterized by the association of B- amyloid plaques and/or tau proteins in the brains of patients with Alzheimer's disease (see, for example, Goedert and Spillantini, Science, 314: 777-781, 2006).
- Herpes simplex virus type 1 has also been proposed to play a causative role in people carrying the susceptible versions of the apoE gene (Itzhaki and Wozniak, J Alzheimers Dis 13: 393-405, 2008).
- the composition may comprise a mixture of B cell epitopes as antigens for inducing a humoral immune response.
- the B cell epitopes may be linked to form a single polypeptide.
- the antigen may be any peptide or polypeptide that is capable of inducing a specific humoral immune response to a specific conformation on targeted tumor cells.
- compositions of the present disclosure may be used to induce humoral and/or cellular immune response in a subject. Accordingly, compositions as described herein may be useful for treating or preventing diseases and/or disorders ameliorated by humoral immune responses (e.g., involving B-cells and antibody production). The compositions may find application in any instance in which it is desired to administer an antigen to a subject to induce a humoral immune response or antibody production.
- a humoral immune response is mediated by secreted antibodies which are produced in the cells of the B lymphocyte lineage (B cells).
- B cells B lymphocyte lineage
- Such secreted antibodies bind to antigens, such as for example those on the surfaces of foreign substances and/or pathogens (e.g., viruses, bacteria, etc.) and flag them for destruction.
- Antibodies are the antigen-specific glycoprotein products of a subset of white blood cells called B lymphocytes (B cells). Engagement of antigen with antibody expressed on the surface of B cells can induce an antibody response comprising stimulation of B cells to become activated, to undergo mitosis and to terminally differentiate into plasma cells, which are specialized for synthesis and secretion of antigen-specific antibody.
- B cells are the sole producers of antibodies during an immune response and are thus a key element to effective humoral immunity. In addition to producing large amounts of antibodies, B cells also act as antigen-presenting cells and can present antigen to T cells, such as T helper CD4 or cytotoxic CD8, thus propagating the immune response. B cells, as well as T cells, are part of the adaptive immune response which is essential for vaccine efficacy. During an active immune response, induced either by vaccination or natural infection, antigen-specific B cells are activated and clonally expand. During expansion, B cells evolve to have higher affinity for the epitope.
- TLRs toll-like receptors
- Antigen presenting cells such as dendritic cells, macrophages and B cells, are drawn to vaccination sites and can interact with antigens and adjuvants contained in the vaccine. The adjuvant stimulates the cells to become activated and the antigen provides the blueprint for the target. Different types of adjuvants provide different stimulation signals to cells. For example, Poly I:C (a TLR3 agonist) can activate dendritic cells, but not B cells.
- Adjuvants such as Pam3Cys, Pam2Cys and FSL-1 are especially adept at activating and initiating proliferation of B cells, which is expected to facilitate the production of an antibody response (Moyle et al., Curr Med Chem, 2008; So., J Immunol, 2012, which are incorporated hereby by reference in their entireties).
- One method of evaluating an antibody response is to measure the titers of antibodies reactive with a particular antigen. This may be performed using a variety of methods known in the art such as enzyme-linked immunosorbent assay (ELISA) of antibody-containing substances obtained from animals. For example, the titers of serum antibodies which bind to a particular antigen may be determined in a subject both before and after exposure to the antigen. A statistically significant increase in the titer of antigen-specific antibodies following exposure to the antigen would indicate the subject had mounted an antibody response to the antigen.
- ELISA enzyme-linked immunosorbent assay
- an antigen-specific antibody include, without limitation, immunological assays (e.g., radioimmunoassay (RIA)), immunoprecipitation assays, and protein blot (e.g., Western blot) assays; and neutralization assays (e.g., neutralization of viral infectivity in an in vitro or in vivo assay).
- immunological assays e.g., radioimmunoassay (RIA)
- immunoprecipitation assays e.g., immunoprecipitation assays
- protein blot e.g., Western blot
- neutralization assays e.g., neutralization of viral infectivity in an in vitro or in vivo assay.
- compositions of the present disclosure by stimulating strong antibody responses, may be capable of protecting a subject from a disease, disorder or ailment associated with an antigen capable of inducing a humoral immune response.
- this includes for example, infectious diseases, cancers involving a membrane surface-bound cancer antigen which is recognized by an antibody, diseases where it is desirable to sequester antigen in circulation, like amyloid protein (e.g., Alzheimer's disease); neutralizing toxins with an antibody; neutralizing viruses or bacteria with an antibody; or neutralizing allergens (e.g., pollen) for the treatment of allergies.
- diseases where it is desirable to sequester antigen in circulation, like amyloid protein (e.g., Alzheimer's disease); neutralizing toxins with an antibody; neutralizing viruses or bacteria with an antibody; or neutralizing allergens (e.g., pollen) for the treatment of allergies.
- amyloid protein e.g., Alzheimer's disease
- neutralizing toxins with an antibody e.g., neutralizing viruses or bacteria with an antibody
- neutralizing allergens e.g., pollen
- a humoral immune response is the main mechanism for effective infectious disease vaccines.
- a humoral immune response can also be useful for combating cancer.
- B cell mediated responses may target cancer cells through other mechanisms which may in some instances cooperate with a cytotoxic CD8 T cell for maximum benefit.
- mechanisms of B cell mediated (e.g., humoral immune response mediated) anti-tumor responses include, without limitation: 1) Antibodies produced by B cells that bind to surface antigens found on tumor cells or other cells that influence tumorigenesis.
- Such antibodies can, for example, induce killing of target cells through antibody-dependent cell-mediated cytotoxicity (ADCC) or complement fixation, potentially resulting in the release of additional antigens that can be recognized by the immune system; 2) Antibodies that bind to receptors on tumor cells to block their stimulation and in effect neutralize their effects; 3) Antibodies that bind to factors released by or associated with tumor or tumor-associated cells to modulate a signaling or cellular pathway that supports cancer; and 4) Antibodies that bind to intracellular targets and mediate anti-tumor activity through a currently unknown mechanism.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the composition may be administered via oral, nasal, rectal or parenteral administration.
- Parenteral administration includes intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular, transepithelial, intrapulmonary, intrathecal, and topical modes of administration.
- the composition is administered via intramuscular, subcutaneous or intradermal injection.
- the amount of composition used in a single treatment may vary depending on factor such as the nature of negatively charged molecule to be delivered, the type of formulation, and the size of the subject.
- factor such as the nature of negatively charged molecule to be delivered, the type of formulation, and the size of the subject.
- One skilled in the art will be able to determine, without undue experimentation, the effective amount of composition to use in a particular application.
- the subject to be treated may be any vertebrate, preferably a mammal, more preferably a human.
- a composition comprising: a) one or more lipids, b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, and d) an ionizable aminoglycoside.
- composition of embodiment 3, wherein the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), di oleoyl phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof.
- DOPC dioleoyl phosphatidylcholine
- DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
- DOPE di oleoyl phosphatidylethanolamine
- DVS 1,2-dipalmitoyl-sn-glycero-3-succinate
- the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin,
- composition of embodiment 6, wherein the ionizable aminoglycoside is chitosan.
- DD degree of deacetylation
- composition of embodiment 11, wherein the chitosan has a degree of deacetylation (DD) of about 25%.
- DD degree of deacetylation
- composition of embodiments 1 and 6-14 comprising: a) one or more positively charged lipids, b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, d) an ionizable aminoglycoside, and e) optionally, an adjuvant.
- composition according to embodiment 16, wherein the one or more positively charged lipids comprise 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 3 ⁇ -[N-(N',N'- dimethylaminoethane)-carbamoyl]cholesterol (DC-chol esterol), 1 ,2-distearoyl-3- dimethylammonium-propane (DAP), N-(4-carboxybenzyl)-N,N-dimethyl-2,3- bis(oleoyloxy)propan-l-aminium (DOBAQ), N-palmitoyl homocysteine (PHC), DC- cholesterol, or a combination thereof.
- DOTAP 1,2-dioleoyl-3-trimethylammonium-propane
- DC-chol esterol 3 ⁇ -[N-(N',N'- dimethylaminoethane)-carbamoyl]cholesterol
- DAP 1,2-distearoy
- composition of any one of embodiments 1-17, wherein the negatively charged molecule is a polynucleotide.
- the composition of any one of embodiments 1-18, wherein the negatively charged molecule is a ribonucleic acid (RNA), or RNA derivative.
- the composition of any one of embodiments 1-18, wherein the negatively charged molecule is a deoxyribonucleic acid (DNA), or DNA derivative.
- the composition of any one of embodiments 18-20, wherein the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme.
- mRNA messenger RNA
- antisense RNA an antisense RNA
- interfering RNA interfering RNA
- catalytic RNA a catalytic RNA
- ribozyme a ribozyme.
- the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
- composition of embodiment 24, wherein the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen, a toxin, or an allergen.
- the composition of embodiment 27, wherein the concentration ratio of the lipids and the negatively charged molecule is about 13200:1.
- the carrier comprises an oil or a water-in-oil emulsion.
- composition of embodiment 29, wherein the oil comprises a natural oil or a synthetic oil.
- the composition of embodiment 30, wherein the oil comprises a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, or combinations thereof.
- the composition of embodiment 31, wherein the carrier comprises a mannide oleate in mineral oil solution.
- the composition of embodiment 32, wherein the carrier comprises Montanide® ISA 51.
- the composition of embodiment 31, wherein the carrier comprises MS80 oil (mixture of mineral oil and Span 80).
- the composition of any one of embodiments 15-34, wherein the adjuvant is a polymer, a protein, a polysaccharide, or a combination thereof.
- composition of any one of embodiments 1-36, wherein the composition is an injectable composition.
- a method for delivering a negatively charged molecule to a target cell comprising administering the composition of any one of embodiments 1-37 to said target cell.
- the method of embodiment 38, wherein the target cell is an antigen-presenting cell (APC).
- a method for delivering a negatively charged molecule to a subject comprising administering the composition of any one of embodiments 1-37 to said subject.
- the negatively charged molecule is a polynucleotide.
- the polynucleotide comprises an mRNA.
- the polynucleotide encodes a polypeptide.
- the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
- the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen or a toxin.
- the method of any one of embodiment 40-46, wherein the composition is administered via subcutaneous, intramuscular or intradermal injection.
- a method for preparing a composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside, comprising: a) dissolving the one or more lipids in one or more organic solvents and optionally an aqueous solvent to create a lipid solution, b) adding the negatively charged molecule to the lipid solution formed in step a) and mixing; c) adding the ionizable aminoglycoside to the mixture formed in step b) and mixing; d) optionally, adding additional amount of the organic solvent(s) or aqueous solvent to the mixture formed in step c) thereby the overall Wt/Wt or V/V percentage ratio of organic: aqueous solvent or aqueous: organic solvent in the mixture is between 20-50%; e) drying the mixture formed in step c) or d) to generate a dried preparation; and f) dissolving the dried preparation in the carrier comprising
- step a) the one or more organic solvents is present in an amount sufficient to prevent the one or more lipids from forming lipid vesicle particles in the lipid solution.
- the one or more organic solvents comprises tert-butanol, ethanol, methanol, chloroform, or a mixture thereof.
- the one or more organic solvent comprises tert-butanol, tert-butanol -ethanol mixture or tert-butanol-chloroform mixture.
- any one of embodiments 49-53 wherein the aqueous solvent is water or a buffer solution.
- the method of any one of embodiments 49-54 wherein the negatively charged molecule is present in an aqueous solution.
- the method of any one of embodiments 49-55 wherein the ionizable aminoglycoside is present in an aqueous solution.
- the method of any one of embodiments 49-56 wherein drying is performed by freeze- drying, spray freeze-drying, spray drying, or rotary evaporation.
- the method of any one of embodiments 49-57 wherein the one or more lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof.
- the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin.
- the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), di oleoyl phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof.
- DOPC dioleoyl phosphatidylcholine
- DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
- DOPE di oleoyl phosphatidylethanolamine
- DRS 1,2-dipalmitoyl-sn-glycero-3-succinate
- the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, diethylaminoethyl (DEAE)-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose- 6,6-dibehenate (TDB) with Dimethyldioctadecylammonium bromide (DDA), heptakis(6- deoxy-6-amino)- ⁇ -cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof.
- DDA Dimethyldioctadecyl
- the method of embodiment 62, wherein the ionizable aminoglycoside is chitosan.
- the method of embodiment 63, wherein the chitosan has a molecular weight of about 60 kDa to 150 kDa.
- the method of embodiment 62 or 63, wherein the chitosan has a molecular weight of about 100 kDa to 120 kDa.
- the method of any one of embodiments 63-66, wherein the chitosan has a degree of deacetylation (DD) of about 15 - 95%.
- DD degree of deacetylation
- chitosan has a degree of deacetylation (DD) of about 25%.
- DD degree of deacetylation
- RNA ribonucleic acid
- the negatively charged molecule is a deoxyribonucleic acid (DNA), or DNA derivative.
- DNA deoxyribonucleic acid
- the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme.
- mRNA messenger RNA
- antisense RNA an antisense RNA
- interfering RNA an interfering RNA
- a catalytic RNA or a ribozyme.
- the polynucleotide comprises an mRNA.
- the polynucleotide encodes a polypeptide.
- polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
- the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen, a toxin, or an allergen.
- the method of any one of embodiments 49-78, wherein the concentration ratio of the lipids and the negatively charged molecule is between about 33000:1 to about 3300:1.
- the method of embodiment 79, wherein the concentration ratio of the lipids and the negatively charged molecule is between about 26400:1 to about 6600:1.
- the method of embodiment 80 wherein the concentration ratio of the lipids and the negatively charged molecule is about 13200:1.
- the carrier comprises an oil or a water-in-oil emulsion.
- the oil comprises a natural oil or a synthetic oil.
- the method of embodiment 83 wherein the oil comprises a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, or combinations thereof.
- the method of embodiment 84 wherein the carrier comprises a mannide oleate in mineral oil solution.
- the method of embodiment 85 wherein the carrier comprises Montanide® ISA 51.
- the method of embodiment 84, wherein the carrier comprises MS80 oil (mixture of mineral oil and Span 80).
- the method of any one of embodiments 49-87, wherein the composition further comprises an adjuvant.
- the method of embodiment 88 wherein the adjuvant is a polymer, a protein, a polysaccharide, or a combination thereof.
- composition further comprises a buffer and/or surfactant.
- composition is an injectable composition.
- kit comprising a composition of any one of embodiments 1-37, and instructions for using said composition to deliver a negatively charged molecule to a subject.
- method of any one of embodiments 40-47 or the kit of embodiment 92, wherein said subject is a human.
- test formulations were prepared with the addition of different lipids, polymers, or transfection agents to the standard formulation (see Formulation Method A). The methods and materials used for preparing each of these formulations are detailed below.
- the vial was then partially stoppered and freeze- dried.
- the freeze-dried cake was then reconstituted with 0.45 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 132 mg/mL, eGFPmRNA 0.1 mg/mL and sodium acetate 0.1 M.
- a 50 ⁇ L of this formulation was injected subcutaneously (SC) in mice.
- eGFP-mRNA 42.5 ⁇ L eGFP-mRNA was added and the solution was gently swirled by hand to mix. 425 ⁇ L of 66 mg/mL DOTAP lipid vesicle particles (Size 87.48 nm, PDI 0.059, pH 5.12) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/ shook by hand to mix and filled to 0.85 mL by adding 170 ⁇ L of DEPC treated water. The final pH of the formulation was pH 7.1. The vial was then partially stoppered and freeze- dried.
- DOTAP lipid vesicle particles Size 87.48 nm, PDI 0.059, pH 5.12
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOTAP 132 mg/mL, eGFPmRNA 0.1 mg/mL and sodium acetate 0.1 M.
- a 50 ⁇ L of this formulation was injected SC in mice.
- eGFP mRNA 42.5 ⁇ L eGFP mRNA was added and the solution was gently swirled by hand to mix.
- 276.25 ⁇ L of DEPC treated water was added followed by the addition of 212.5 ⁇ L of 66 mg/mL DOTAP nanoparticles prepared in DEPC treated water (Size 87.48 nm, PDI 0.059, pH 5.12). The solution was gently swirled/shook by hand to mix.
- the final pH of the formulation was pH 6.90.
- the vial was then partially stoppered and freeze-dried.
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOTAP 33 mg/mL, DOPC/Chol 33 mg/mL, eGFP mRNA 0.1 mg/mL and sodium acetate 0.1 M.
- a 50 ⁇ L of this formulation was injected SC in mice.
- eGFP mRNA 42.5 ⁇ L eGFP mRNA was added and gently swirled by hand to mix. 425 ⁇ L of 66 mg/mL DC- Cholesterol lipid vesicle particles prepared in DEPC treated water (Size 137.3 nm, PDI 0.038, pH 4.08) was added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix. Next, 170 ⁇ L of DEPC treated water was added. The solution was gently swirled/shook by hand to mix. The final pH of the formulation was pH 6.2. The vial was then partially stoppered and freeze-dried.
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DC-Cholesterol 66 mg/mL, eGFP mRNA 0.1 mg/mL and sodium acetate 0.1 M.
- a 50 ⁇ L of this formulation was injected SC in mice.
- the percent of GFP positive cells in the site of injection was determined on SD8 ( Figures 2 and 3) and Day 14 ( Figure 4) after injection. It was shown that addition of chitosan polymer (Figure 2) or using cationic lipids DOTAP ( Figure 3), DC-Cholesterol ( Figure 4) in the formulation strongly enhance mRNA delivery to cells compared to the standard formulation.
- Test formulations were prepared with the addition of different amounts of chitosan and DOTAP to the standard formulation (see Formulation Method A).
- a modified formulation method (Formulation Method B) was used. The methods and materials used for preparing each of these formulations are detailed below.
- the freeze-dried cake was then reconstituted with 0.369 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 132 mg/mL, eGFP mRNA 0.1 mg/mL and sodium acetate 0.1 M.
- a 50 ⁇ L of this formulation was injected SC in mice.
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOTAP 66 mg/mL, eGFP mRNA 0. 1 mg/mL and sodium acetate 0.1 M. A 50 ⁇ L of this formulation was injected SC in mice.
- eGFP mRNA 42.5 ⁇ L eGFP mRNA was added and the solution was gently swirled by hand to mix. 425 ⁇ L of 132 mg/mL DOTAP lipid vesicle particles (Size 116.5 nm, PDI 0.125) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix and filled to 0.85 mL by adding 170 ⁇ L of DEPC treated water. The final pH of the formulation was pH 6.37. The vial was then partially stoppered and freeze-dried.
- DOTAP lipid vesicle particles Size 116.5 nm, PDI 0.125
- the freeze-dried cake was then reconstituted with 0.369 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOTAP 66 mg/mL, eGFP mRNA 0. 1 mg/mL and sodium acetate 0.1 M. A 50 ⁇ L of this formulation was injected SC in mice.
- eGFP mRNA 42.5 ⁇ L eGFP mRNA was added and the solution was gently swirled by hand to mix. 212.5 ⁇ L of 132 mg/mL DOPC/Chol lipid vesicle particles (Size 81.02 nm, PDI 0.053, pH 6.77) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix. 42.5 ⁇ L of chitosan stock (60-120 kDa/ 15-25% DD, 10 mg/mL in 0.25% Acetic Acid) was added and the pH was adjusted from 5.91 to 6.15 with 10 ⁇ L 0.1 M NaOH.
- chitosan stock 60-120 kDa/ 15-25% DD, 10 mg/mL in 0.25% Acetic Acid
- the solution was filled to 0.85 mL by adding 330 ⁇ L of DEPC treated water and freeze-dried.
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL, chitosan 1 mg/mL and sodium acetate 0. 1 M.
- a 50 ⁇ L of this formulation was injected SC in mice.
- eGFP mRNA 42.5 ⁇ L eGFP mRNA was added and the solution was gently swirled by hand to mix.
- the solution was gently swirled/shook by hand to mix.
- 85 ⁇ L of chitosan stock 60-120 kDa/ 15-25% DD, 10 mg/mL in 0.25% Acetic Acid
- adjusted the pH from 5.36 to 6.21 with 40 ⁇ L 0.1 M NaOH was added.
- the solution was filled to 0.85 mL by adding 257.5 ⁇ L of DEPC treated water and freeze-dried.
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL, chitosan 2 mg/mL and sodium acetate 0.1 M.
- a 50 ⁇ L of this formulation was injected SC in mice.
- chitosan stock 100 kDa/ 25% DD, 5 mg/mL in 0.25% Acetic Acid
- the solution was filled to 0.85 mL by adding 282.5 ⁇ L of DEPC treated water and freeze-dried.
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL, chitosan 1 mg/mL and sodium acetate 0.1 M.
- a 50 ⁇ L of this formulation was injected SC in mice.
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL and chitosan 1 mg/mL.
- a 50 ⁇ L of this formulation was injected SC in mice.
- the freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL and chitosan 2 mg/mL.
- a 50 ⁇ L of this formulation was injected SC in mice.
- Groups 1, 2 and 4-6 received the respective lipid formulations via subcutaneous injection in the right flank.
- Mice were sacrificed on Day 15 followed by collection of cells from the SOI, spleen and right inguinal lymph nodes. The spleen and the lymph node samples were assessed for interferon-gamma (IFN-y) release using an enzyme-linked immune absorbent spot (ELISpot) assay.
- the SOI samples were analyzed for the immune cell composition present in the sample using flow cytometry.
- the ELISpot assay was performed as previously described (Weir et al, Oncoimmunology. 2014 Nov 14;3(8):e953407). Briefly, syngeneic dendritic cells (DCs) were prepared by culturing bone marrow derived cells with GM-CSF for 8 days, on study day 14 DCs were loaded with OVA peptide SIINFEKL (SEQ ID NO: 6) or an irrelevant peptide, or remained unloaded and used as antigen presenting cells for the ELISpot assay. On study day 15, single cell suspensions of lymph nodes were prepared in complete RPMI media.
- DCs syngeneic dendritic cells
- Lymph node cells and DCs were added to ELISpot plates (BD Bioscience) and incubated overnight at 37°C, 5% CO2. Plates were developed the next day as per the manufacturer’s instructions using AEC substrate (Sigma-Aldrich). Spots were enumerated using an ImmunoSpot Analyzer (C.T.L. Ltd, Shaker Heights, OH) as the number of spot-forming units (SFU) per well.
- An IFN-y ELISpot performed using splenocytes had the following modifications.
- Single cell suspensions of splenocytes were prepared by lysing RBCs with ammonium- chloride-potassium solution; cells were added into ELISpot plates and stimulated with OVA peptide SIINFEKL (SEQ ID NO: 6) or an irrelevant peptide, or remained unstimulated.
- OVA peptide SIINFEKL SEQ ID NO: 6
- Tissues from the site of injection were collected and processed by crushing in PBS buffer, centrifuging and resuspending in PBS buffer. Cells were stained using basic surface IMF staining protocol and antibody panel in Table 4. Multi-parametric flow cytometry analysis was performed using FACS Celesta and FlowJo software.
- composition of the formulations listed in Table 1 is detailed in Tables 2A and 2B.
- mRNA containing formulations were prepared using OVA mRNA stock according to specifications described in the previous example.
- Lipid-peptide control formulation listed in Table 2B was prepared by adding 80 ⁇ L of OVA peptide stock (5 mg/mL in sterile RNase free water) to 200 ⁇ L sodium acetate 200 mM, pH 7.0. To the diluted peptide stock solution, 400 ⁇ L lipid vesicle particles (132 mg/mL DOPC/Chol prepared in sterile RNase free water, particle size 89.27 nm and PDI 0.088) was added, mixed well by vortexing for 30 seconds. The pH was adjusted to 7.03 with 0.1 M NaOH before the addition of 16 ⁇ L poly dldC adjuvant stock (10 mg/mL in sterile RNase free water).
- the final formulation volume was then filled to 0.8 mL by adding 97 ⁇ L of RNase free water, mixed well by vortexing for 30 seconds.
- the vial was then partially stoppered and freeze-dried.
- the freeze-dried cake was then reconstituted with 0.35 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 132 mg/mL, OVA peptide 1 mg/mL, dldC adjuvant 0.4 mg/mL and sodium acetate 0.1 M.
- a 50 ⁇ L of this formulation was injected subcutaneously (SC) in mice.
- OVA mRNA has 1437 nucleotides and encodes the full-length ovalbumin.
- nucleic acid extraction was carried out as follows: aliquoted sample (25 ⁇ L) was diluted with 0.1 M sodium bicarbonate (50 ⁇ L). To this diluted sample, water- saturated 1 -butanol (75 ⁇ L) was added, vortexed for 15 seconds and centrifuged for 2 minutes at 5,500 rpm. Using a gel-loading pipette tip, a portion of the bottom layer was collected for nucleic acid analysis. Nucleic acid quantity was measured by UV spectroscopy. mRNA and DNA integrity was assessed by gel electrophoresis assay. mRNA and DNA expression efficiency was evaluated in transient transfection experiments.
- Nucleic acid quantity as measured by UV spectroscopy using NanoDrop OneC spectrophotometer is shown in Figure 10A for mRNA and in Figure 10B for DNA. The data accompanying the figures are also shown in Tables 5 A and 5B. No substantial changes in nucleic acid quantity was observed over time.
- RNA integrity 1 pg of eGFP mRNA after butanol extraction was resolved on 0.8% agarose denaturing gel, visualized by staining with ethidium bromide and photographed. Intact eGFP mRNA was loaded on the same gel and used as a positive control.
- mice were immunized SC with a mix of E7 and eGFP mRNA formulated in lipid formulation or with lipid formulation containing no RNA (negative control, Empty).
- Formulations were prepared using Formulation Method A described in Examples 1 or 2 and reconstituted in Montanide® ISA 51 oil diluent.
- SOIs were collected and processed for mRNA extraction.
- Total mRNA was purified using RNeasy Mini Kit (Qiagen) and used in RT-PCR to evaluate mRNA integrity and in transient transfections to determine the capacity of the extracted RNA to produce functional protein.
- E7 transcript was amplified via RT-PCR. Briefly, extracted RNA was quantified using a Nanodrop and processed for reverse transcription of eluted RNA to cDNA. Template cDNA was then used in PCR to amplify E7 and GAPDH transcripts (positive control; data not shown) using primers listed in Table 6. E7 transcript was amplified using primers specific to the 5’ and 3’ ends of E7 mRNA. Amplifications were performed using the HotStarTaq DNA Polymerase kit (Qiagen) according to the manufacturer’s instructions.
- PCRs were performed in a thermocycler using the following conditions: initial denaturing (95°C) for 15 min, 40 cycles of denaturing (94°C) for 1 min, annealing (57°C) for 30 sec, and elongation (72°C) for 1 min. PCR products were resolved on a 1% agarose gel, visualized by staining with ethidium bromide and photographed.
- RNA extracted from SOIs was used to transfect 293T cells using LipofectamineTM Messenger MAXTM Transfection Reagent (Invitrogen). 48 hours after transfection cells were harvested and flow cytometry analysis was performed using FACS Celesta and FlowJo software to evaluate GFP expression.
- RNA instability is known to be one of the factors that hinder the application of RNA- based therapeutics. Exogenous RNA tends to be rapidly eliminated from the body due to degradation by RNase, exonuclease, or endonuclease, or via renal or hepatic clearance.
- the studies described in this Example showed that intact mRNA and plasmid DNA are present in the lipid formulations after 14-day incubation at 37° C in vitro, however the integrity of mRNA and DNA gradually decreases.
- mRNA is stable in vivo in the lipid formulation for up to 14 days as assessed by RT-PCR and transfection. As a result of these two studies, it can be concluded that mRNA formulated in the lipid formulation described herein is stable for at least
Abstract
The present disclosure provides liposomal compositions comprising lipids, in particular phospholipids and cholesterol, a negatively charged biomolecule, such as a polynucleotide, an ionizable aminoglycoside, such as chitosan, and an oil-based carrier. The compositions can be used for delivery of the biomolecule to targeted cells. The disclosure also provides the use of the composition for the treatment or prevention of cancer or infectious disease or ailment ameliorated by humoral and cellular immune response. The compositions can also be used for expressing polypeptides encoded by the nucleic acid components in the targeted cells.
Description
LIPID COMPOSITIONS COMPRISING POLYNUCLEOTIDE ANTIGENS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63/084,179, filed September 28, 2020, the disclosure of which is herein incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to lipids compositions for delivery of negatively charged molecules such as a polynucleotide. The present invention also relates to use of such compositions for delivering a negatively charged molecule (e.g., polynucleotide) to a subject.
BACKGROUND
[0003] Effective delivery of nucleic acids into target cells remains a key problem preventing the clinical application of nucleic acid-based therapies. Such nucleic acids may be, for example, sequences encoding a gene product or instead short sequences of nucleotides that correspond to the sense or antisense sequence of specific genes or their products and hence have a direct effect on the expression of these genes and/or their products.
[0004] Nucleic acid delivery presents unique challenges due to their molecular size, electric charge, and significant susceptibility to enzymatic degradation. There continues to exist problems in delivering nucleic acids to the correct target site and to a sufficient number of target cells. A wide variety of delivery methods have been proposed, including microinjection, scrape loading, and receptor-mediated endocytosis. Lipid-based delivery systems, including those involving the use of liposomes, are frequently used to package therapeutic nucleic acids. However, the use of lipids alone may pose problems such as poor encapsulation efficacy and rapid clearance from circulation. There may also be problems in packaging enough nucleic acid molecules without increasing the size of the particle to the point where delivery to the target tissues is impaired.
[0005] Accordingly, there exists a need to improve lipid-based delivery systems for efficient delivery of nucleic acids to the correct target site.
SUMMARY OF THE INVENTION
[0006] The present disclosure provides, among other things, lipid compositions suitable for the delivery of negatively charged molecules (e.g., polynucleotides). Methods of using such
lipid compositions for delivering a negatively charged molecule to a target cell or a subject, or for treatment of a disorder or a disease are also provided. Further provided are methods of preparing the lipid compositions and kits comprising the lipid compositions.
[0007] In one aspect, provided herein is a composition, comprising: a) one or more lipids, b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, and d) an ionizable aminoglycoside.
[0008] In some embodiments, the lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof. In some embodiments, the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin. In some embodiments, the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3- phosphocholine (DPPC), dioleoyl phosphatidylethanolamine (DOPE), 1 ,2-dipalmitoyl-sn- glycero-3-succinate (DGS), or a combination thereof. In some embodiments, the one or more lipids comprise DOPC and cholesterol.
[0009] In some embodiments, the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, DEAE-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose-6,6-dibehenate (TDB) with Dimethyldioctadecylammonium bromide (DDA), heptakis(6-deoxy-6-amino)-β-cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof.
[0010] In some embodiments, the ionizable aminoglycoside is chitosan. In some embodiments, the chitosan has a molecular weight of about 60 kDa to 150 kDa (e.g., about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, or about 150 kDa). In some embodiments, the chitosan has a molecular weight of about 100 kDa to 120 kDa. In one embodiment, the chitosan has a molecular weight of about 100 kDa. In some embodiments, the chitosan has a degree of deacetylation (DD) of about 15 - 95%. In one embodiment, the chitosan has a degree of deacetylation (DD) of about 25%.
[0011] In some embodiments, the chitosan is added in a concentration of about 0.5 mg/mL to about 3 mg/mL (e.g., about 0.5 mg/mL, about 0.75 mg/mL, about 1 mg/mL, about 1.25 mg/mL, about 1.5 mg/mL, about 1.75 mg/mL, about 2 mg/mL, about 2.25 mg/mL, about 2.5
mg/mL, about 2.75 mg/mL or about 3 mg/mL). In some embodiments, the chitosan is added in a concentration of about 1 mg/mL to about 2 mg/mL.
[0012] In some embodiments, the composition described above further comprises an adjuvant.
[0013] In some embodiments, provided herein is a composition, comprising: a) one or more positively charged lipids, b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, d) an ionizable aminoglycoside, and e) optionally, an adjuvant.
[0014] In some embodiments, the one or more positively charged lipids comprise 1,2- dioleoyl-3-trimethylammonium-propane (DOTAP), 3β-[N-(N',N'-dimethylaminoethane)- carbamoyl] cholesterol (DC-cholesterol), 1,2-distearoyl-3-dimethylammonium-propane (DAP), N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-l-aminium (DOBAQ), N-palmitoyl homocysteine (PHC), DC-cholesterol, or a combination thereof.
[0015] In some embodiments, the negatively charged molecule is a polynucleotide. In some embodiments, the negatively charged molecule is a ribonucleic acid (RNA), or RNA derivative. In some embodiments, the negatively charged molecule is a deoxyribonucleic acid (DNA), or DNA derivative. In some embodiments, the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme. In some embodiments, the polynucleotide comprises an mRNA.
[0016] In some embodiments, the polynucleotide encodes a polypeptide. In some embodiments, the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor. In some embodiments, the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen, a toxin, or an allergen.
[0017] In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 33000:1 to about 3300:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 30800:1 to about 4400:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 28600:1 to about 5500:1. In some
embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 26400:1 to about 6600:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 24200:1 to about 7700:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 22000:1 to about 8800:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 19800:1 to about 9900:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 17600:1 to about 11000: 1. As anon-limiting example, the concentration ratio of the lipids and the negatively charged molecule may be about 4400:1, 5500:1, 6600:1, 7700:1, 8800:1, 9900:1, 11000:1, 12100:1, 13200:1, 14300:1, 15400:1, 16500:1, 17600:1, 18700:1, 19800:1, 22000:1, 23100:1, 24200:1, 25300:1, 26400:1, 27500:1, 28600:1, 29700:1, 30800:1, 31900:1, or 33000:1. In one embodiment, the concentration ratio of the lipids and the negatively charged molecule is about 13200:1.
[0018] In some embodiments, the carrier comprises an oil or a water-in-oil emulsion. [0019] In some embodiments of the composition, a) the one or more lipids comprise DOPC and cholesterol, b) the negatively charged molecule is a polynucleotide, c) the carrier comprises an oil or a water-in-oil emulsion, and d) the ionizable aminoglycoside is chitosan.
[0020] In some embodiments, the oil comprises a natural oil or a synthetic oil. In some embodiments, the oil comprises a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, or combinations thereof. In some embodiments, the carrier comprises a mannide oleate in mineral oil solution. In some embodiments, the carrier comprises Montanide® ISA 51. In some embodiments, the carrier comprises MS80 oil (mixture of mineral oil and Span 80). [0021] In some embodiments, the adjuvant is a polymer, a protein, a polysaccharide, or a combination thereof.
[0022] In some embodiments, the composition further comprises a buffer and/or surfactant. [0023] In some embodiments, the composition is an injectable composition.
[0024] In another aspect, provided herein is a method for delivering a negatively charged molecule to a target cell, comprising administering the composition of any one of the embodiments above to said target cell. In some embodiments, the target cell is an antigen- presenting cell (APC).
[0025] In another aspect, provided herein is a method for delivering a negatively charged molecule to a subject, comprising administering the composition of any one of the embodiments above to said subject.
[0026] In another aspect, provided herein is a method for treating or preventing cancer, an infectious disease or an disease and/or disorder ameliorated by humoral and/or cellular immune response in a subject in need thereof, said method comprising administering to the subject an effective amount of the composition of composition of any one of the embodiments above. In some embodiments, the negatively charged molecule is a polynucleotide. In some embodiments, the polynucleotide comprises an mRNA. In some embodiments, the polynucleotide encodes a polypeptide. In some embodiments, the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor. In some embodiments, the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen or a toxin. In some embodiments, the composition is administered via subcutaneous, intramuscular or intradermal injection.
[0027] In another aspect, provided herein is a method for preparing a composition of any of the embodiments described above.
[0028] In another aspect, provided herein is a method for preparing a composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside, comprising: a) dissolving the one or more lipids in one or more organic solvents and optionally an aqueous solvent to create a lipid solution, b) adding the negatively charged molecule to the lipid solution formed in step a) and mixing; c) adding the ionizable aminoglycoside to the mixture formed in step b) and mixing; d) optionally, adding additional amount of the organic solvent(s) or aqueous solvent to the mixture formed in step c) thereby the overall Wt/Wt or V/V percentage ratio of organic: aqueous solvent or aqueous: organic solvent in the mixture is between 20-50%; e) drying the mixture formed in step c) or d) to generate a dried preparation; and
f) dissolving the dried preparation in the carrier comprising a continuous phase of a hydrophobic substance, thereby generating said composition.
[0029] In some embodiments of the method of preparing a composition described herein, in step a) the one or more organic solvents is present in an amount sufficient to prevent the one or more lipids from forming lipid vesicle particles in the lipid solution. In some embodiments, the organic solvent is tert-butanol, ethanol, methanol, chloroform, or a mixture thereof. In some embodiments, the organic solvent is tert-butanol, tert-butanol-ethanol mixture or tert-butanol-chloroform mixture. In some embodiments, the lipid solution comprises about 30% tert-butanol.
[0030] In some embodiments of the method of preparing a composition described herein, the aqueous solvent is water or a buffer solution.
[0031] In some embodiments of the method of preparing a composition described herein, drying is performed by freeze-drying, spray freeze-drying, spray drying, or rotary evaporation.
[0032] In some embodiments of the method of preparing a composition described herein, the lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof. In some embodiments, the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin. In some embodiments, the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), dioleoyl phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof. In some embodiments, the one or more lipids comprise DOPC and cholesterol.
[0033] In some embodiments of the method of preparing a composition described herein, the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, DEAE-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose- 6,6-dibehenate (TDB) with Dimethyldioctadecylammonium (DDA), heptakis(6-deoxy-6- amino)-β-cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof.
[0034] In some embodiments of the method of preparing a composition described herein, the ionizable aminoglycoside is chitosan. In some embodiments, the chitosan has a molecular weight of about 60 kDa to 150 kDa (e.g., about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, or
about 150 kDa). In some embodiments, the chitosan has a molecular weight of about 100 kDa to 120 kDa. In one embodiment, the chitosan has a molecular weight of about 100 kDa. In some embodiments, the chitosan has a degree of deacetylation (DD) of about 15 - 95%. In one embodiment, the chitosan has a degree of deacetylation (DD) of about 25%.
[0035] In some embodiments of the method of preparing a composition described herein, the chitosan is added in a concentration of about 0.5 mg/mL to about 3 mg/mL (e.g., about 0.5 mg/mL, about 0.75 mg/mL, about 1 mg/mL, about 1.25 mg/mL, about 1.5 mg/mL, about 1.75 mg/mL, about 2 mg/mL, about 2.25 mg/mL, about 2.5 mg/mL, about 2.75 mg/mL or about 3 mg/mL). In some embodiments, the chitosan is added in a concentration of about 1 mg/mL to about 2 mg/mL.
[0036] In some embodiments of the method of preparing a composition described herein, the negatively charged molecule is a polynucleotide. In some embodiments, the negatively charged molecule is a ribonucleic acid (RNA), or RNA derivative. In some embodiments, the negatively charged molecule is a deoxyribonucleic acid (DNA), or DNA derivative. In some embodiments, the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme. In some embodiments, the polynucleotide comprises an mRNA.
[0037] In some embodiments of the method of preparing a composition described herein, the polynucleotide encodes a polypeptide. In some embodiments, the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor. In some embodiments, the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen, a toxin, or an allergen.
[0038] In some embodiments of the method of preparing a composition described herein, the concentration ratio of the lipids and the negatively charged molecule is between about 33000:1 to about 3300:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 30800: 1 to about 4400: 1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 28600:1 to about 5500:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 26400:1 to about 6600:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule
is between about 24200:1 to about 7700:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 22000:1 to about 8800:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 19800:1 to about 9900:1. In some embodiments, the concentration ratio of the lipids and the negatively charged molecule is between about 17600:1 to about 11000:1. As a non-limiting example, the concentration ratio of the lipids and the negatively charged molecule may be about 4400:1, 5500:1, 6600:1, 7700:1, 8800:1, 9900:1, 11000:1, 12100:1, 13200:1, 14300:1, 15400:1, 16500:1, 17600:1, 18700:1, 19800:1, 22000:1, 23100:1, 24200:1, 25300:1, 26400:1, 27500:1, 28600:1, 29700:1, 30800:1, 31900:1, or 33000: 1. In one embodiment, the concentration ratio of the lipids and the negatively charged molecule is about 13200:1.
[0039] In some embodiments of the method of preparing a composition described herein, the carrier comprises an oil or a water-in-oil emulsion.
[0040] In some embodiments of the method of preparing a composition described herein, a) the one or more lipids comprise DOPC and cholesterol, b) the negatively charged molecule is a polynucleotide, c) the carrier comprises an oil or a water-in-oil emulsion, and d) the ionizable aminoglycoside is chitosan.
[0041] In some embodiments, the oil comprises a natural oil or a synthetic oil. In some embodiments, the oil comprises a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, or combinations thereof. In some embodiments, the carrier comprises a mannide oleate in mineral oil solution. In some embodiments, the carrier comprises Montanide® ISA 51. In some embodiments, the carrier comprises MS80 oil (mixture of mineral oil and Span 80). [0042] In some embodiments of the method of preparing a composition described herein, the composition further comprises an adjuvant. In some embodiments, the adjuvant is a polymer, a protein, a polysaccharide, or a combination thereof.
[0043] In some embodiments of the methods of preparing a composition described herein, the composition further comprises a buffer and/or surfactant.
[0044] In some embodiments of the methods of preparing a composition described herein, the composition is an injectable composition.
[0045] In another aspect, provided herein is a kit comprising a composition of any one of the embodiments above, and instructions for using said composition to deliver a negatively charged molecule to a subject.
[0046] In various embodiments, the subject is a mammal. In some embodiments, the subject is a human.
[0047] These and other aspects of the present invention will be apparent to those of ordinary skill in the art in the following description, claims and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 depicts a schematic of the nucleic acid delivery using an exemplary lipid vesicle particle of the present disclosure.
[0049] Figure 2 shows green fluorescent protein (GFP) expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing different polymers and transfection agents. Sample 1 : formulation method A (standard) without addition of different polymers and transfection agents.
[0050] Figure 3 shows GFP expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing 1,2-dioleoyl-3-trimethylammonium- propane (DOTAP). Sample 1: formulation method A (standard) without addition of 1,2- dioleoyl-3-trimethylammonium-propane (DOTAP).
[0051] Figure 4 shows GFP expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing DC-Cholesterol. Sample 1: formulation method A (standard) without addition of DC-Cholesterol.
[0052] Figure 5 shows GFP expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing DOTAP. Sample 1 : formulation method A (standard) without addition of DOTAP.
[0053] Figure 6 shows GFP expression levels at the site of injection after administration of eGFP mRNA loaded lipid vesicle particles containing chitosan. Sample 1: formulation method A (standard) without addition of chitosan.
[0054] Figure 7A-7B show antigen-specific interferon-gamma (IFN-γ) response in the spleens (Figure 7A) and lymph nodes (Figure 7B) collected from mice receiving the indicated lipid formulations. The IFN-y response was determined using an enzyme-linked immunospot (ELISpot) assay.
[0055] Figure 8A-8B show immune profiles of site of injections (SOIs) collected from mice receiving the indicated lipid formulations.
[0056] Figure 9 shows the study design of an in vitro stability study of lipid-nucleic acid formulations.
[0057] Figure 10A-10B show mRNA (Figure 10A) and DNA (Figure 10B) quantities in the investigated lipid-nucleic acid formulations as measured by UV spectroscopy.
[0058] Figure 11A-11B show gel electrophoresis analyses of mRNA (Figure 11A) and DNA (Figure 11B) in the investigated lipid-nucleic acid formulations.
[0059] Figures 12A-12B show quantification of RNA or DNA expression efficiency (Figure 12A) evaluated in transient transfection experiments as well as representative fluorescence microscopy images (Figure 12B).
[0060] Figure 13 shows the study design of an in vivo stability study of lipid-mRNA formulations.
[0061] Figures 14A-14B show that mRNA formulated in the investigated lipid-mRNA formulation is stable for up to 14 days in vivo. Figure 14A shows evaluation of E7 mRNA integrity by detection of E7 transcripts using RT-PCR and gel electrophoresis. Complete sequence of the E7 transcript was amplified via RT-PCR from total RNA extracted from SOIs. Figure 14B shows quantification of GFP expression in cells transfected with total RNA extracted from SOIs.
DETAILED DESCRIPTION
[0062] The present disclosure provides, among other things, lipid vesicle particles that facilitate delivery of molecules (e.g., polynucleotides) into a biological system, for example into cells such as mammalian cells.
Definitions
[0063] As used herein, the term "lipid vesicle particle" may be used interchangeably with "lipid vesicle". A lipid vesicle particle refers to a complex or structure having an internal environment separated from the external environment by a continuous layer of enveloping lipids. In the context of the present disclosure, the expression "layer of enveloping lipids" can mean a single layer lipid membrane (e.g., as found on a micelle or reverse micelle), a bilayer lipid membrane (e.g., as found on a liposome) or any multilayer membrane formed from single and/or bilayer lipid membranes. The layer of enveloping lipids is typically a single layer, bilayer or multilayer throughout its circumference, but it is contemplated that other conformations may be possible such that the layer has different configurations over its circumference. The lipid vesicle particle may contain, within its internal environment, other vesicle structures (i.e., it may be multivesicular).
[0064] The term "lipid vesicle particle" encompasses many different types of structures, including without limitation micelles, reverse micelles, unilamellar liposomes, multilamellar
liposomes and multivesicular liposomes. The lipid vesicle particles may take on various different shapes, and the shape may change at any given time (e.g., upon sizing, mixing with the second therapeutic agent, and/or drying). Typically, lipid vesicle particles are spherical or substantially spherical structures. By "substantially spherical" it is meant that the lipid vesicle particles are close to spherical, but may not be a perfect sphere. Other shapes of the lipid vesicle particles include, without limitation, oval, oblong, square, rectangular, triangular, cuboid, crescent, diamond, cylinder or hemisphere shapes. Any regular or irregular shape may be formed. Further, a single lipid vesicle particle may comprise different shapes if it is multivesicular. For example, the outer vesicle shape may be oblong or rectangular while an inner vesicle may be spherical.
[0065] The lipid vesicle particles may be formed from single layer lipid membranes, bilayer lipid membranes and/or multilayer lipid membranes. The lipid membranes are predominantly comprised of and formed by lipids, but may also comprise additional components. For example, and without limitation, the lipid membrane may include stabilizing molecules to aid in maintaining the size and/or shape of the lipid vesicle particle. Any stabilizing molecule known in the art may be used so long as it does not negatively affect the ability of the lipid vesicle particles to be used in the disclosed methods.
[0066] Depending on the definition ascribed to lipid nanoparticles, the lipid vesicle particles of the present disclosure may be synonymous with lipid nanoparticles. However, there are contrasting views in the art on the meaning of the term “lipid nanoparticle”. One view is that a lipid nanoparticle refers to any nano-sized particle (i.e. , having a diameter of between 1 nanometer and 1000 nanometers) formed by a lipid membrane. Another view is that the size threshold for a nanoparticle material is limited to between 1 nanometer and 100 nanometers. This latter definition excludes lipid vesicle sizes that are encompassed by the present disclosure (e.g., lipid vesicle particles >100 nm in size), and to this extent is inconsistent with the term “lipid vesicle particles” as used in the present disclosure.
[0067] The term "lipid" has its common meaning in the art in that it is any organic substance or compound that is soluble in nonpolar solvents, but generally insoluble in polar solvents (e.g., water). Lipids are a diverse group of compounds including, without limitation, fats, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides and phospholipids. For the lipid vesicle particles herein, any lipid may be used so long as it is a membrane-forming lipid. The lipid vesicle particles may comprise a single type of lipid or two or more different types of lipids.
[0068] The term “negatively charged molecule” as used herein, includes molecules such as naturally occurring and chemically modified nucleic acid molecules (e.g., RNA, DNA, polynucleotides, oligonucleotides, mixed polymers, peptide nucleic acid, and the like), peptides (e.g., polyaminoacids, polypeptides, proteins and the like), nucleotides, pharmaceutical and biological compositions, that have negatively charged groups.
[0069] As used herein the term “polynucleotide” encompasses a chain of nucleotides of any length (e.g., 9, 12, 18, 24, 30, 60, 150, 300, 600, 1500, 2000, 2500, 3000, 4000, 5000, 6000, 7000, 8000 or more nucleotides) or number of strands (e.g., single-stranded or doublestranded). Polynucleotides may be DNA (e.g., genomic DNA or cDNA) or RNA (e.g., mRNA, siRNA, miRNA, shRNA, self-amplifying RNA) or combinations thereof. They may be naturally occurring or synthetic (e.g., chemically synthesized). It is contemplated that the polynucleotide may contain modifications of one or more nitrogenous bases, pentose sugars or phosphate groups in the nucleotide chain. Such modifications are well-known in the art and may be for the purpose of e.g., improving stability of the polynucleotide.
[0070] As used herein, the term “polypeptide” or “protein” means any chain of amino acids, regardless of length (e.g., 4, 6, 8, 10, 20, 50, 100, 200, 500 or more amino acids) or post- translational modification (e.g., glycosylation or phosphorylation). Both terms are used interchangeably.
[0071] The term “ionizable aminoglycoside” refers to any poly amino sugar having the ability to bind with a negatively charged molecule (e.g., polynucleotide such as RNA) through electrostatic interactions. The polyamino sugar may be naturally occurring, semi-synthetic, or fully synthetic. Through interaction with the negatively charged molecule such as a polynucleotide (e.g., RNA), the ionizable aminoglycoside may protect the polynucleotide (e.g., RNA) from nuclease attack.
[0072] The term “adjuvant” refers to a compound or mixture that enhances the immune response to an antigen.
[0073] As used herein, the term "antigen" refers to any substance or molecule that can bind specifically to components of the immune system. In some embodiments, suitable antigens are those that are capable of inducing or generating an immune response in a subject. An antigen that is capable of inducing an immune response is said to be immunogenic, and may also be called an immunogen. Thus, as used herein, the term "antigen" includes immunogens and the terms may be used interchangeably unless specifically stated otherwise.
[0074] A “toxin”, as used herein, refers to any substance produced by living cells or organisms (e.g., plants, animals, microorganisms, etc.) that is capable of causing a disease or
ailment, or an infectious substance, or a recombinant or synthesized molecule capable of adverse effect. Toxins may be for example small molecules (e.g., cocaine), peptides, or proteins.
[0075] An “allergen”, as used herein, refers to any substance that can cause an allergy.
[0076] An “antibody” is a protein comprising one or more polypeptides substantially or partially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the κ, λ. α, γ, ε and μ constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either K or X. Heavy chains are classified as γ, μ. α, δ, or ε, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. A typical immunoglobulin (antibody) structural unit comprises a protein containing four polypeptides. Each antibody structural unit is composed of two identical pairs of polypeptide chains, each having one “light” and one “heavy” chain. The N-terminus of each chain defines a variable region primarily responsible for antigen recognition. Antibody structural units (e.g., of the IgA and IgM classes) may also assemble into oligomeric forms with each other and additional polypeptide chains, for example as IgM pentamers in association with the J-chain polypeptide.
[0077] As used herein, the terms “cancer”, “cancer cells”, “tumor” and “tumor cells”, (used interchangeably) refer to cells that exhibit abnormal growth, characterized by a significant loss of control of cell proliferation or cells that have been immortalized. The term “cancer” or “tumor” includes metastatic as well as non-metastatic cancer or tumors. A cancer may be diagnosed using criteria generally accepted in the art, including the presence of a malignant tumor.
[0078] “Treating” or “treatment of”, or “preventing” or “prevention of”, as referred to herein refers to an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilization of the state of disease, prevention of development of disease, prevention of spread of disease, delay or slowing of disease progression, delay or slowing of disease onset, conferring protective immunity against a disease-causing agent and amelioration or palliation of the disease state. “Treating” or “preventing” can also mean prolonging survival of a patient beyond that expected in the absence of treatment and can also mean inhibiting the progression of disease temporarily, although more preferably, it involves preventing the occurrence of disease such as by preventing infection in a subject.
[0079] The term “effective amount” as used herein means an amount effective, at dosages and for periods of time necessary, to achieve the desired result.
[0080] As used herein, to “induce” an immune response is to elicit and/or potentiate an immune response. Inducing an immune response encompasses instances where the immune response is enhanced, elevated, improved or strengthened to the benefit of the host relative to the prior immune response status, for example, before the administration of a composition of the disclosure.
[0081] As used herein, the term “antibody response” refers to an increase in the amount of antigen-specific antibodies in the body of a subject in response to introduction of the antigen into the body of the subject.
[0082] “Humoral immune response” as referred to herein relates to antibody production and the accessory processes that accompany it, such as for example T-helper 2 (Th2) cell activation and cytokine production, isotype switching, affinity maturation and memory cell activation. It also refers to the effector functions of an antibody, such as for example toxin neutralization, classical complement activation, and promotion of phagocytosis and pathogen elimination. The humoral immune response is aided by CD4+Th2 cells and therefore the activation or generation of this cell type is also indicative of a humoral immune response as referred to herein.
[0083] A “humoral immune response” as referred to herein may also encompass the generation and/or activation of T-helper 17 (Thl7) cells. Thl7 cells are a subset of helpereffector T-lymphocytes characterized by the secretion of host defense cytokines such as IL-17, IL-17F, IL-21, and IL-22. Th 17 cells are considered developmentally distinct from Thl and Th2 cells, and have been postulated to facilitate the humoral immune response, such as for example, providing an important function in anti-microbial immunity and protecting against infections. Their production of IL-22 is thought to stimulate epithelial cells to produce antimicrobial proteins and production of IL-17 may be involved in the recruitment, activation and migration of neutrophils to protect against host infection by various bacterial and fungal species.
[0084] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Unless defined otherwise all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.
[0085] As used throughout herein, the term “about” means reasonably close. For example, “about” can mean within an acceptable standard deviation and/or an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend on how
the particular value is measured. Further, when whole numbers are represented, about can refer to decimal values on either side of the whole number. When used in the context of a range, the term “about” encompasses all of the exemplary values between the one particular value at one end of the range and the other particular value at the other end of the range, as well as reasonably close values beyond each end.
Compositions of the Invention
[0086] In one aspect, provided herein is a composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside.
[0087] In another aspect, provided herein is a composition comprising one or more positively charged lipids (or cationic lipids), a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and optionally an adjuvant.
Negatively charged molecules
[0088] Negatively charged molecules that can be delivered using the composition of the present disclosure include, but are not limited to, naturally occurring and chemically modified nucleic acid molecules (e.g., RNA, DNA, polynucleotides, oligonucleotides, mixed polymers, peptide nucleic acid, and the like), peptides (e.g., polyaminoacids, polypeptides, proteins and the like), nucleotides, pharmaceutical and biological compositions, that have negatively charged groups. While not wishing to be bound by theory, the negatively charged groups may ion-pair with the positively charged groups of any positively charged molecules (e.g., lipids, adjuvant) in the lipid vesicle particles of the disclosure.
[0089] In some embodiments, the negatively charged molecule in the composition of the present disclosure is a polynucleotide.
[0090] The use of polynucleotides as described herein refers specifically to polynucleotides that contain sequences that correspond largely to the sense or antisense sequence of specific genes or their products, and hence have a direct effect on the expression of these genes and/or their products. For example, the use of polynucleotides that contain gene coding sequences affects the transcription and/or translation of the genes of interest in cells that uptake such polynucleotides. Similarly, the use of RNA interference polynucleotides affects the expression of specific genes of interest by directly affecting the levels of mRNA in cells that uptake such nucleotides. This differs significantly from other polynucleotide-based molecules such as CpG and polylC adjuvants, which do not act through the presence of gene specific sequences. Furthermore, polynucleotide-based adjuvants are believed to modulate an immune response in
a non-specific manner, and their actions start at the site of vaccination where they interact with extracellular receptors to enhance the activity of immune cells in a non-specific manner. In some cases, polynucleotide-based adjuvants are internalized whereby they exert their effects by interacting with intracellular receptors, similarly leading to the activation of downstream pathways, and resulting collectively in the enhancement of immune cell activity to aid in the generation of an immune response. Such adjuvants do not directly affect the expression of specific genes that are being targeted by polynucleotide constructs as contemplated herein. Such adjuvants do not directly interact with the expression products of targeted genes, nor do they contain sequences that correspond to the sense or antisense sequence of targeted genes.
[0091] In some embodiments, the composition is useful for enhancing the expression of a polypeptide-encoding polynucleotide in vivo. For example, the polynucleotide encode a polypeptide that is deficient in the subject. In other embodiments, the polynucleotide may not encode a polypeptide, but may instead be e.g., a polynucleotide comprising or encoding an antisense RNA or other molecule that is not a polypeptide.
[0092] In some embodiments, the compositions comprise a polynucleotide of interest, optionally operably linked to regulatory sequences suitable for directing protein expression from the polynucleotide (e.g., a promoter), lipids, and a carrier comprising a continuous phase of a hydrophobic substance.
[0093] The compositions of the disclosure are useful for delivering polynucleotides of all kinds to a subject in vivo. In some embodiments, the polynucleotide is not expressed as a protein in the subject, but rather encodes e.g., an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme. In some embodiments, the polynucleotide encodes a polypeptide to be expressed in vivo in a subject. In one embodiment, the polynucleotide is a messenger RNA (mRNA). The disclosure is not limited to the expression of any particular type of polypeptide. The polypeptide may be, merely by way of illustrative examples, an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
[0094] In some embodiments, the polynucleotides delivered with the compositions of the present disclosure may encode an antigen such as, but not limited to: those derived from Cholera toxoid, tetanus toxoid, diphtheria toxoid, hepatitis B surface antigen, hemagglutinin, neuraminidase, influenza M protein, PfHRP2, pLDH, aldolase, MSP1, MSP2, AMA1, Der-p-
1, Der-f-1, Adipophilin, AFP, AIM-2, ART-4, BAGE, alpha-fetoprotein, BCL-2, Bcr-Abl, BING-4, CEA, CPSF, CT, cyclin DIEp-CAM, EphA2, EphA3, ELF-2, FGF-5, G250, Gonadotropin Releasing Hormone, HER-2, intestinal carboxyl esterase (iCE), IL13Ralpha2, MAGE-1, MAGE-2, MAGE-3, MART-1, MART-2, M-CSF, MDM-2, MMP-2, MUC-1, NY- EOS-1, MUM-1, MUM-2, MUM-3, p53, PBF, PRAME, PSA, PSMA, RAGE-1, RNF43, RU1, RU2AS, SART-1, SART-2, SART-3, SAGE-1, SCRN 1, SOX2, SOXIO, STEAP1, survivin (BIRC5), Telomerase, TGFbetaRl l, TRAG-3, TRP-1, TRP-2, TERT, or WT1; those derived from a virus, such as Cowpoxvirus, Vaccinia virus, Pseudocowpox virus, Human herpesvirus 1, Human herpesvirus 2, Cytomegalovirus, Human adenovirus A-F, Polyomavirus, Human papillomavirus, Parvovirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Human immunodeficiency virus, Orthoreo virus, Rotavirus, Ebolavirus, parainfluenza virus, influenza virus (e.g., H5N1 influenza virus, influenza A virus, influenza B virus, influenza C virus). Measles virus, Mumps virus, Rubella virus, Pneumovirus, Human respiratory syncytial virus, Rabies virus, California encephalitis virus, Japanese encephalitis virus, Hantaan virus, Lymphocytic choriomeningitis virus, Coronavirus (e.g., SARS-CoV-2), Enterovirus, Rhino virus, Poliovirus, Norovirus, Flavivirus, Dengue virus, West Nile virus, Yellow fever virus and varicella; those derived from a bacterium, such as Anthrax (Bacillus anthracis), Brucella, Bordetella pertussis, Candida, Chlamydia pneumoniae, Chlamydia psittaci, Cholera, Clostridium botulinum, Coccidioides immitis, Cryptococcus, Diphtheria, Escherichia coll 0151: H7, Enterohemorrhagic Escherichia coll, Enterotoxigenic Escherichia coll, Haemophilus influenzae, Helicobacter pylori, Legionella, Leptospira, Listeria, Meningococcus, Mycoplasma pneumoniae, Mycobacterium,
Pertussis, Pneumonia, Salmonella, Shigella, Staphylococcus, Streptococcus pneumoniae and Yersinia enterocolitica,' or those derived from a protozoa, e.g., of the genus Plasmodium (Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale or Plasmodium knowlesif
[0095] The antigen may be an allergen derived from, without limitation, cells, cell extracts, proteins, polypeptides, peptides, peptide mimics of polysaccharides and other molecules, such as small molecules, lipids, glycolipids, and carbohydrates of plants, animals, fungi, insects, food, drugs, dust, and mites. Allergens include but are not limited to environmental aeroallergens; plant pollens (e.g., ragweed/hayfever); weed pollen allergens; grass pollen allergens; Johnson grass; tree pollen allergens; ryegrass; arachnid allergens (e.g., house dust mite allergens); storage mite allergens; Japanese cedar pollen/hay fever; mold/fungal spore allergens; animal allergens (e.g., dog, guinea pig, hamster, gerbil, rat, mouse, etc., allergens);
food allergens (e.g., crustaceans; nuts; citrus fruits; flour; coffee); insect allergens (e.g., fleas, cockroach); venoms: (Hymenoptera, yellow jacket, honey bee, wasp, hornet, fire ant); bacterial allergens (e.g., streptococcal antigens; parasite allergens such as Ascaris antigen); viral antigens; drug allergens; hormones (e.g., insulin); enzymes (e.g., streptokinase); and drugs or chemicals capable of acting as incomplete antigens or haptens (e.g., the acid anhydrides and the isocyanates). Where a hapten is used in a composition of the disclosure, it may be attached to a carrier to form a hapten-carrier adduct. The hapten-carrier adduct is capable of initiating a humoral immune response, whereas the hapten itself would not elicit antibody production. Non-limiting examples of haptens are aniline, urushiol (a toxin in poison ivy), hydralazine, fluorescein, biotin, digoxigenin and dinitrophenol.
[0096] In another embodiment, the antigen may be an antigen associated with a disease where it is desirable to sequester the antigen in circulation, such as for example an amyloid protein (e.g., Alzheimer's disease).
[0097] In some embodiments, the polynucleotide may encode a T-helper epitope. T helper epitope is a sequence of amino acids (natural or non-natural amino acids) that have T helper activity. T helper epitopes are recognized by T helper lymphocytes, which play an important role in establishing and maximizing the capabilities of the immune system, and are involved in activating and directing other immune cells, such as for example B cell antibody class switching.
[0098] A T-helper epitope can consist of a continuous or discontinuous epitope. Hence not every amino acid of a T-helper is necessarily part of the epitope. Accordingly, T-helper epitopes, including analogs and segments of T-helper epitopes, are capable of enhancing or stimulating an immune response. Immunodominant T-helper epitopes are broadly reactive in animal and human populations with widely divergent MHC types (Celis et al. (1988) J. Immunol. 140:1808-1815; Demotz et al. (1989) J. Immunol. 142:394-402; Chong et al. (1992) Infect. Immun. 60:4640-4647). The T-helper domain of the subject peptides has from about 10 to about 50 amino acids and preferably from about 10 to about 30 amino acids. When multiple T-helper epitopes are present, then each T-helper epitope acts independently.
[0099] In some embodiments, the T-helper epitope may be encoded in a polynucleotide as part of an antigen described herein. In particular, if the antigen is of sufficient size, it may contain an epitope that functions as a T-helper epitope. In other embodiments, the T-helper epitope is encoded in a polynucleotide as a separate molecule from the antigen. In some embodiments, the T helper epitope is encoded in a polynucleotide with at least one antigen (i.e., a peptide), or a mixture of antigens, to make a fusion peptide.
[00100] In another embodiment, T-helper epitope analogs may include substitutions, deletions and insertions of from one to about 10 amino acid residues in the T-helper epitope. T-helper segments are contiguous portions of a T-helper epitope that are sufficient to enhance or stimulate an immune response. An example of T-helper segments is a series of overlapping peptides that are derived from a single longer peptide.
[00101] RNA interference (RNAi) is a sequence specific post-transcriptional gene silencing mechanism, which is triggered by double-stranded RNA such as small (or short) interference RNA (siRNA) and single stranded intracellular RNA such as microRNA (miRNA), both of which can cause degradation of mRNAs homologous in sequence to siRNA or miRNA (Fire et al, 1998, Nature, 391:806-811; Montgomery et al, 1998, PNAS, 95: 15502-15507; Elbashir et al, 2001, Nature, 411:494-498). RNAi is a conserved pathway common to plants and mammals that suppress expression of genes with complementary sequences (Hannon and Rossi, 2004, Nature, 431:371-378; Meister and Tuschl, 2004, Nature, 431, 343-349). RNAi was first observed in lower organisms, such as plants or nematodes. In these systems, long dsRNAs serve as effective triggers of RNAi. Long dsRNAs are not the actual triggers but are degraded by the endoribonuclease Dicer into small effector molecules called siRNAs. In mammals, Dicer processing occurs as a complex with the RNA-binding protein TRBP. The nascent siRNA associates with Dicer, TRBP, and Ago2 to form the RNA-Induced Silencing Complex (RISC) that mediates gene silencing (Chendrimada et al, 2005, Nature, 436:740-744). Once in RISC, one strand of the siRNA (the passenger strand) is degraded or discarded while the other strand (the guide strand) remains to direct sequence specificity of the silencing complex. The Ago2 component of RISC is a ribonuclease that cleaves a target RNA under direction of the guide strand.
[00102] Although long dsRNAs (several hundred bp) are commonly employed to trigger RNAi in C. elegans or D. melanogaster , these molecules will activate the innate immune system and trigger interferon (IFN) responses in higher organisms. RNAi can be performed in mammalian cells using short RNAs, which generally do not induce IFN responses. Many researchers today employ synthetic 21-mer RNA duplexes as their RNAi reagents, which mimic the natural siRNAs that result from Dicer processing of long substrate RNAs. An alternative approach is to use synthetic RNA duplexes that are greater than 21-mer in length, which are substrates for Dicer (Tuschl, T. 2002, Nature Biotechnology, 20:446).
[00103] Recently developed Dicer-substrate RNAs (DsiRNAs) are chemically synthesized RNA duplexes that have increased potency in RNA interference (Kim et al, 2005, Nat Biotechnol, 23:222-226). DsiRNAs are processed by Dicer into 21-mer siRNAs and designed
so that cleavage results in a single, desired product. This is achieved through use of a novel asymmetric design where the RNA duplex has a single 2-base 3 '-overhang on the AS strand and is blunt on the other end; the blunt end is modified with DNA bases. This design provides Dicer with a single favorable PAZ binding site that helps direct the cleavage reaction. Functional polarity is introduced by this processing event, which favors AS strand loading into RISC, and the increased potency of these reagents is thought to relate to linkage between Dicer processing and RISC loading (Rose et al, 2005, Nucleic Acids Res, 33:4140-4156). The Dicersubstrate approach can result in reagents having as much as 10-fold higher potency than traditional 21-mer siRNAs at the same site. miRNA, first described in 1993 (Lee et al, 1993, Cell 75:843-854), are single-stranded RNA molecules of about 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes that are transcribed from DNA but not translated into protein (non-coding RNA); instead they are processed from primary transcripts known as pri-miRNA to short stem-loop structures called pre-miRNA and finally to functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to downregulate gene expression. Although miRNA is generated within the cell and is highly conserved, it rarely has perfect complementarity with mRNA sequences. However, miRNA can affect protein translation and mRNA decay by binding to its imperfectly matched target sites on 3' UTR region of mRNA, which also requires Ago protein (not necessarily Ago2 as in seen in siRNA). Comparing and contrasting siRNA with miRNA shows that if siRNA hits an imperfect complementary target on 3 UTR, it behaves similar to microRNA, and if a miRNA hits a perfectly matched target on a mRNA, it can behave like an siRNA. Hence, although structurally different, both siRNA and miRNA might possess similar biological functions in the cells of host animal, with some differences in the mechanism of action.
[00104] Thus, RNAi molecules, siRNA and/or miRNA, provide a powerful tool for inhibiting endogenous gene expression and thereby could provide a means to effectively modulate biological responses. Studies have shown that RNAi can be induced in antigen presenting dendritic cells (DC) to polarize immune responses. By transfecting DC with synthetic siRNA specific for cytokine IL-12 p35 sub-unit, it was possible to inhibit bioactive IL-12 which subsequently led to Th2 polarization (Hill et al, J Immunology, 2003, 171:691). Similarly, modification of professional antigen presenting cells with siRNA in vivo has been used to enhance cancer vaccine potency (Kim et al, Cancer Research, 2005, 65:309-316). In this study, co-administration of DNA vaccine encoding human papilloma virus type 16 E7 with siRNA targeting key pro-apoptotic proteins Bac and Bax was shown to prolong the life span of antigen
expressing DCs in the lymph nodes, enhancing antigen-specific CD8 T cell responses that had potent anti -tumor effects against an E7-expressing tumor model in vaccinated mice. Thus, there is a good prospect for the use of siRNA for silencing specific undesirable responses during effective vaccination against infectious/autoimmune diseases, cancer and during transplantation. Efficient delivery of siRNA to the intracellular compartment of cells of interest is critical for the success of such strategies, requiring the use of enhanced delivery formulations.
[00105] siRNA may be a naturally occurring or synthetic double stranded nucleotide (RNA) chain of varying length. siRNA can be duplexes, usually but not always limited to, 20 to 25-nt long that have 19 base pair central double stranded domain with terminal 2-base 3' overhangs. siRNA can be further modified chemically to enhance its in vivo efficacy, induce nuclease- resistance to prevent degradation and enhance stability. In this regard, the anti-sense strand may have either a free 5'-OH or 5 '-phosphate terminus, the latter results in natural Dicer processing and represents the active form of the molecule. siRNA may have phosphorothioate or boranohosphate modification of the intemucleoside linkage to improve nuclease stability and prolong life of the duplex when exposed to serum or other nuclease sources. siRNA may have modifications at 2' position, for example, 2'-O-methyl RNA residue incorporation to retain full potency compared with unmodified RNA, retaining stability in serum and significantly reducing the risk of potential IFN responses in the cell. siRNA may also have 2'- fluoro modification, which is usually incorporated selectively at pyrimidine bases, to improve stability and potency.
[00106] siRNA and miRNA used as mediators of RNAi may be used as targets in, but not limited to, various infectious diseases, autoimmune/allergic diseases, heart diseases, metabolic disorders, solid tumors/cancers, hematological disorders/cancers.
[00107] In some embodiments of the present disclosure, the polynucleotide in the composition may be a polynucleotide for use in RNAi, including, without limitation, an siRNA, an miRNA, small hairpin RNA (shRNA), a long dsRNA for cleavage by Dicer, or a DsiRNA, all as described above.
[00108] In an embodiment, the negatively charged molecule may be an antagomir. Antagomirs (also known as anti-miRs or blockmirs) are synthetically engineered oligonucleotides that silence endogenous miRNA. It is unclear how antagomirization (the process by which an antagomir inhibits miRNA activity) operates, but it is believed to inhibit by irreversibly binding the miRNA. Because of the promiscuity of microRNAs, antagomirs could affect the regulation of many different mRNA molecules. Antagomirs are designed to
have a sequence that is complementary to an mRNA sequence that serves as a binding site for microRNA.
[00109] In an embodiment, the negatively charged molecule may be a catalytic DNA (deoxyribozyme) or a catalytic RNA (ribozyme). As used herein, the term “catalytic DNA” refers to any DNA molecule with enzymatic activity. In an embodiment, the catalytic DNA is a single-stranded DNA molecule. In an embodiment, the catalytic DNA is synthetically produced as opposed to naturally occurring.
[00110] The catalytic DNA may perform one or more chemical reactions. In an embodiment, the catalytic DNA is a ribonuclease, whereby the catalytic DNA catalyzes the cleavage of ribonucleotide phosphodiester bonds. In another embodiment, the catalytic DNA is a DNA ligase, whereby the catalytic DNA catalyzes the joining of two polynucleotide molecules by forming a new bond. Tn other embodiments, the catalytic DNA can catalyze DNA phosphorylation, DNA adenylation, DNA deglycosylation, porphyrin metalation, thymine dimer photoreversion, or DNA cleavage.
[00111] As used herein, the term “ catalytic RNA” refers to any RNA molecule with enzymatic activity. Catalytic RNAs are involved in a number of biological processes, including RNA processing and protein synthesis. In an embodiment, the catalytic RNA is a naturally occurring RNA. In an embodiment, the catalytic RNA is synthetically produced.
[00112] The subject may be any subject to which it is desired to deliver a polynucleotide. The subject is preferably a vertebrate, such as a bird, fish or mammal, preferably a human.
[00113] The polynucleotide may delivered in various forms. In some embodiments, a naked polynucleotide may be used, either in linear form, or inserted into a plasmid, such as an expression plasmid. In other embodiments, a live vector such as a viral or bacterial vector may be used.
[00114] Depending on the nature of the polynucleotide and the intended use, one or more regulatory sequences that aid in transcription of DNA into RNA and/or translation of RNA into a polypeptide may be present. For example, if it is intended or not required that the polynucleotide be transcribed or translated, such regulatory sequences may be absent. In some instances, such as in the case of a polynucleotide that is a messenger RNA (mRNA) molecule, regulatory sequences relating to the transcription process (e.g., a promoter) are not required, and protein expression may be effected in the absence of a promoter. The skilled artisan can include suitable regulatory sequences as the circumstances require.
[00115] In some embodiments, the polynucleotide is present in an expression cassette, in which it is operably linked to regulatory sequences that will permit the polynucleotide to be
expressed in the subject to which the composition of the disclosure is administered. The choice of expression cassette depends on the subject to which the composition is administered as well as the features desired for the expressed polypeptide.
[00116] Typically, an expression cassette includes a promoter that is functional in the subject and can be constitutive or inducible; a ribosome binding site; a start codon (ATG) if necessary; the polynucleotide encoding the polypeptide of interest; a stop codon; and optionally a 3' terminal region (translation and/or transcription terminator). Additional sequences such as a region encoding a signal peptide may be included. The polynucleotide encoding the polypeptide of interest may be homologous or heterologous to any of the other regulatory sequences in the expression cassette. Sequences to be expressed together with the polypeptide of interest, such as a signal peptide encoding region, are typically located adjacent to the polynucleotide encoding the protein to be expressed and placed in proper reading frame. The open reading frame constituted by the polynucleotide encoding the protein to be expressed solely or together with any other sequence to be expressed (e.g., the signal peptide), is placed under the control of the promoter so that transcription and translation occur in the subject to which the composition is administered.
[00117] Promoters suitable for expression of polynucleotides in a wide range of host systems are well-known in the art. Promoters suitable for expression of polynucleotides in mammals include those that function constitutively, ubiquitously or tissue-specifically. Examples of nontissue specific promoters include promoters of viral origin. Examples of viral promoters include Mouse Mammary Tumor Virus (MMTV) promoter, Human Immunodeficiency Virus Long Terminal Repeat (HIV LTR) promoter, Moloney virus, avian leukosis virus (ALV), Cytomegalovirus (CMV) immediate early promoter/enhancer, Rous Sarcoma Virus (RSV), adeno-associated virus (AAV) promoters; adenoviral promoters, and Epstein Barr Virus (EBV) promoters. Compatibility of viral promoters with certain polypeptides is a consideration since their combination may affect expression levels. It is possible to use synthetic promoter/enhancers to optimize expression (see e.g., US patent publication 2004/0171573, which is hereby incorporated by reference in its entirety).
[00118] An example of a tissue-specific promoter is the desmin promoter which drives expression in muscle cells (Li et al. 1989, Gene 78:243; Li & Paulin 1991, J. Biol. Chem. 266:6562 and Li & Paulin 1993, J. Biol. Chem. 268:10403, which are hereby incorporated by reference in their entireties). Other examples include artificial promoters such as a synthetic muscle specific promoter and a chimeric muscle-specific/CMV promoter (Li et al. 1999, Nat.
Biotechnol. 17:241-245; Hagstrom et al. 2000, Blood 95:2536-2542, which are hereby incorporated by reference in their entireties).
[00119] Useful vectors are described in numerous publications, specifically WO 94/21797 and Hartikka et al. 1996, Human Gene Therapy 7 : 1205, which are hereby incorporated by reference in their entireties.
[00120] As noted above, the polynucleotide of interest, together with any necessary regulatory sequences, may be delivered naked, e.g., either alone or as part of a plasmid, or may be delivered in a viral or bacterial or bacterial vector.
[00121] Whether a plasmid-type vector, or a bacterial or viral vector is used, it may be desirable that the vector be unable to replicate or integrate substantially in the subject. Such vectors include those whose sequences are free of regions of substantial identity to the genome of the subject, as to minimize the risk of host-vector recombination. One way to do this is to use promoters not derived from the recipient genome to drive expression of the polypeptide of interest. For example, if the recipient is a mammal, the promoter is preferably non-mammalian derived though it should be able to function in mammalian cells, e.g., a viral promoter.
[00122] Viral vectors that may be used to deliver the polynucleotide include e.g., adenoviruses, lentiviruses and poxviruses. Useful bacterial vectors include e.g., Shigella, Salmonella, Vibrio cholerae, Lactobacillus, Bacille bilie de Calmette-Guerin (BCG), and Streptococcus.
[00123] An example of an adenovirus vector, as well as a method for constructing an adenovirus vector capable of expressing a polynucleotide, is described in U.S. Pat. No. 4,920,209, which is hereby incorporated by reference in its entirety. Poxvirus vectors include vaccinia and canary pox virus, described in U.S. Pat. No. 4,722,848 and U.S. Pat. No. 5,364,773 (which are hereby incorporated by reference in their entireties), respectively. Also see, e.g., Tartaglia et al. 1992, Virology 188:217 (which is hereby incorporated by reference in its entirety) for a description of a vaccinia virus vector and Taylor et al. 1995, Vaccine 13:539 (which is hereby incorporated by reference in its entirety) for a reference of a canary pox. Poxvirus vectors capable of expressing a polynucleotide of interest may be obtained by homologous recombination as described in Kieny et al. 1984, Nature 312:163 (which is hereby incorporated by reference in its entirety), so that the polynucleotide is inserted in the viral genome under appropriate conditions for expression in mammalian cells.
[00124] With respect to bacterial vectors, non-toxicogenic Vibrio cholerae mutant strains that are useful for expressing a foreign polynucleotide in a host are known. Mekalanos et al. 1983, Nature 306:551 and U.S. Pat. No. 4,882,278 (which are hereby incorporated by reference in
their entireties) describe strains which have a substantial amount of the coding sequence of each of the two ctxA alleles deleted so that no functional cholerae toxin is produced. WO 92/11354 (which is hereby incorporated by reference in its entirety) describes a strain in which the irgA locus is inactivated by mutation; this mutation can be combined in a single strain with ctxA mutations. WO 94/01533 (which is hereby incorporated by reference in its entirety) describes a deletion mutant lacking functional ctxA and attRSl DNA sequences. These mutant strains are genetically engineered to express heterologous proteins, as described in WO 94/19482 (which is hereby incorporated by reference in its entirety).
[00125] Attenuated Salmonella typhimurium strains, genetically engineered for recombinant expression of heterologous proteins are described in Nakayama et al. 1988, Bio/Technology 6:693 and WO 92/11361, which are hereby incorporated by reference in their entireties.
[00126] Other bacterial strains which may be used as vectors to express a foreign protein in a subject are described for Shigella flexneri in High et al. 1992, EMBO 11:1991 and Sizemore et al. 1995, Science 270:299; for Streptococcus gordonii in Medaglini et al. 1995, Proc. Natl. Acad. Sci. USA. 92:6868; and for Bacille Calmette Guerin in Flynn 1994, Cell. Mol. Biol. 40 (suppl. I):31, WO 88/06626, WO 90/00594, WO 91/13157, WO 92/01796, and WO 92/21376, all of which are hereby incorporated by reference in their entireties.
[00127] In bacterial vectors, the polynucleotide of interest may be inserted into the bacterial genome or remain in a free state as part of a plasmid.
[00128] In some embodiments, the negatively charged molecule (e.g., polynucleotide) may be present in the composition of the present disclosure at about 0.01-2 mg/mL. In some embodiments, the negatively charged molecule (e.g., polynucleotide) may be present in the composition of the present disclosure at about 0.01 mg/mL, 0.02 mg/mL, 0.03 mg/mL, 0.04 mg/mL 0.05 mg/mL, 0.06 mg/mL, 0.07 mg/mL, 0.08 mg/mL, 0.09 mg/mL, 0.1 mg/mL, 0.11 mg/mL, 0.12 mg/mL, 0.13 mg/mL, 0.14 mg/mL 0.15 mg/mL, 0.16 mg/mL, 0.17 mg/mL, 0.18 mg/mL, 0.19 mg/mL, 0.2 mg/ml, 0.25 mg/mL, 0.3 mg/mL, 0.35 mg/mL, 0.4 mg/mL, 0.45 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 1.1 mg/mL, 1.2 mg/mL, 1.3 mg/mL, 1.4 mg/mL, 1.5 mg/mL, 1.6 mg/mL, 1.7 mg/mL, 1.8 mg/mL, 1.9 mg/mL, or 2 mg/mL. In some embodiments, the negatively charged molecule (e.g., polynucleotide) may be present in the composition of the present disclosure at about 0.01-0.1 mg/mL, 0.05-0.2 mg/mL, 0.1-0.3 mg/mL, 0.2-0.4 mg/mL, 0.3-0.6 mg/mL, 0.4-0.8 mg/mL, 0.5- 1 mg/mL, 0.8-1.2 mg/mL, 1-1.5 mg/mL, or 1-2 mg/mL. In one embodiment, the negatively charged molecule (e.g., polynucleotide) may be present in the composition of the present disclosure at about 0.1 mg/mL.
[00129] In an embodiment, the composition disclosed herein comprise a single type of negatively charged molecule in a composition. In another embodiment, the composition disclosed herein comprise a mixture of multiple different negatively charged molecules in a single composition. In an embodiment, the composition disclosed herein comprise a mixture of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more different negatively charged molecules in a single composition.
Lipids
[00130] Any lipid may be used in the composition described herein so long as it is a membrane-forming lipid.
[00131] Although any lipid as defined above may be used, particularly suitable lipids may include those with at least one fatty acid chain containing at least 4 carbons, and typically about 4 to 28 carbons. The fatty acid chain may contain any number of saturated and/or unsaturated bonds. The lipid may be a natural lipid or a synthetic lipid. Non-limiting examples of lipids may include phospholipids, sphingolipids, sphingomyelin, cerobrocides, gangliosides, ether lipids, sterols, cardiolipin, cationic lipids and lipids modified with poly (ethylene glycol) and other polymers. Synthetic lipids may include, without limitation, the following fatty acid constituents: lauroyl, myristoyl, palmitoyl, stearoyl, arachidoyl, oleoyl, linoleoyl, erucoyl, or combinations of these fatty acids. In some embodiments, the lipid or lipids of the lipid vesicle particle are amphiphilic lipids, meaning that they possess both hydrophilic and hydrophobic (lipophilic) properties.
[00132] Lipids suitable for use in the composition of the present disclosure include, but are not limited to phospholipids, cationic lipids, cholesterol and/or cholesterol derivatives, or a combination thereof. It is to be understood that the terms “phospholipids”, “cationic lipids” or “cholesterol derivatives”, are not necessarily mutually exclusive of each other.
[00133] Broadly defined, a "phospholipid" is a member of a group of lipid compounds that yield on hydrolysis phosphoric acid, an alcohol, fatty acid, and nitrogenous base. Phospholipids that are preferably used in the preparation of the composition of the present disclosure are those with at least one head group selected from the group consisting of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine and phosphoinositol. More preferred are lipids which are about 94-100% phosphatidylcholine. Such lipids are available commercially in the lecithin Phospholipon® 90 G (Phospholipid GmBH, Germany) or lecithin S100 (Lipoid GmBH, Germany). In some embodiments, the phospholipid used in the preparation of the composition of the present disclosure is dioleoyl phosphatidylcholine
(DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), Dioleoyl Phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof. In one embodiment, the phospholipid used in the preparation of the composition of the present disclosure is dioleoyl phosphatidylcholine (DOPC). In some embodiments, a mixture of DOPC and unesterified cholesterol may be used. In other embodiments, a mixture of Lipoid S 100 lecithin and unesterified cholesterol may be used.
[00134] In one embodiment, the lipid vesicle particles comprise a synthetic lipid. In an embodiment, the lipid vesicle particles comprise synthetic DOPC. In another embodiment, the lipid vesicle particles comprise synthetic DOPC and cholesterol.
[00135] Another common phospholipid is sphingomyelin. Sphingomyelin contains sphingosine, an amino alcohol with a long unsaturated hydrocarbon chain. A fatty acyl side chain is linked to the amino group of sphingosine by an amide bond, to form ceramide. The hydroxyl group of sphingosine is esterified to phosphocholine. Like phosphoglycerides, sphingomyelin is amphipathic.
[00136] Lecithin, which also may be used, is a natural mixture of phospholipids typically derived from chicken eggs, sheep's wool, soybean and other vegetable sources.
[00137] All of these and other phospholipids may be used in the practice of the disclosure. Phospholipids can be purchased, for example, from Av anti lipids (Alabastar, AL, USA), Lipoid LLC (Newark, NJ, USA) and Lipoid GmbH (Germany), among various other suppliers.
[00138] Cholesterol and/or cholesterol derivatives may be used in the composition of the present disclosure. When unesterified cholesterol is used in the composition, the cholesterol is usually used in an amount equivalent to about 10% of the amount of phospholipid. If a compound other than cholesterol is used to stabilize the composition, one skilled in the art can readily determine the amount needed in the composition. Cholesterol derivatives suitable for use in the present disclosure include cholesterol [3-D-glucoside, cholesterol 3-sulfate sodium salt, positively charged cholesterol such as DC-cholesterol and other cholesterol like molecules such as Campesterol, Ergosterol, Betulin, Lupeol, [3-Sitosterol, a, [3-Amyrin and bile acids.
[00139] In some embodiments, the lipid vesicle particles comprise DOPC and cholesterol at a DOPC: Cholesterol ratio of about 10:1 (w/w). In some embodiments, the lipid vesicle particles comprise DOPC and cholesterol at a DOPC: cholesterol ratio of about 8:1 (w/w), about 9:1 (w/w), about 11:1 (w/w), or about 12:1 (w/w).
[00140] In one embodiment, the compositions disclosed herein comprise about 66 mg/ml of DOPC and cholesterol. In other embodiments, the compositions disclosed herein comprise about 55 mg/ml, 56 mg/ml, 57 mg/ml, 58 mg/ml, 59 mg/ml, 60 mg/ml, 61 mg/ml, 62 mg/ml,
63 mg/ml, 64 mg/ml, 65 mg/ml, 67 mg/ml, 68 mg/ml, 69 mg/ml, 70 mg/ml, 71 mg/ml, 72 mg/ml, 73 mg/ml, 74 mg/ml, or 75 mg/ml of DOPC and cholesterol.
[00141] In one embodiment, the compositions disclosed herein comprise about 60 mg/ml of DOPC and about 6 mg/ml of cholesterol.
[00142] In some embodiments, positively charged lipids (or cationic lipids) are used in the composition of the present disclosure. Exemplary cationic lipids suitable for use in the compositions of the present disclosure include but are not limited to, 1,2-dioleoyl-3- trimethylammonium-propane (DOTAP), 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2- hydroxyethyl)imidazolinium chloride (DOTIM), N-[1-(2,3-dioleyloxy)propyl]-N,N,N- trimethylammonium chloride (DOTMA), dioctadecylamidoglycylspermine-4trifluoroacetic acid (DOGS), dioleyldimethylammonium chloride (DODAC), dimethyldioctadecylammonium bromide (DDAB), 1,2-distearoyl-3-dimethylammonium-propane (DAP), N-(4- carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-1-aminium (DOBAQ), 1,2- dipalmitoyl-sn-glycero-3-succinate (DGS), N-palmitoyl homocysteine ammonium salt (PHC),
1.2-dioleyloxy-3-dimethylaminopropane (DODMA), Dimethyldioctadecylammonium Bromide Salt (DDAB), 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine chloride salt (EPC), N4-Cholesteryl-Spermine HC1 Salt (GL67), 1,2-dioleoyloxypropyl-3-dimethyl- hydroxy ethyl ammonium bromide (DORI), N-(3-aminopropyl)-N,N-dimethyl-2,3- bis(dodecyloxy)-1-propanammonium bromide (GAP-DLRIE), 2,3dioleyloxy-N- [2[sperminecarboxaminino]ethyl]-N,N-dimethyl-1-propanaminium trifluroacetate (DOSPA),
1.2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE), 1,2- distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and SAINT 2. Further examples of cationic lipids include those described in, for example, Audouy and Hoekstra, Mol Membr Biol, Apr- Jun 2001;18(2):129-43; Shim et al., Asian Journal of Pharmaceutical Sciences 8(2):72-80, April 2013; and Faneca et al (2013) Cationic Liposome-Based Systems for Nucleic Acid Delivery: From the Formulation Development to Therapeutic Applications. In: Coelho J. (eds) Drug Delivery Systems: Advanced Technologies Potentially Applicable in Personalised Treatment. Advances in Predictive, Preventive and Personalised Medicine, vol 4. Springer, Dordrecht, which are incorporated herein by reference in their entireties.
[00143] The lipid vesicle particles may have closed vesicular structures. They are typically spherical in shape, but other shapes and conformations may be formed and are not excluded. Exemplary embodiments of lipid vesicle particles include, without limitation, single layer vesicular structures (e.g., micelles) and bilayer vesicular structures (e.g., unilamellar or multilamellar vesicles), or various combinations thereof.
[00144] By "single layer" it is meant that the lipids do not form a bilayer, but rather remain in a layer with the hydrophobic part oriented on one side and the hydrophilic part oriented on the opposite side. By "bilayer" it is meant that the lipids form a two-layered sheet, typically with the hydrophobic part of each layer internally oriented toward the center of the bilayer with the hydrophilic part externally oriented. However, the opposite configuration is also possible. The term "multilayer" is meant to encompass any combination of single and bilayer structures. The form adopted may depend upon the specific lipid that is used. .
[00145] In an embodiment, the lipid vesicle particle is a bilayer vesicular structure, such as for example, a liposome. Liposomes are completely closed lipid bilayer membranes. Liposomes may be unilamellar vesicles (possessing a single bilayer membrane), multilamellar vesicles (characterized by multimembrane bilayers whereby each bilayer may or may not be separated from the next by an aqueous layer) or multivesicular vesicles (possessing one or more vesicles within a vesicle). A general discussion of liposomes can be found in Gregoriadis 1990; and Frezard 1999, which are incorporated herein by reference in their entirety.
[00146] Thus, in an embodiment, the lipid vesicle particles are liposomes. In an embodiment, the liposomes are unilamellar, multilamellar, multivesicular or a mixture thereof.
Carriers
[00147] In some embodiments, the carrier of the composition comprises a continuous phase of a hydrophobic substance, preferably a liquid hydrophobic substance. The continuous phase may be an essentially pure hydrophobic substance or a mixture of hydrophobic substances. In addition, the carrier may be an emulsion of water in a hydrophobic substance or an emulsion of water in a mixture of hydrophobic substances, provided the hydrophobic substance constitutes the continuous phase. Further, in another embodiment, the carrier may function as an adjuvant.
[00148] Hydrophobic substances that are useful in the compositions as described herein are those that are pharmaceutically and/or immunologically acceptable. The carrier is preferably a liquid but certain hydrophobic substances that are not liquids at atmospheric temperature may be liquefied, for example by warming, and are also useful in this disclosure. In one embodiment, the hydrophobic carrier may be a PBS/FIA emulsion.
[00149] Oil or water-in-oil emulsions are particularly suitable carriers for use in the present disclosure. Oils should be pharmaceutically and/or immunologically acceptable. Suitable oils include, for example, mineral oils (especially light or low viscosity mineral oil such as Drakeo® 6VR), vegetable oils (e.g., soybean oil), nut oils (e.g., peanut oil), or mixtures thereof.
In an embodiment, the oil is a mannide oleate in mineral oil solution, commercially available as Montanide® ISA 51. In one embodiment, the oil is MS80 oil (mixture of mineral oil and Span 80). Animal fats and artificial hydrophobic polymeric materials, particularly those that are liquid at atmospheric temperature or that can be liquefied relatively easily, may also be used. Mixtures of different hydrophobic substances, such as mixtures that include one or more different oils, animal fats or artificial hydrophobic polymeric materials, may be used.
Ionizable aminoglycoside
[00150] In some aspects, composition of the present disclosure contains an ionizable aminoglycoside. Ionizable aminoglycosides useful in the compositions of the present disclosure include, but are not limited to, chitosan, cationic alginate, cationic gelatin, cationic dextran, DEAE-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, glycyrrhizic acid ammonium salt, or derivatives thereof.
[00151] In one embodiment, the ionizable aminoglycoside is a polymer. In one embodiment, the ionizable aminoglycoside is chitosan, chitosan derivative, or a chitosan like molecule. Chitosan derivatives suitable for use in the present disclosure include, but are not limited to N- trimethyl chitosan, mono-N-carboxymethyl chitosan (MCC), N-palmitoyl chitosan (NPCS), EDTA-chitosan, low molecular weight chitosan, galactosylated chitosan, N-dodecylated chitosan, thiolated chitosan or combinations thereof. The chitosan like molecules include, but are not limited to, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, galactosamine, N-acetylgalactosamine, cellulose acetate, mannosamine, N-acetylneuraminic acid, alginic acid, Trehalose-6,6-dibehenate (TDB) with Dimethyldioctadecylammonium bromide (DDA), heptakis(6-deoxy-6-amino)-β-cyclodextrin heptahydrochloride, DEAE-dextran hydrochloride, and glycyrrhizic acid ammonium salt. It is contemplated that the chitosan, chitosan derivative, or a chitosan like molecule may also function as a carrier (e.g., a structural carrier).
[00152] In some embodiments, the chitosan or chitosan derivative used in the composition has a molecular weight of about 10 kDa to 200 kDa. In some embodiments, the chitosan or chitosan derivative used in the composition has a molecular weight of about 60 kDa to 150 kDa, about 80 kDa to 150 kDa, about 90 kDa to 110 kDa, about 100 kDa to 120 kDa, about 100 kDa, or about 120 kDa. In some embodiments, the chitosan or chitosan derivative used in the composition has a molecular weight of about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, or about 150 kDa. In one embodiment,
the chitosan or chitosan derivative used in the composition has a molecular weight of about 100 kDa.
[00153] Degree of deacetylation (DD) is another main parameter characterizing chitosan. The degree of deacetylation (DD, %) is defined as the molar fraction of D-glusoamine units in the copolymers (chitosan) composed of N-acetylglucosamine units and D-glusoamine units (Shigemasa Y et al., Int. J. Biol. Macromol. 1996;18:237-242, which is incorporated hereby by reference in its entirety). In some embodiments, the chitosan or chitosan derivative used in the composition has a degree of deacetylation (DD) of about 15% to 95%. In some embodiments, the chitosan or chitosan derivative used in the composition has a degree of deacetylation (DD) of about 15% to 30%, about 20% to 30%, about 20% to 40%, about 25% to 50%, about 30% to 60%, about 40% to 70%, about 50% to 80%, about 60% to 90%, about 70% to 95%. In some embodiments, the chitosan or chitosan derivative used in the composition has a degree of deacetylation (DD) of about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%. In one embodiment, the chitosan or chitosan derivative has a DD% of about 25%.
[00154] In some embodiments, the chitosan or chitosan derivative is added in a concentration of about 0.1 mg/mL to about 5 mg/mL. In some embodiments, the chitosan or chitosan derivative is added in a concentration of about 0.25 mg/mL to about 4 mg/mL, about 0.5 mg/mL to about 3 mg/mL, about 0.75 mg/mL to about 2.5 mg/mL, about 1 mg/mL to about 2 mg/mL. In some embodiments, the chitosan or chitosan derivative is added in a concentration of about 0.5 mg/mL to about 3 mg/mL or about 1 mg/mL to about 2 mg/mL. In some embodiments, the chitosan or chitosan derivative is added in a concentration of about 0.1 mg/ml, about 0.25 mg/ml, about 0.5 mg/ml, about 0.75 mg/ml, about 1 mg/mL, about 1.25 mg/ml, about 1.5 mg/mL, about 1.75 mg/ml, about 2 mg/mL, about 2.25 mg/ml, about 2.5 mg/ml, about 2.75 mg/ml, about 3 mg/ml, about 3.25 mg/ml, about 3.5 mg/ml, about 3.75 mg/ml, about 4 mg/ml, about 4.25 mg/ml, about 4.5 mg/ml, about 4.75 mg/ml, about 5 mg/ml. In some embodiments, the chitosan or chitosan derivative is added in a concentration of about 0.1 mg/ml, about 1.5 mg/mL, about 2 mg/mL, about 2.5 mg/mL, or about 3 mg/mL.
Adjuvants
[00155] The composition may comprise one or more adjuvants. For example, if the encoded polypeptide is a vaccine antigen, an adjuvant may be present. An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non- specifically enhances the immune response (Hood et al, Immunology, 2d ed.,
Benjamin/Cummings: Menlo Park, C.A., 1984; see Wood and Williams, In: Nicholson, Webster and May (eds.), Textbook of Influenza, Chapter 23, pp. 317-323, which are incorporated hereby by reference in their entireties). Often, a primary challenge with an antigen alone, in the absence of an adjuvant, will fail to elicit an adaptive immune response. It should be noted that the polynucleotide of interest to be delivered to the subject may itself function as an adjuvant, or may encode a polypeptide that constitutes an adjuvant (e.g., IL-12, IFN-gamma, or Granulocyte-Macrophage Colony Stimulating Factor (“GMCSF”)).
[00156] In some embodiments, the adjuvant is a protein, a polymer, a polysaccharide, or a combination thereof. The adjuvant may be a natural or synthetic substance.
[00157] The amount of adjuvant used depends on the amount of antigen expressed by the polynucleotide and on the type of adjuvant. One skilled in the art can readily determine the amount of adjuvant needed in a particular application.
[00158] Suitable adjuvants include, but are not limited to, alum, other compounds of aluminum, Bacillus of Calmette and Guerin (BCG), TiterMax®, incomplete Freund's adjuvant (IF A), saponin, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, Corynebacteriumparvum, QS-21, and Freund's Complete Adjuvant (FCA), adjuvants of the STING family Bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP), Bis-(3'- 5')-cyclic dimeric adenosine monophosphate (c-di-AMP) and cyclic di-inosine monophosphate (c-di-IMP), adjuvants of the TLR agonist family such as CpG-containing oligodeoxynucleotides (CpG ODN), polyLC, falgellin, lipopeptides, peptidoglycans, lipid- based adjuvant (e.g., palmitic acid adjuvant), imidazoquinolines, single stranded RNA, lipopolysaccharides (LPS), heat shock proteins (HSP), cationic albumin, and ceramides and derivatives such as alpha Gal-cer. Suitable adjuvants also include cytokines or chemokines in their polypeptide or DNA coding forms such as, but not limited to, GM-CSF, TNF-alpha, IFN- gamma, IL-2, IL-12, IL-15, IL-21. Suitable adjuvants that activate or increases the activity of TLR2 include those described in U.S. Patent Nos. 10,105,435 and 10,022,441, which are hereby incorporated by reference in their entirety.
[00159] In an embodiment, the adjuvant is a CpG ODN. CpG ODNs are DNA molecules that contain one or more unmethylated CpG motifs (consisting of a central unmethylated CG dinucleotide plus flanking regions). An exemplary CpG ODN is 5'- TCCATGACGTTCCTGACGTT-3' (SEQ ID NO: 1). The skilled person can readily select other appropriate CpG ODNs on the basis of the target species and efficacy.
[00160] In an embodiment, the adjuvant may be a polyLC polynucleotide. PolyLC polynucleotides are polynucleotide molecules (either RNA or DNA or a combination of DNA
and RNA) containing inosinic acid residues (I) and cytidylic acid residues (C), and which induce the production of inflammatory cytokines, such as interferon. In an embodiment, the polyI:C polynucleotide is double-stranded. In such embodiments, they may be composed of one strand consisting entirely of cytosine-containing nucleotides and one strand consisting entirely of inosine-containing nucleotides, although other configurations are possible. For instance, each strand may contain both cytosine-containing and inosine-containing nucleotides. In some instances, either or both strands may additionally contain one or more non-cytosine or non-inosine nucleotides.
[00161] It has been reported that polyI:C can be segmented every 16 residues without an effect on its interferon activating potential (Bobst 1981). Furthermore, the interferon inducing potential of a polyI:C molecule mismatched by introducing a uridine residue every 12 repeating cytidylic acid residues (Hendrix 1993), suggests that a minimal double stranded polyI:C molecule of 12 residues is sufficient to promote interferon production. Others have also suggested that regions as small as 6-12 residues, which correspond to 0.5-1 helical turn of the double stranded polynucleotide, are capable of triggering the induction process (Greene 1978). If synthetically made, polyI:C polynucleotides are typically about 20 or more residues in length (commonly 22, 24, 26, 28 or 30 residues in length). If semi-synthetically made (e.g. using an enzyme), the length of the strand may be 500, 1000 or more residues.
[00162] Accordingly, as used herein, a “ polyI:C”, “ polyI:C polynucleotide” or “ polyI:C polynucleotide adjuvant” is a double- or single-stranded polynucleotide molecule (RNA or DNA or a combination of DNA and RNA), each strand of which contains at least 6 contiguous inosinic or cytidylic acid residues, or 6 contiguous residues selected from inosinic acid and cytidylic acid in any order (e.g., IICIIC or ICICIC), and which is capable of inducing or enhancing the production of at least one inflammatory cytokine, such as interferon, in a mammalian subject. PolyI:C polynucleotides will typically have a length of about 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, 26, 28, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 500, 1000 or more residues. Preferred polyI:C polynucleotides may have a minimum length of about 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30 nucleotides and a maximum length of about 1000, 500, 300, 200, 100, 90, 80, 70, 60, 50, 45 or 40 nucleotides.
[00163] Each strand of a double-stranded polyI:C polynucleotide may be a homopolymer of inosinic or cytidylic acid residues, or each strand may be a heteropolymer containing both inosinic and cytidylic acid residues. In either case, the polymer may be interrupted by one or more non-inosinic or non-cytidylic acid residues (e.g. uridine), provided there is at least one contiguous region of 6 I, 6 C or 6 I/C residues as described above. Typically, each strand of a
polyI:C polynucleotide will contain no more than 1 non-I/C residue per 6 1/C residues, more preferably, no more than 1 non-I/C residue per every 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 or 30 I/C residues.
[00164] The inosinic acid or cytidylic acid (or other) residues in the polyI:C polynucleotide may be derivatized or modified as is known in the art, provided the ability of the polyI:C polynucleotide to promote the production of an inflammatory cytokine, such as interferon, is retained. Non-limiting examples of derivatives or modifications include e.g. azido modifications, fluoro modifications, or the use of thioester (or similar) linkages instead of natural phosphodiester linkages to enhance stability in vivo. The polyI:C polynucleotide may also be modified to e.g. enhance its resistance to degradation in vivo by e.g. complexing the molecule with positively charged poly-lysine and carboxymethylcellulose, or with a positively charged synthetic peptide.
[00165] In an embodiment, the polyI:C polynucleotide may be a single-stranded molecule containing inosinic acid residues (I) and cytidylic acid residues (C). As an example, and without limitation, the single-stranded polyI:C may be a sequence of repeating dldC. In a particular embodiment, the sequence of the single-stranded polyI:C may be a 26-mer sequence of (IC) 13, i.e. ICICICICICICICICICICICICIC (SEQ ID NO: 2). As the skilled person will appreciate, due to their nature (e.g., complementarity), it is anticipated that these singlestranded molecules of repeating dldC would naturally form homodimers, so they are conceptually similar to polyl/polyC dimers.
[00166] In an embodiment, the polyI:C polynucleotide adjuvant is a traditional form of polyI:C with an approximate molecular weight of 989,486 Daltons, containing a mixture of varying strand lengths of polyl and polyC of several hundred base pairs (Thermo Scientific; USA).
[00167] In an embodiment, the adjuvant may be one that activates or increases the activity of TLR2. As used herein, an adjuvant which “activates” or “increases the activity” of a TLR2 includes any adjuvant, in some embodiments a lipid-based adjuvant, which acts as a TLR2 agonist. Further, activating or increasing the activity of TLR2 encompasses its activation in any monomeric, homodimeric or heterodimeric form, and particularly includes the activation of TLR2 as a heterodimer with TLR1 or TLR6 (i.e. TLR1/2 or TLR2/6). Exemplary embodiments of an adjuvant that activates or increases the activity of TLR2 include lipid-based adjuvants, such as those described in WO2013/049941, which is hereby incorporated by reference in its entirety.
[00168] In an embodiment, the adjuvant may be a lipid-based adjuvant, such as disclosed for example in WO2013/049941, which is hereby incorporated by reference in its entirety. In an embodiment, the lipid-based adjuvant is one that comprises a palmitic acid moiety such as dipalmitoyl-S-glyceryl-cysteine (PAM2Cys) or tripalmitoyl-S-glyceryl-cysteine (PAM3Cys). In an embodiment, the adjuvant is a lipopeptide. Exemplary lipopeptides include, without limitation, PAM2Cys-Ser-(Lys)4 (SEQ ID NO: 3) or PAM3Cys-Ser-(Lys)4 (SEQ ID NO: 4). [00169] In an embodiment, the adjuvant is PAM3Cys-SKKKK (EMC Microcollections, Germany; SEQ ID NO: 5) or a variant, homolog and analog thereof. The PAM2 family of lipopeptides has been shown to be an effective alternative to the PAM3 family of lipopeptides. [00170] In an embodiment, the adjuvant may be a lipid A mimic or analog adjuvant, such as for example those disclosed in WO2016/109880 and the references cited therein, which are hereby incorporated by reference in their entireties. In a particular embodiment, the adjuvant may be JL-265 or JL-266 as disclosed in W02016/109880, which is hereby incorporated by reference in its entirety.
[00171] In an embodiment, a combination of a polyI:C polynucleotide adjuvant and a lipid- based adjuvant may be used, such as described in the adjuvanting system disclosed in WO2017/083963, which is hereby incorporated by reference in its entirety.
[00172] Further examples of compatible adjuvants may include, without limitation, chemokines, Toll like receptor agonists, colony stimulating factors, cytokines, 1018 ISS, aluminum salts, Amplivax, AS04, AS 15, ABM2, Adjumer, Algammulin, AS01B, AS02 (SBASA). ASO2A, BCG, Calcitriol, Cholera toxin, CP-870,893, CpG, polylC, CyaA, Dimethyldioctadecylammonium bromide (DDA), Dibutyl phthalate (DBP), Trehalose-6,6- dibehenate (TDB), dSLIM, Gamma inulin, GM-CSF, GMDP, Glycerol, IC30, IC31, Imiquimod, ImuFact IMP321. IS Patch, ISCOM, ISCOMATRIX, Juvlmmune, LipoVac, LPS, lipid core protein, MF59, monophosphoryl lipid A, Montanide® IMS 1312, Montanide® based adjuvants, OK-432, OM-174, OM-197-MP-EC, ONTAK, PepTel vector system, other palmitoyl based molecules, PLG microparticles, resiquimod, squalene, SLR172, YF-17 DBCG, QS21, QuilA, P1005, Poloxamer, synthetic polynucleotides, Zymosan, and pertussis toxin.
[00173] A wide range of pharmaceutically acceptable adjuvants, excipients, etc. are known in the art and may be used in the compositions of the disclosure: See, for example, Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985) and The United States Pharmacopoeia: The National Formulary (USP 24 NF 19) published in 1999, which are incorporated hereby by reference in their entireties.
Additional components
[00174] The composition may further comprise one or more additional components that may facilitate the delivery of the negatively charged molecule (e.g., polynucleotide) to the subject. The additional components may enhance the stability of the composition, or complement or enhance the function of the negatively charged molecule (e.g., polynucleotide) to be delivered to the subject.
[00175] In some embodiments, the composition further comprises a buffer. A buffer works to maintain the pH of solution to prevent a sharp pH change in the liquid formulation for stabilizing the composition. The buffer may include an alkaline salt (sodium or potassium phosphate or hydrogen or dihydrogen salts thereof), sodium citrate/citric acid, sodium acetate/acetic acid, and any other pharmaceutically acceptable pH buffer known in the art, and a combination thereof. The preferred example of such buffer includes an acetate buffer, citrate buffer, and phosphate buffer. The buffer may also include zwitterionic salts such THAM tris(hydroxymethyl)aminomethane, HEPES (4-(2-hydroxy ethyl)- 1 -piperazineethanesulfonic acid), MOPS (3-(N-Morpholino) propanesulfonic acid) and MES (2-(N- morpholino)ethanesulfonic acid).
[00176] In some embodiments, the buffer is sodium acetate. In some embodiments, the concentration of the sodium acetate buffer is about 25-250 mM. In some embodiments, the concentration of the sodium acetate buffer is about 100 mM. In some embodiments, the sodium acetate buffer has a pH of 6.0-10.5. In some embodiments, the sodium acetate buffer has a pH of about 7.
[00177] In some embodiments, the composition further comprises a surfactant. Exemplary surfactants may include, but are not limited to sorbitan monooleate, Cremophor, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamers, polyethylene glycol, transcutol, Capmul®, labrasol, isopropyl myristate, and/or Span 80.
[00178] If an additional component in the composition is a polypeptide, a polynucleotide encoding the additional polypeptide may instead be provided, in the same manner as for the polynucleotide encoding the polypeptide of primary interest. Such polypeptides could be expressed from the same or separate expression vectors, or could be expressed in the form of a fusion protein.
Formulation of Compositions
[00179] The lipid vesicle particles of the present disclosure may be prepared by methods known in the art, and/or described herein, e.g., in the Examples section below.
[00180] In some embodiments, the lipid vesicle particles of the present disclosure are prepared using the methods described in International PCT Application WO/2019/090411, U.S. Patent No. 9,498,493, which are incorporated herein by reference in their entirety.
[00181] In some embodiments, the lipid vesicle particles may form structures such as liposomes. Methods for making liposomes are well known in the art: see, for example, Gregoriadis (1990) and Frezard (1999), both cited previously. Any suitable method for making liposomes may be used in the practice of the disclosure. Liposomes are typically prepared by hydrating the liposome components that will form the lipid bilayer (e.g., phospholipids and cholesterol) with an aqueous solution, which may be pure water or any other physiologically compatible solution such as saline, e.g., phosphate-buffered saline (PBS).
[00182] In one aspect, the present disclosure provides a method for preparing a composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside. The method can comprise one or more of the following steps: a) dissolving the one or more lipids in one or more organic solvents and optionally an aqueous solvent to create a lipid solution, b) adding the negatively charged molecule to the lipid solution formed in step a) and mixing; c) adding the ionizable aminoglycoside to the mixture formed in step b) and mixing; d) optionally, adding additional amount of the organic solvent(s) or aqueous solvent to the mixture formed in step c) thereby the overall Wt/Wt or V/V percentage ratio of organic: aqueous solvent or aqueous: organic solvent in the mixture is between 20-50%; e) drying the mixture formed in step c) or d) to generate a dried preparation; and
I) dissolving the dried preparation in the carrier comprising a continuous phase of a hydrophobic substance, thereby generating said composition.
[00183] In some embodiments, a lipid component or mixture of lipid components, such as a phospholipid (e.g., DOPC) and cholesterol, may be solubilized in one or more organic solvent, such as tert-butanol, ethanol, methanol, chloroform, or a mixture of chloroform and methanol, tert-butanol, a mixture of tert-butanol and ethanol, a mixture of tert-butanol and chloroform, or mixture of tert-butanol and water followed by filtering (e.g., a PTFE 0.2 pm filter) and drying, e.g., by rotary evaporation, freeze-drying to remove the solvents.
[00184] In some embodiments, the organic solvent(s) is present in an amount sufficient to prevent the one or more lipids from forming lipid vesicle particles in the lipid solution. In
some embodiments, the organic solvent(s) and the aqueous solvent are present in a percentage ratio of organic: aqueous solvent or aqueous: organic solvent ratio between 20- 50%. In some embodiments, the organic solvent(s) and the aqueous solvent are present in a percentage ratio of organic: aqueous solvent or aqueous: organic solvent ratio of about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50%.
[00185] In some embodiments, the organic solvent is tert-butanol. In some embodiments, the lipid solution comprises about 20%-50% tert-butanol. In some embodiments, the lipid solution comprises about 20% tert-butanol, about 25% tert-butanol, about 30% tert-butanol, about 35% tert-butanol, about 40% tert-butanol, about 45% tert-butanol, or about 50% tertbutanol. In one embodiment, the lipid solution comprises about 30% tert-butanol.
[00186] Hydration of the resulting lipid mixture may be effected by e.g., injecting the lipid mixture into an aqueous solution or sonicating the lipid mixture and an aqueous solution. During formation of the lipid vesicle particles (e.g., liposomes), the lipid components form single bilayers (unilamellar) or multiple bilayers (multilamellar) surrounding a volume of the aqueous solution with which the lipid components are hydrated.
[00187] In some embodiments, the lipid vesicle particles are then dehydrated, such as by freeze-drying or lyophilization, spray freeze-drying, spray drying, or rotary evaporation, and subsequently reconstituted with an aqueous solution.
[00188] In some embodiments, the lipid vesicle particles are combined with the carrier comprising a continuous hydrophobic phase. In some embodiments, the hydrophobic phase is essentially water-free. This can be done in a variety of ways.
[00189] If the carrier is essentially water-free, and is composed solely of a hydrophobic substance or a mixture of hydrophobic substances (e.g., use of a 100% mineral oil carrier), lipid vesicle particles may simply be mixed with the hydrophobic substance, or if there are multiple hydrophobic substances, mixed with any one or a combination of them. An exemplary preparation method is further described below and in the Examples section (see Formulation Method A (standard). In this method, any negatively charged molecules (e.g., polynucleotide) presented in an aqueous solution (e.g., sterile RNase free water) is added to a suitable buffer solution. To this diluted polynucleotide solution, previously prepared lipid vesicle particles in sterile RNase free water (e.g., particle size < 120 nm, poly dispersity index (PDI) < 0.1) is added, mixed well gently by e.g., hand or vortexing for 30 seconds. In some embodiments, formulation method A is prepared with different polymers and transfection agents by adding the respective stock solutions to the polynucleotide loaded lipid vesicle particles obtained from the above step, mixed well gently by e.g., hand or vortexing for 30 seconds. The final
formulation (with and without different polymers and transfection agents) is then dehydrated by freeze-drying or lyophilization or spray-drying; and subsequently reconstituted with an aqueous solution or with a hydrophobic substance or amixture of hydrophobic substances (e.g., use of a 100% mineral oil carrier) prior to administration.
[00190] If instead the carrier comprising a continuous phase of a hydrophobic substance contains a discontinuous aqueous phase, the carrier will typically take the form of an emulsion of the aqueous phase in the hydrophobic phase, such as a water-in-oil emulsion. Such compositions may contain an emulsifier to stabilize the emulsion and to promote an even distribution of the lipid vesicle particles (e.g., liposomes). In this regard, emulsifiers may be useful even if water-free carrier is used, for the purpose of promoting an even distribution of the lipid vesicle particles (e.g., liposomes) in the carrier. Typical emulsifiers include mannide oleate (Arlacel™ A), lecithin, Tween™ 80, and Spans™ 20, 80, 83 and 85. Typically, the weight to volume ratio (w/v) of hydrophobic substance to emulsifier is in the range of about 5:1 to about 15:1 with a ratio of about 10:1 being preferred.
[00191] The lipid vesicle particles may be added to the finished emulsion, or they may be present in either the aqueous phase or the hydrophobic phase prior to emulsification.
[00192] The negatively charged molecule such as polynucleotide to be expressed may be introduced at various different stages of the formulation process. In this section, the term “polynucleotide” includes the polynucleotide in naked form including, for example, in an mRNA or a plasmid such as an expression plasmid, or in a live vector such as a bacteria or virus.
[00193] An exemplary preparation method is further described below and in the Examples section (see Formulation Method B). In this method, lipid or lipid-mixture is dissolved in 20- 50% or 100% tert-butanol or ethanol by, e.g., simple vortexing or by shaking at 150-300 RPM in an incubator shaker at room temperature or at 37°C until dissolved. To the dissolved lipid solution, any negatively charged molecules (e.g., polynucleotide) presented in an aqueous solution (e.g., sterile RNase free water) or suitable buffer solution or complexed with another positively charged molecule/ adjuvant with known cryoprotectants is added, mixed well gently by e.g., hand or vortexing for 30 seconds. The overall Wt/Wt or V/V percentage ratio of organic: aqueous solvent mixture aqueous: organic solvent mixture in the final formulation prior to dehydration is maintained between 20-50%. Although not wishing to be bound by theory, it is believed that the one or more lipids when dissolved in the organic solvent(s) are presented in clear solution form. When admixed or exposed to the aqueous solution(s) containing the negatively charged molecule (e.g., polynucleotide) and/or ionizable aminoglycoside, the one
or more lipids form lipid vesicle particles. The formed lipid vesicle particles are then dehydrated, such as by freeze-drying or lyophilization or spray-drying; and subsequently reconstituted with an aqueous solution or with a hydrophobic substance or a mixture of hydrophobic substances (e.g., use of a 100% mineral oil carrier) prior to administration. In general, this method has several advantages over the conventional lipid nanoparticles method including increased solubility and encapsulation of hydrophobic molecules, decreased freeze- drying time, and better oil reconstitution characteristics for hydrophobic or complex compounds.
[00194] More than one polynucleotide may be incorporated into the composition. For example, two or more polynucleotides encoding different proteins may be incorporated into the composition, or a polynucleotide encoding a protein may be present as well as a polynucleotide encoding an antisense RNA or interfering RNA. Proteins may be expressed as the fusion product of two different polynucleotides. More than one polynucleotide may be under the control of the same regulatory elements, e.g., two or more polynucleotides under transcriptional control of a single promoter.
[00195] In some embodiments, the polynucleotide is present in the aqueous solution used to hydrate the components that are used to form the lipid bilayers of the lipid vesicle particles (e.g., liposomes). In this case, the polynucleotide will be encapsulated in the lipid vesicle particles , present in its aqueous interior. If the resulting liposomes are not washed or dried, such that there is residual aqueous solution present that is ultimately mixed with the carrier comprising a continuous phase of a hydrophobic substance, it is possible that additional polynucleotide may be present outside the lipid vesicle particles in the final product. In a related technique, the polynucleotide may be mixed directly with the lipid vesicle particles or with the components used to form the lipid bilayers of the lipid vesicle particles, prior to hydration with the aqueous solution.
[00196] In an alternative approach, the polynucleotide may instead be mixed with the carrier comprising a continuous phase of a hydrophobic substance, before, during, or after the carrier is combined with the lipid vesicle particles. If the carrier is an emulsion, the polynucleotide may be mixed with either or both of the aqueous phase or hydrophobic phase prior to emulsification. Alternatively, the polynucleotide may be mixed with the carrier after emulsification.
[00197] The technique of combining the polynucleotide with the carrier may be used together with encapsulation of the polynucleotide in the lipid vesicle particles as described above, such
that polynucleotide is present both within the lipid vesicle particles and in the carrier comprising a continuous phase of a hydrophobic substance.
[00198] Generally, the composition may comprise about 0.1 to 5 mg polynucleotide per ml of the composition and about 1 mg to 300 mg lipid vesicle particles per ml of the composition.
[00199] In some embodiments, the particle size of the lipid vesicle particles prepared according the methods described herein prior to dehydration is about 100-5000 nm (0.1 to 5 microns). The particle size of the lipid vesicle particles may vary depending upon the ratio of organic: aqueous or aqueous: organic solvent composition in the final formulation prior to dehydration and also on the choice of organic solvent. In some embodiments, the particle size of the lipid vesicle particles prepared according the methods described herein prior to dehydration is about 100-200 nm, about 100-300 nm, about 100-400 nm, about 100-500 nm, about 100-1000 nm, about 100-1500 nm, about 110-1500 nm, about 110-1800 nm, about 120- 1500 nm, about 120-2000 nm, about 130-2000 nm, about 130-2500 nm, about 150-3000 nm, about 150-4000 nm, about 200-4000 nm, or about 200-5000 nm.
[00200] In some embodiments, the mean particle size of the lipid vesicle particles prepared according the methods described herein prior to dehydration is about 100-1000 nm (0.1 to 1 microns). In some embodiments, the mean particle size of the lipid vesicle particles prepared according the methods described herein prior to dehydration is about 100 nm, about 115 nm, about 120 nm, about 125 nm, about 130 nm, about 135 nm, about 140 nm, about 145 nm, about 150 nm, about 160 nm, about 170 nm, about 180 nm, about 190 nm, about 200 nm, about 300 nm, about 400 nm, about 500 nm, about 600 nm, about 700 nm, about 800 nm, about 900 nm, or about 1000 nm.
[00201] In some embodiments, the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance form reverse micelles.
[00202] In some embodiments, the particle size of the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance is about 1-50 nm. In some embodiments, the particle size of the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance is about 1-10 nm, 2-8 nm, 4-9 nm, 5-10 nm, 6-12 nm, 7-15 nm, 8-20 nm, 10-30 nm, 15-40 nm, 20-45 nm, or 30-50 nm.
[00203] In some embodiments, the mean particle size of the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a
continuous phase of a hydrophobic substance is about 1-20 nm. In some embodiments, the mean particle size of the lipid vesicle particles prepared according the methods described herein after reconstitution in a carrier comprising a continuous phase of a hydrophobic substance is about 1 nm, about 2 nm, about 3 nm, about 4 nm, about 5 nm, about 6 nm, about 7 nm, about 8 nm, about 9 nm, about 10 nm, about 11 nm, about 12 nm, about 13 nm, about 14 nm, about 15 nm, about 16 nm, about 17 nm, about 18 nm, about 19 nm, or about 20 nm.
[00204] There are several techniques, instruments and services that are available to measure the mean particle size of lipid vesicle particles, such as electron microscopy (transmission, TEM, or scanning, SEM), atomic force microscopy (AFM), Fourier-transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), powder X-ray diffraction (XRD), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI- TOF-MS), nuclear magnetic resonance (NMR) and dynamic light scattering (DLS). DLS is a well-established technique for measuring the particle size in the submicron size range, with available technology to measure particle sizes of less than 1 nm (LS Instruments, CH; Malvern Instruments, UK).
[00205] Polydispersity index (PDI) is a measure of the size distribution of the lipid vesicle particles. It is known in the art that the term “poly dispersity” may be used interchangeably with “dispersity”. The PDI can be calculated by determining the mean particle size of the lipid vesicle particles and the standard deviation from that size. There are techniques and instruments available for measuring the PDI of lipid vesicle particles. For example, DLS is a well- established technique for measuring the particle size and size distribution of particles in the submicron size range, with available technology to measure particle sizes of less than 1 nm (LS Instruments, CH; Malvern Instruments, UK). For a perfectly uniform sample, the PDI would be 0.0.
[00206] In some embodiments, PDI of a lipid vesicle particle prepared according the methods described herein prior to dehydration is between about 0.1 to about 0.7. In some embodiments, PDI of a lipid vesicle particle prepared according the methods described herein prior to dehydration is about 0.1 to about 0.4, about 0.2 to about 0.5, about 0.3 to about 0.6, about 0.4 to about 0.7, or about 0.5 to 0.7. In some embodiments, PDI of a lipid vesicle particle described herein is about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, or about 0.7.
[00207] In an embodiment, the PDI is measured by any instrument and/or machine suitable for measuring the PDI of lipid vesicle particles. In an embodiment, the PDI size distribution is determined by DLS (Malvern Instruments, UK). In an embodiment, the PDI is measured by DLS using a Malvern Zetasizer series instrument, such as for example the Zetasizer Nano S,
Zetasizer APS, Zetasizer pV or Zetasizer AT machines (Malvern Instruments, UK). In an embodiment, the PDI is measured by DLS using a Malvern Zetasizer Nano S machine. Exemplary conditions and system settings are described above in respect of determining mean particle size.
[00208] If the composition contains one or more adjuvants and/or additional components, the adjuvant(s) and/or additional component(s) can be incorporated in the composition together with the polynucleotide at the same processing step, or separately, at a different processing step. For instance, the polynucleotide and the adjuvant(s) and/or additional component(s) may both be present in the aqueous solution used to hydrate the lipid bilayer-forming components, such that both the polynucleotide and adjuvant(s) and/or additional component(s) become encapsulated in the lipid vesicle particles. Alternatively, the polynucleotide may be encapsulated in the lipid vesicle particles, and the adjuvant(s) and/or additional component(s) mixed with the carrier comprising a continuous phase of a hydrophobic substance. It will be appreciated that many such combinations are possible.
[00209] In some embodiments, the polynucleotide and the adjuvant(s) and/or additional component(s) may be in the form of a complex, in which they are in intimate contact at least prior to incorporation into the composition. Complexing may but need not necessarily involve a chemical linkage, such as covalent bonding.
[00210] The compositions as described herein may be formulated in a form that is suitable for any administration routes, such as oral, nasal, aerosol, rectal or parenteral administration. Parenteral administration includes intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular, transepithelial, intrapulmonary, intrathecal, and topical modes of administration. The compositions may be formulated for systemic or localized distribution in the body of the subject. The preferred routes are intramuscular, subcutaneous and intradermal to achieve a depot effect. In practice, a depot effect is achieved when the therapeutic agent remains at the site of injection for more than about one hour.
[00211] The injection site may be anywhere close to, or directly into a lymph node, for example. Alternatively, the injection site may be directly into a spleen, a tumor or other diseased tissue. The volume that may be injected is within the professional judgment of the clinician. The volume depends on the injecting device used and the site of injection. When the injection is intramuscularly or subcutaneous, the injection volume may be about 1 mL. When needleless injection is used, the volume may be as low as 0.01 mL. The volume may be increased by injecting multiple sites. Suitable injection volumes may be about 0.01 mL, about 0.02 mL, about 0.05 mL, about 0.1 mL, about 0.2 mL, about 0.3 mL, about 0.4 mL, about 0.5
mL, about 0.6 mL, about 0.7 mL, about 0.8 mL, about 0.9 mL, about 1 mL, about 1.5 mL, about 2 mL, about 0.01-0.05 mL, about 0.05-0.1 mL, about 0.1-0.2 mL, about 0.2-0.4 mL, about 0.1-0.5 mL, about 0.4-0.8 mL, about 0.5-1 mL, about 0.8-1.2 mL, or about 1-1.5 mL.
[00212] Upon administration, formulations of the present disclosure may create stable depot at the site of delivery that protects active ingredient (e.g., a polynucleotide) from degradation by nucleases or by renal or hepatic clearance for an extended period of time (e.g., up to one week or two weeks). In some embodiments, formulations of the present disclosure may also provide controlled and prolonged exposure of active ingredients (e.g., a polynucleotide) to the cells at the delivery site allowing a direct delivery of treatment into target and limits drug distribution specifically to its target site, thus avoiding systemic effects.
Kits and Reagents
[00213] The present disclosure may be optionally provided to a user as a kit. For example, a kit of the disclosure contains one or more of the compositions of the disclosure. The kit can further comprise one or more additional reagents, packaging material, containers for holding the components of the kit, and an instruction set or user manual detailing preferred methods of using the kit components for a desired purpose.
Methods of the Invention
[00214] The invention finds application in any instance in which it is desired to deliver a negatively charged molecule (e.g., polynucleotide) to a target cell or a subject.
[00215] In one aspect, provided herein is a method for delivering a negatively charged molecule to a target cell, comprising administering a composition of the present disclosure to the target cell. In some embodiments, the target cell is an antigen-presenting cell (APC).
[00216] In another aspect, provided herein is a method for delivering a negatively charged molecule to a subject, comprising administering the composition of the present disclosure to the subject.
[00217] The compositions of the present disclosure may have applications in the treatment or prevention of a disease. Representative applications of the disclosure include cancer treatment and prevention, gene therapy, adjuvant therapy, infectious disease treatment and prevention, allergy treatment and prevention, autoimmune disease treatment and prevention, neuron- degenerative disease treatment, and arteriosclerosis treatment.
[00218] Prevention or treatment of disease includes obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent
of disease, stabilization of the state of disease, prevention of development of disease, prevention of spread of disease, delay or slowing of disease progression, delay or slowing of disease onset, conferring protective immunity against a disease-causing agent and amelioration or palliation of the disease state. Prevention or treatment can also mean prolonging survival of a patient beyond that expected in the absence of treatment and can also mean inhibiting the progression of disease temporarily, although more preferably, it involves preventing the occurrence of disease such as by preventing infection in a subject.
[00219] In another embodiment, the antigen encoded by a polynucleotide in the composition of the disclosure may be a cancer or tumor-associated protein, such as for example, a membrane surface-bound cancer antigen which is capable of being recognized by an antibody.
[00220] Cancers that may be treated and/or prevented by the use or administration of a composition of the disclosure include, without limitation, carcinoma, adenocarcinoma, lymphoma, leukemia, sarcoma, blastoma, myeloma, and germ cell tumors. In one embodiment, the cancer may be caused by a pathogen, such as a virus. Viruses linked to the development of cancer are known to the skilled person and include, but are not limited to, human papillomaviruses (HPV), John Cunningham virus (JCV), Human herpes virus 8, Epstein Barr Virus (EBV), Merkel cell polyomavirus, Hepatitis C Virus and Human T cell leukemia virus- 1. A composition of the disclosure may be used for either the treatment or prophylaxis of cancer, for example, in the reduction of the severity of cancer or the prevention of cancer recurrences. Cancers that may benefit from the compositions of the disclosure include any malignant cell that expresses one or more tumor specific antigens.
[00221] In another embodiment, the antigen may be a toxin or an allergen that is capable of being neutralized by an antibody.
[00222] In another embodiment, the antigen may be an antigen associated with a disease where it is desirable to sequester the antigen in circulation, such as for example an amyloid protein (e.g., Alzheimer's disease). Thus, a composition of the disclosure may be suitable for use in the treatment and/or prevention of a neurodegenerative disease in a subject in need thereof, wherein the neurodegenerative disease is associated with the expression of an antigen. The subject may have a neurodegenerative disease or may be at risk of developing a neurodegenerative disease. Neurodegenerative diseases that may be treated and/or prevented by the use or administration of a composition of the disclosure include, without limitation, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). For example, Alzheimer's disease is characterized by the association of B- amyloid plaques and/or tau proteins in the brains of patients with Alzheimer's disease (see, for
example, Goedert and Spillantini, Science, 314: 777-781, 2006). Herpes simplex virus type 1 has also been proposed to play a causative role in people carrying the susceptible versions of the apoE gene (Itzhaki and Wozniak, J Alzheimers Dis 13: 393-405, 2008).
[00223] In a further embodiment, the composition may comprise a mixture of B cell epitopes as antigens for inducing a humoral immune response. The B cell epitopes may be linked to form a single polypeptide.
[00224] In another embodiment, the antigen may be any peptide or polypeptide that is capable of inducing a specific humoral immune response to a specific conformation on targeted tumor cells.
[00225] In some embodiments, the composition of the present disclosure may be used to induce humoral and/or cellular immune response in a subject. Accordingly, compositions as described herein may be useful for treating or preventing diseases and/or disorders ameliorated by humoral immune responses (e.g., involving B-cells and antibody production). The compositions may find application in any instance in which it is desired to administer an antigen to a subject to induce a humoral immune response or antibody production.
[00226] A humoral immune response, as opposed to cell-mediated immunity, is mediated by secreted antibodies which are produced in the cells of the B lymphocyte lineage (B cells). Such secreted antibodies bind to antigens, such as for example those on the surfaces of foreign substances and/or pathogens (e.g., viruses, bacteria, etc.) and flag them for destruction.
[00227] Antibodies are the antigen-specific glycoprotein products of a subset of white blood cells called B lymphocytes (B cells). Engagement of antigen with antibody expressed on the surface of B cells can induce an antibody response comprising stimulation of B cells to become activated, to undergo mitosis and to terminally differentiate into plasma cells, which are specialized for synthesis and secretion of antigen-specific antibody.
[00228] B cells are the sole producers of antibodies during an immune response and are thus a key element to effective humoral immunity. In addition to producing large amounts of antibodies, B cells also act as antigen-presenting cells and can present antigen to T cells, such as T helper CD4 or cytotoxic CD8, thus propagating the immune response. B cells, as well as T cells, are part of the adaptive immune response which is essential for vaccine efficacy. During an active immune response, induced either by vaccination or natural infection, antigen-specific B cells are activated and clonally expand. During expansion, B cells evolve to have higher affinity for the epitope. Proliferation of B cells can be induced indirectly by activated T-helper cells, and also directly through stimulation of receptors, such as the toll-like receptors (TLRs).
[00229] Antigen presenting cells, such as dendritic cells, macrophages and B cells, are drawn to vaccination sites and can interact with antigens and adjuvants contained in the vaccine. The adjuvant stimulates the cells to become activated and the antigen provides the blueprint for the target. Different types of adjuvants provide different stimulation signals to cells. For example, Poly I:C (a TLR3 agonist) can activate dendritic cells, but not B cells. Adjuvants such as Pam3Cys, Pam2Cys and FSL-1 are especially adept at activating and initiating proliferation of B cells, which is expected to facilitate the production of an antibody response (Moyle et al., Curr Med Chem, 2008; So., J Immunol, 2012, which are incorporated hereby by reference in their entireties).
[00230] One method of evaluating an antibody response is to measure the titers of antibodies reactive with a particular antigen. This may be performed using a variety of methods known in the art such as enzyme-linked immunosorbent assay (ELISA) of antibody-containing substances obtained from animals. For example, the titers of serum antibodies which bind to a particular antigen may be determined in a subject both before and after exposure to the antigen. A statistically significant increase in the titer of antigen-specific antibodies following exposure to the antigen would indicate the subject had mounted an antibody response to the antigen.
[00231] Other assays that may be used to detect the presence of an antigen-specific antibody include, without limitation, immunological assays (e.g., radioimmunoassay (RIA)), immunoprecipitation assays, and protein blot (e.g., Western blot) assays; and neutralization assays (e.g., neutralization of viral infectivity in an in vitro or in vivo assay).
[00232] The compositions of the present disclosure, by stimulating strong antibody responses, may be capable of protecting a subject from a disease, disorder or ailment associated with an antigen capable of inducing a humoral immune response.
[00233] Without limitation, this includes for example, infectious diseases, cancers involving a membrane surface-bound cancer antigen which is recognized by an antibody, diseases where it is desirable to sequester antigen in circulation, like amyloid protein (e.g., Alzheimer's disease); neutralizing toxins with an antibody; neutralizing viruses or bacteria with an antibody; or neutralizing allergens (e.g., pollen) for the treatment of allergies.
[00234] A humoral immune response is the main mechanism for effective infectious disease vaccines. However, a humoral immune response can also be useful for combating cancer. Unlike a cancer vaccine designed to produce a cytotoxic CD8 T cell response that can recognize and destroy cancer cells, B cell mediated responses may target cancer cells through other mechanisms which may in some instances cooperate with a cytotoxic CD8 T cell for maximum benefit. Examples of mechanisms of B cell mediated (e.g., humoral immune response
mediated) anti-tumor responses include, without limitation: 1) Antibodies produced by B cells that bind to surface antigens found on tumor cells or other cells that influence tumorigenesis. Such antibodies can, for example, induce killing of target cells through antibody-dependent cell-mediated cytotoxicity (ADCC) or complement fixation, potentially resulting in the release of additional antigens that can be recognized by the immune system; 2) Antibodies that bind to receptors on tumor cells to block their stimulation and in effect neutralize their effects; 3) Antibodies that bind to factors released by or associated with tumor or tumor-associated cells to modulate a signaling or cellular pathway that supports cancer; and 4) Antibodies that bind to intracellular targets and mediate anti-tumor activity through a currently unknown mechanism.
[00235] Several methods can be used to demonstrate the induction of humoral immunity following vaccination. These can be broadly classified into detection of: i) specific antigen presenting cells; ii) specific effector cells and their functions; and iii) release of soluble mediators such as cytokines.
[00236] In various embodiments, the composition may be administered via oral, nasal, rectal or parenteral administration. Parenteral administration includes intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular, transepithelial, intrapulmonary, intrathecal, and topical modes of administration. In some embodiments, the composition is administered via intramuscular, subcutaneous or intradermal injection.
[00237] The amount of composition used in a single treatment may vary depending on factor such as the nature of negatively charged molecule to be delivered, the type of formulation, and the size of the subject. One skilled in the art will be able to determine, without undue experimentation, the effective amount of composition to use in a particular application.
[00238] The skilled artisan can determine suitable treatment regimes, routes of administration, dosages, etc., for any particular application in order to achieve the desired result. Factors that may be taken into account include, e.g., the nature of a polypeptide to be expressed; the disease state to be prevented or treated; the age, physical condition, body weight, sex and diet of the subject; and other clinical factors.
[00239] The subject to be treated may be any vertebrate, preferably a mammal, more preferably a human.
Exemplary Embodiments
1. A composition, comprising: a) one or more lipids,
b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, and d) an ionizable aminoglycoside. The composition of embodiment 1, wherein the one or more lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof. The composition of embodiment 2, wherein the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin. The composition of embodiment 3, wherein the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), di oleoyl phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof. The composition of any one of embodiments 2-4, wherein the one or more lipids comprise DOPC and cholesterol. The composition of any one of embodiments 1-5, wherein the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, diethylaminoethyl (DEAE)-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose- 6,6-dibehenate (TDB) with Dimethyldioctadecylammonium (DDA), heptakis(6-deoxy-6- amino)-β-cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof. The composition of embodiment 6, wherein the ionizable aminoglycoside is chitosan. The composition of embodiment 7, wherein the chitosan has a molecular weight of about 60 kDa to 150 kDa. The composition of embodiment 7 or 8, wherein the chitosan has a molecular weight of about 100 kDa to 120 kDa. The composition of any one of embodiments 7-9, wherein the chitosan has a molecular weight of about 100 kDa. The composition of any one of embodiments 7-10, wherein the chitosan has a degree of deacetylation (DD) of about 15 - 95%. The composition of embodiment 11, wherein the chitosan has a degree of deacetylation (DD) of about 25%. The composition of any one of embodiments 7-12, wherein the chitosan is added in a concentration of about 0.5 mg/mL to about 3 mg/mL.
The composition of any one of embodiments 7-13, wherein the chitosan is added in a concentration of about 1 mg/mL to about 2 mg/mL. The composition of any one of embodiments 1-14, further comprising an adjuvant. The composition of embodiments 1 and 6-14, comprising: a) one or more positively charged lipids, b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, d) an ionizable aminoglycoside, and e) optionally, an adjuvant. The composition according to embodiment 16, wherein the one or more positively charged lipids comprise 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 3β-[N-(N',N'- dimethylaminoethane)-carbamoyl]cholesterol (DC-chol esterol), 1 ,2-distearoyl-3- dimethylammonium-propane (DAP), N-(4-carboxybenzyl)-N,N-dimethyl-2,3- bis(oleoyloxy)propan-l-aminium (DOBAQ), N-palmitoyl homocysteine (PHC), DC- cholesterol, or a combination thereof. The composition of any one of embodiments 1-17, wherein the negatively charged molecule is a polynucleotide. The composition of any one of embodiments 1-18, wherein the negatively charged molecule is a ribonucleic acid (RNA), or RNA derivative. The composition of any one of embodiments 1-18, wherein the negatively charged molecule is a deoxyribonucleic acid (DNA), or DNA derivative. The composition of any one of embodiments 18-20, wherein the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme. The composition of embodiment 21, wherein the polynucleotide comprises an mRNA. The composition of any one of embodiments 18-22, wherein the polynucleotide encodes a polypeptide. The composition of embodiment 23, wherein the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
The composition of embodiment 24, wherein the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen, a toxin, or an allergen. The composition of any one of embodiments 1-25, wherein the concentration ratio of the lipids and the negatively charged molecule is between about 33000:1 to about 3300:1. The composition of embodiment 26, wherein the concentration ratio of the lipids and the negatively charged molecule is between about 26400:1 to about 6600:1. The composition of embodiment 27, wherein the concentration ratio of the lipids and the negatively charged molecule is about 13200:1. The composition of any one of embodiments 1-28, wherein the carrier comprises an oil or a water-in-oil emulsion. The composition of embodiment 29, wherein the oil comprises a natural oil or a synthetic oil. The composition of embodiment 30, wherein the oil comprises a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, or combinations thereof. The composition of embodiment 31, wherein the carrier comprises a mannide oleate in mineral oil solution. The composition of embodiment 32, wherein the carrier comprises Montanide® ISA 51. The composition of embodiment 31, wherein the carrier comprises MS80 oil (mixture of mineral oil and Span 80). The composition of any one of embodiments 15-34, wherein the adjuvant is a polymer, a protein, a polysaccharide, or a combination thereof. The composition of any one of embodiments 1-35, further comprising a buffer and/or surfactant. The composition of any one of embodiments 1-36, wherein the composition is an injectable composition. A method for delivering a negatively charged molecule to a target cell, comprising administering the composition of any one of embodiments 1-37 to said target cell. The method of embodiment 38, wherein the target cell is an antigen-presenting cell (APC). A method for delivering a negatively charged molecule to a subject, comprising administering the composition of any one of embodiments 1-37 to said subject. A method for treating or preventing cancer, an infectious disease or an disease and/or disorder ameliorated by humoral and/or cellular immune response in a subject in need thereof, said method comprising administering to the subject an effective amount of the composition of any one of embodiments 1-37.
The method of any one of embodiments 38-40, wherein the negatively charged molecule is a polynucleotide. The method of embodiment 42, wherein the polynucleotide comprises an mRNA. The method of embodiment 42 or 43, wherein the polynucleotide encodes a polypeptide. The method of embodiment 44, wherein the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor. The method of embodiment 45, wherein the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen or a toxin. The method of any one of embodiment 40-46, wherein the composition is administered via subcutaneous, intramuscular or intradermal injection. A method for preparing a composition of any one of embodiments 1-37. A method for preparing a composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside, comprising: a) dissolving the one or more lipids in one or more organic solvents and optionally an aqueous solvent to create a lipid solution, b) adding the negatively charged molecule to the lipid solution formed in step a) and mixing; c) adding the ionizable aminoglycoside to the mixture formed in step b) and mixing; d) optionally, adding additional amount of the organic solvent(s) or aqueous solvent to the mixture formed in step c) thereby the overall Wt/Wt or V/V percentage ratio of organic: aqueous solvent or aqueous: organic solvent in the mixture is between 20-50%; e) drying the mixture formed in step c) or d) to generate a dried preparation; and f) dissolving the dried preparation in the carrier comprising a continuous phase of a hydrophobic substance, thereby generating said composition. The method of embodiment 49, wherein in step a) the one or more organic solvents is present in an amount sufficient to prevent the one or more lipids from forming lipid vesicle particles in the lipid solution.
The method of embodiment 49 or 50, wherein the one or more organic solvents comprises tert-butanol, ethanol, methanol, chloroform, or a mixture thereof. The method of embodiment 49 or 50, wherein the one or more organic solvent comprises tert-butanol, tert-butanol -ethanol mixture or tert-butanol-chloroform mixture. The method of any one of embodiments 49-52, wherein the lipid solution comprises about 30% tert-butanol. The method of any one of embodiments 49-53, wherein the aqueous solvent is water or a buffer solution. The method of any one of embodiments 49-54, wherein the negatively charged molecule is present in an aqueous solution. The method of any one of embodiments 49-55, wherein the ionizable aminoglycoside is present in an aqueous solution. The method of any one of embodiments 49-56, wherein drying is performed by freeze- drying, spray freeze-drying, spray drying, or rotary evaporation. The method of any one of embodiments 49-57, wherein the one or more lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof. The method of embodiment 58, wherein the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin. The method of embodiment 59, wherein the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), di oleoyl phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof. The method of any one of embodiments 58-60, wherein the one or more lipids comprise DOPC and cholesterol. The method of any one of embodiments 49-61, wherein the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, diethylaminoethyl (DEAE)-dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl-D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose- 6,6-dibehenate (TDB) with Dimethyldioctadecylammonium bromide (DDA), heptakis(6- deoxy-6-amino)-β-cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof. The method of embodiment 62, wherein the ionizable aminoglycoside is chitosan.
The method of embodiment 63, wherein the chitosan has a molecular weight of about 60 kDa to 150 kDa. The method of embodiment 62 or 63, wherein the chitosan has a molecular weight of about 100 kDa to 120 kDa. The method of any one of embodiments 63-65, wherein the chitosan has a molecular weight of about 100 kDa. The method of any one of embodiments 63-66, wherein the chitosan has a degree of deacetylation (DD) of about 15 - 95%. The method of embodiment 67, wherein the chitosan has a degree of deacetylation (DD) of about 25%. The method of any one of embodiments 63-68, wherein the chitosan is added in a concentration of about 0.5 mg/mL to about 3 mg/mL. The method of any one of embodiments 63-69, wherein the chitosan is added in a concentration of about 1 mg/mL to about 2 mg/mL. The method of any one of embodiments 49-70, wherein the negatively charged molecule is a polynucleotide. The method of any one of embodiments 49-71, wherein the negatively charged molecule is a ribonucleic acid (RNA), or RNA derivative. The method of any one of embodiments 49-72, wherein the negatively charged molecule is a deoxyribonucleic acid (DNA), or DNA derivative. The method of any one of embodiments 71-73, wherein the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme. The method of embodiment 74, wherein the polynucleotide comprises an mRNA. The method of any one of embodiments 72-75, wherein the polynucleotide encodes a polypeptide. The method of embodiment 76, wherein the polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor. The method of embodiment 77, wherein the antigen is derived from a virus, bacterium or protozoan, a membrane surface-bound cancer antigen, a toxin, or an allergen.
The method of any one of embodiments 49-78, wherein the concentration ratio of the lipids and the negatively charged molecule is between about 33000:1 to about 3300:1. The method of embodiment 79, wherein the concentration ratio of the lipids and the negatively charged molecule is between about 26400:1 to about 6600:1. The method of embodiment 80, wherein the concentration ratio of the lipids and the negatively charged molecule is about 13200:1. The method of any one of embodiments 49-81, wherein the carrier comprises an oil or a water-in-oil emulsion. The method of embodiment 82, wherein the oil comprises a natural oil or a synthetic oil. The method of embodiment 83, wherein the oil comprises a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, or combinations thereof. The method of embodiment 84, wherein the carrier comprises a mannide oleate in mineral oil solution. The method of embodiment 85, wherein the carrier comprises Montanide® ISA 51. The method of embodiment 84, wherein the carrier comprises MS80 oil (mixture of mineral oil and Span 80). The method of any one of embodiments 49-87, wherein the composition further comprises an adjuvant. The method of embodiment 88, wherein the adjuvant is a polymer, a protein, a polysaccharide, or a combination thereof. The method of any one of embodiments 49-89, wherein the composition further comprises a buffer and/or surfactant. The method of any one of embodiments 49-90, wherein the composition is an injectable composition. A kit comprising a composition of any one of embodiments 1-37, and instructions for using said composition to deliver a negatively charged molecule to a subject. The method of any one of embodiments 40-47 or the kit of embodiment 92, wherein said subject is a mammal. The method of any one of embodiments 40-47 or the kit of embodiment 92, wherein said subject is a human.
EXAMPLES
[00240] The following examples are provided to further describe some of the embodiments disclosed herein. The examples are intended to illustrate, not to limit, the disclosed embodiments.
Example 1. Addition of different lipids/polymers/transfection agents in nucleic acid formulation
[00241] Seven test formulations were prepared with the addition of different lipids, polymers, or transfection agents to the standard formulation (see Formulation Method A). The methods and materials used for preparing each of these formulations are detailed below.
[00242] Formulation Method A (Standard)
[00243] 250 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next, 50 μL eGFP mRNA was added and the solution was gently swirled by hand to mix. 500 μL of 132 mg/mL DOPC/Chol lipid vesicle particles (Size 85.05 nm, polydispersity index (PDI) 0.047, pH 6.36) prepared in di ethylpyrocarbonate (DEPC) treated water was then added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix and filled to 1.0 mL by adding 200 μL of DEPC treated water. The vial was then partially stoppered and freeze- dried. The freeze-dried cake was then reconstituted with 0.45 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 132 mg/mL, eGFPmRNA 0.1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected subcutaneously (SC) in mice.
[00244] Formulation Method A with transfection agent Protamine 0.5%
[00245] 2.122 mg of Protamine using BL-5 Sartorius Microbalance was weighed in a sterile baked 2-mL vial. 380.38 μL of DEPC treated water was added. The vial was vortexed for 2 minutes and incubated at 37°C with shaking at 200 revolutions per minute (RPM) for 30 mins. Next, 212.5 μL of 0.2 M sodium acetate, pH 7 was added to the prepared protamine solution and mixed well. 212.5 μL of 132 mg/mL DOPC/Chol lipid vesicle particles in DEPC treated water (Size 85.05 nm, PDI 0.047, pH 6.36) was added. The solution was gently swirled/shook by hand to mix. The pH was adjusted to 7 and 42.5 μL eGFP mRNA was added. The solution was gently swirled by hand to mix and the vial was freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL, Protamine 0.5% and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00246] Formulation Method A with transfection agent Mannose 2%
[00247] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a 2-mL baked vial. Next, 212.5 μL of 132 mg/mL DOPC/Chol lipid vesicle particles in DEPC treated water (Size 85.05 nm, PDI 0.047, pH 6.36) was added. The solution was gently swirled/shook by hand to mix. 85 μL of 10% mannose stock (dissolved 119.1 mg of Mannose in 1.19 mL DEPC treated water and vortexed for 1 minute to obtain clear solution) was added and the solution was gently swirled by hand to mix. pH was adjusted to 6.5 and then 297.5 μL of DEPC treated water was added. Finally, 42.5 μL eGFP-mRNA was added, the solution was gently swirled by hand and the vial was freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL, Mannose 2% and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00248] Formulation Method A with transfection agent Chloroquine 1%
[00249] 212.5 μL of 0.2M Sodium Acetate, pH 7 was added to a 2-mL baked vial, Next, 212.5 μL of 132 mg/mL DOPC/Chol lipid vesicle particles in DEPC treated water (Size 85.05 nm, PDI 0.047, pH 6.36) was added and the solution was gently swirled/shook by hand to mix. 42.5 μL of 10% chloroquine stock (dissolved 138.1 mg of chloroquine in 1.381 mL 10% acetic acid and vortexed for 2 minutes to obtain clear solution) was added. The solution was gently swirled by hand to mix. pH was adjusted from 4. 14 to 7.43 using 160 μL 0.5M NaOH and then 180 μL of DEPC treated water was added. Finally, 42.5 μL eGFP mRNA was added, the solution was gently swirled by hand and the vial was freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP-mRNA 0.1 mg/mL, Chloroquine 1% and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00250] Formulation Method A with Chitosan polymer (60-120 kDa/15-25% DD; 1 mg/mL)
[00251] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next, 42.5 μL eGFP mRNA was added and the solution was gently swirled by hand to mix. 212.5 μL of 132 mg/mL DOPC/Chol lipid vesicle particles (Size 85.05 nm, PDI 0.047, pH 6.36) prepared in DEPC treated water was added to this eGFP-mRNA solution. The solution was gently swirled/shook by hand to mix. 42.5 μL of chitosan stock (60-120 kDa/15-25% DD, 10 mg/mL in 0.25% Acetic Acid) was added and the solution was filled to 0.85 mL by adding 340 μL of DEPC treated water. pH was measured as 6.1. The vial was then partially stoppered and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1
mg/mL, chitosan 1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00252] Formulation Method A with Cationic lipid DOTAP
[00253] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next,
42.5 μL eGFP-mRNA was added and the solution was gently swirled by hand to mix. 425 μL of 66 mg/mL DOTAP lipid vesicle particles (Size 87.48 nm, PDI 0.059, pH 5.12) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/ shook by hand to mix and filled to 0.85 mL by adding 170 μL of DEPC treated water. The final pH of the formulation was pH 7.1. The vial was then partially stoppered and freeze- dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOTAP 132 mg/mL, eGFPmRNA 0.1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00254] Formulation Method A with Cationic lipid DOTAP & DOPC/Chol Mixture
[00255] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next,
42.5 μL eGFP mRNA was added and the solution was gently swirled by hand to mix. 106.25 μL of 132 mg/mL DOPC/Chol lipid vesicle particles prepared in DEPC treated water (Size 85.05 nm, PDI 0.047, pH 6.36) was added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix. Next, 276.25 μL of DEPC treated water was added followed by the addition of 212.5 μL of 66 mg/mL DOTAP nanoparticles prepared in DEPC treated water (Size 87.48 nm, PDI 0.059, pH 5.12). The solution was gently swirled/shook by hand to mix. The final pH of the formulation was pH 6.90. The vial was then partially stoppered and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOTAP 33 mg/mL, DOPC/Chol 33 mg/mL, eGFP mRNA 0.1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00256] Formulation Method A with Cationic lipid DC-Cholesterol
[00257] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next,
42.5 μL eGFP mRNA was added and gently swirled by hand to mix. 425 μL of 66 mg/mL DC- Cholesterol lipid vesicle particles prepared in DEPC treated water (Size 137.3 nm, PDI 0.038, pH 4.08) was added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix. Next, 170 μL of DEPC treated water was added. The solution was gently swirled/shook by hand to mix. The final pH of the formulation was pH 6.2. The vial was then partially stoppered and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DC-Cholesterol 66
mg/mL, eGFP mRNA 0.1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00258] Mice (Female, CD57BL/6, 6-8 weeks, 15-25g n=4 per group ) were treated with 50 μL formulations described above on study day (SD) 0. Formulations were administered subcutaneously in the right flank. Mice were terminated on SD8 or 14 when tissues from the site of injection were collected and processed by crushing in PBS buffer, centrifuging and resuspending in PBS buffer. Intracellular eGFP expression was quantified using a BD FACSCelesta flow cytometer and FlowJo software. Up to 300,000 events was acquired for each sample in the FITC channel using the 518/528 filter. The percent of GFP positive cells in the site of injection (SOI) was determined on SD8 (Figures 2 and 3) and Day 14 (Figure 4) after injection. It was shown that addition of chitosan polymer (Figure 2) or using cationic lipids DOTAP (Figure 3), DC-Cholesterol (Figure 4) in the formulation strongly enhance mRNA delivery to cells compared to the standard formulation.
Example 2. Optimizing nucleic acid formulation with chitosan/ cationic lipids
[00259] Seven test formulations were prepared with the addition of different amounts of chitosan and DOTAP to the standard formulation (see Formulation Method A). For two of the test formulations, a modified formulation method (Formulation Method B) was used. The methods and materials used for preparing each of these formulations are detailed below.
[00260] Formulation Method A (Standard)
[00261] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next, 42.5 μL eGFP mRNA was added, and the solution was gently swirled by hand to mix. 425 μL of 132 mg/mL DOPC/Chol lipid vesicle particles (Size 81.02 nm, PDI 0.053, pH 6.77) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/ shook by hand to mix and filled to 0.85 mL by adding 170 μL of DEPC treated water. The vial was then partially stoppered and freeze-dried. The freeze-dried cake was then reconstituted with 0.369 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 132 mg/mL, eGFP mRNA 0.1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00262] Formulation Method A with Cationic lipid DOTAP (66 mg/mL)
[00263] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next, 42.5 μL eGFP mRNA was added, and the solution was gently swirled by hand to mix. 212.5 μL of 132 mg/mL DOTAP lipid vesicle particles (Size 116.5 nm, PDI 0.125) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/shook
by hand to mix and filled to 0.85 mL by adding 382.5 μL of DEPC treated water. The final pH of the formulation was pH 6.37. The vial was then partially stoppered and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOTAP 66 mg/mL, eGFP mRNA 0. 1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00264] Formulation Method A with Cationic lipid DOTAP (132 mg/mL)
[00265] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next,
42.5 μL eGFP mRNA was added and the solution was gently swirled by hand to mix. 425 μL of 132 mg/mL DOTAP lipid vesicle particles (Size 116.5 nm, PDI 0.125) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix and filled to 0.85 mL by adding 170 μL of DEPC treated water. The final pH of the formulation was pH 6.37. The vial was then partially stoppered and freeze-dried. The freeze-dried cake was then reconstituted with 0.369 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOTAP 66 mg/mL, eGFP mRNA 0. 1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00266] Formulation Method A with Chitosan polymer (60-120 kDa/15-25% DD, 1 mg/mL)
[00267] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next,
42.5 μL eGFP mRNA was added and the solution was gently swirled by hand to mix. 212.5 μL of 132 mg/mL DOPC/Chol lipid vesicle particles (Size 81.02 nm, PDI 0.053, pH 6.77) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix. 42.5 μL of chitosan stock (60-120 kDa/ 15-25% DD, 10 mg/mL in 0.25% Acetic Acid) was added and the pH was adjusted from 5.91 to 6.15 with 10 μL 0.1 M NaOH. The solution was filled to 0.85 mL by adding 330 μL of DEPC treated water and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL, chitosan 1 mg/mL and sodium acetate 0. 1 M. A 50 μL of this formulation was injected SC in mice.
[00268] Formulation Method A with Chitosan polymer (60-120 kDa/ 15-25% DD, 2 mg/mL)
[00269] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next,
42.5 μL eGFP mRNA was added and the solution was gently swirled by hand to mix. 212.5 μL of 132 mg/mL DOPC/Chol lipid vesicle particles (Size 81.02 nm, PDI 0.053, pH 6.77) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was
gently swirled/shook by hand to mix. 85 μL of chitosan stock (60-120 kDa/ 15-25% DD, 10 mg/mL in 0.25% Acetic Acid) and adjusted the pH from 5.36 to 6.21 with 40 μL 0.1 M NaOH was added. The solution was filled to 0.85 mL by adding 257.5 μL of DEPC treated water and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL, chitosan 2 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00270] Formulation Method A with Chitosan polymer (100 kDa/ 25% DD, 1 mg/mL) [00271] 212.5 μL of 0.2 M sodium acetate, pH 7 was added to a sterile baked 2-mL vial. Next, 42.5 μL eGFP mRNA was added and the solution was gently swirled by hand to mix. 212.5 μL of 132 mg/mL DOPC/Chol lipid vesicle particles (Size 81.02 nm, PDI 0.053, pH 6.77) prepared in DEPC treated water was added to this eGFP mRNA solution. The solution was gently swirled/shook by hand to mix. 85 μL of chitosan stock (100 kDa/ 25% DD, 5 mg/mL in 0.25% Acetic Acid) was added and the pH was adjusted from 5.61 to 6.08 with 15 μL 0.1 M NaOH. The solution was filled to 0.85 mL by adding 282.5 μL of DEPC treated water and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL, chitosan 1 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected SC in mice.
[00272] Formulation Method B with Chitosan polymer (100 kDa/ 25% DD, 1 mg/mL)
[00273] 425 μL of 66 mg/mL DOPC/Chol solution prepared in DEPC treated water with 30% tert-butanol was added to a sterile baked 2-mL vial. Next, 42.5 μL eGFP mRNA was added. The solution was gently swirled by hand to mix. 85 μL of chitosan stock (100 kDa/ 25% DD, 5 mg/mL in 0.25% acetic acid) was added to this lipid-eGFP mRNA solution. The solution was gently swirled/shook by hand to mix and filled to 0.85 mL with 297.5 μL of 30% tert-butanol and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL and chitosan 1 mg/mL. A 50 μL of this formulation was injected SC in mice.
[00274] Formulation Method B with Chitosan polymer (100 kDa/ 25% DD, 2 mg/mL)
[00275] 425 μL of 66 mg/mL DOPC/Chol solution prepared in DEPC treated water with 30% tert-butanol was added to a sterile baked 2-mL vial. Next, 42.5 μL eGFP mRNA was added. The solution was gently swirled by hand to mix. 170 μL of chitosan stock (100 kDa/ 25% DD, 5 mg/mL in 0.25% Acetic Acid) was added to this lipid-eGFP mRNA solution. The solution was gently swirled/ shook by hand to mix and filled to 0.85 mL with 212.5 μL of 30% tert-
butanol and freeze-dried. The freeze-dried cake was then reconstituted with 0.397 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 66 mg/mL, eGFP mRNA 0.1 mg/mL and chitosan 2 mg/mL. A 50 μL of this formulation was injected SC in mice.
[00276] The expression of GFP in SOI cells was evaluated as described in Example 1. The results are shown in Figures 5 and 6. Consistent with previous observations, using DOTAP and addition of chitosan improved mRNA delivery to cells compared to the standard formulation, with the formulation having 100 pg chitosan polymer (100 kDa/ 25% DD) yielding the highest percentage of GFP+ cells.
Example 3. Immunogenicity of lipid-RNA formulation
[00277] To evaluate immunogenicity of the lipid-RNA formulation, C57BL/6 mice were separated into 6 treatment groups (N=5/group) and received the respective lipid_formulations listed in Table 1. On Day 0 of the study, Group 3 received the indicated lipid formulation via subcutaneous injection in the right flank. On Day 7, Groups 1, 2 and 4-6 received the respective lipid formulations via subcutaneous injection in the right flank. Mice were sacrificed on Day 15 followed by collection of cells from the SOI, spleen and right inguinal lymph nodes. The spleen and the lymph node samples were assessed for interferon-gamma (IFN-y) release using an enzyme-linked immune absorbent spot (ELISpot) assay. The SOI samples were analyzed for the immune cell composition present in the sample using flow cytometry.
[00278] The ELISpot assay was performed as previously described (Weir et al, Oncoimmunology. 2014 Nov 14;3(8):e953407). Briefly, syngeneic dendritic cells (DCs) were prepared by culturing bone marrow derived cells with GM-CSF for 8 days, on study day 14 DCs were loaded with OVA peptide SIINFEKL (SEQ ID NO: 6) or an irrelevant peptide, or remained unloaded and used as antigen presenting cells for the ELISpot assay. On study day 15, single cell suspensions of lymph nodes were prepared in complete RPMI media. Lymph node cells and DCs were added to ELISpot plates (BD Bioscience) and incubated overnight at 37°C, 5% CO2. Plates were developed the next day as per the manufacturer’s instructions using AEC substrate (Sigma-Aldrich). Spots were enumerated using an ImmunoSpot Analyzer (C.T.L. Ltd, Shaker Heights, OH) as the number of spot-forming units (SFU) per well.
[00279] An IFN-y ELISpot performed using splenocytes had the following modifications. Single cell suspensions of splenocytes were prepared by lysing RBCs with ammonium- chloride-potassium solution; cells were added into ELISpot plates and stimulated with OVA peptide SIINFEKL (SEQ ID NO: 6) or an irrelevant peptide, or remained unstimulated.
[00280] Tissues from the site of injection were collected and processed by crushing in PBS buffer, centrifuging and resuspending in PBS buffer. Cells were stained using basic surface IMF staining protocol and antibody panel in Table 4. Multi-parametric flow cytometry analysis was performed using FACS Celesta and FlowJo software.
Table 1. Treatment Groups
[00281] The composition of the formulations listed in Table 1 is detailed in Tables 2A and 2B. mRNA containing formulations were prepared using OVA mRNA stock according to specifications described in the previous example.
Table 2A. Lipid-mRNA Formulations
Table 2B. Lipid-peptide Control
[00282] Lipid-peptide control formulation listed in Table 2B was prepared by adding 80 μL of OVA peptide stock (5 mg/mL in sterile RNase free water) to 200 μL sodium acetate 200 mM, pH 7.0. To the diluted peptide stock solution, 400 μL lipid vesicle particles (132 mg/mL DOPC/Chol prepared in sterile RNase free water, particle size 89.27 nm and PDI 0.088) was added, mixed well by vortexing for 30 seconds. The pH was adjusted to 7.03 with 0.1 M NaOH before the addition of 16 μL poly dldC adjuvant stock (10 mg/mL in sterile RNase free water). The final formulation volume was then filled to 0.8 mL by adding 97 μL of RNase free water, mixed well by vortexing for 30 seconds. The vial was then partially stoppered and freeze-dried. The freeze-dried cake was then reconstituted with 0.35 mL of Montanide® ISA 51 oil diluent to obtain final concentrations of DOPC/Chol 132 mg/mL, OVA peptide 1 mg/mL, dldC adjuvant 0.4 mg/mL and sodium acetate 0.1 M. A 50 μL of this formulation was injected subcutaneously (SC) in mice.
[00283] Table 3 below lists the material used in the experiments above and their sources.
Table 3. Materials
*OVA mRNA has 1437 nucleotides and encodes the full-length ovalbumin.
Table 4. IMF panel to profile immune cells at the site of injection
[00284] The spleen and lymph node IFN-y ELISpot response are shown in Figures 7A and 7B, respectively. Single immunization with lipid formulations containing Ovalbumin mRNA and modified with chitosan polymer induced detectable immune responses in draining lymph nodes and spleens 8 days post administration. Consistently, results of the previous experiment (see Figure 6) indicate that this formulation delivers the highest number of mRNA molecules to the cells at the SOI.
[00285] Immune profile of SOIs is shown in Figures 8A and 8B. In general, lipid formulation modified with chitosan attracted similar types of immune cells as did the standard lipid-peptide formulation, suggesting a potentially similar mechanism of action (MOA). However, differently from lipid-peptide formulation, lipid formulation modified with chitosan surprisingly attracted higher number of B cells. Lipid formulation modified with DC-Chol and DOTAP attracted different types of immune cells compared to the standard lipid-peptide formulation, suggesting differences in MOA.
Example 4. In vitro and in vivo stability of lipid-nucleic acid formulations
[00286] In vitro stability testing of mRNA and DNA formulated in the lipid formulation was carried our as outlined in Figure 9. The lipid-RNA containing eGFP mRNA or lipid-DNA formulation containing pGFP plasmid DNA or lipid formulation without mRNA or DNA (negative control Empty) was prepared using Formulation Method A described in Examples 1 or 2 and reconstituted in Montanide® ISA 51 oil diluent. The oil reconstituted sample was then stored at 37°C for two weeks. On each study day D=0, 1, 3, 7, 10, 14, 25 μL aliquot of the stored oil reconstituted sample was removed from each group for the nucleic acid extraction and analysis. Briefly, nucleic acid extraction was carried out as follows: aliquoted sample (25 μL) was diluted with 0.1 M sodium bicarbonate (50 μL). To this diluted sample, water- saturated 1 -butanol (75 μL) was added, vortexed for 15 seconds and centrifuged for 2 minutes at 5,500 rpm. Using a gel-loading pipette tip, a portion of the bottom layer was collected for nucleic acid analysis. Nucleic acid quantity was measured by UV spectroscopy. mRNA and DNA integrity was assessed by gel electrophoresis assay. mRNA and DNA expression efficiency was evaluated in transient transfection experiments.
[00287] Nucleic acid quantity as measured by UV spectroscopy using NanoDrop OneC spectrophotometer is shown in Figure 10A for mRNA and in Figure 10B for DNA. The data
accompanying the figures are also shown in Tables 5 A and 5B. No substantial changes in nucleic acid quantity was observed over time.
Table 5A. mRNA quantity
Table 5B. DNA quantity
*Day 14 had a deviation in extraction procedure that affected the quantity of nucleic acids extracted.
[00288] To evaluate DNA integrity, 0.5 pg of pGFP DNA after butanol extraction was resolved on a 1% TBE agarose gel, visualized by staining with EtBr and photographed. Intact pGFP DNA was loaded on the same gel and used as a positive control.
[00289] To evaluate RNA integrity, 1 pg of eGFP mRNA after butanol extraction was resolved on 0.8% agarose denaturing gel, visualized by staining with ethidium bromide and photographed. Intact eGFP mRNA was loaded on the same gel and used as a positive control.
[00290] Gel electrophoresis analyses of mRNA and DNA integrity are shown in Figures 11A and 11B, respectively. No significant changes were observed in the mRNA integrity in any of the extracted samples as compared to the intact eGFP mRNA control. Some smears below the intact eGFP mRNA band were visible at day 10 and 14, suggesting some degree of degradation in these samples. Apparent changes in the pGFP DNA conformation were detected from DO
to D14; these may include gradual reduction of the supercoiled form (intact plasmid conformation) and gradual increase of the linear and nicked forms (degraded conformations). [00291] To further confirm nucleic acid integrity a functional test of gene expression was conducted through a transfection assay on the collected samples. To confirm that extracted eGFP mRNA is capable of producing functional protein 293T cells were transfected with 2.5 pg of extracted eGFP mRNA using Lipofectamine™ Messenger MAXTM Transfection Reagent (Invitrogen).
[00292] To confirm that extracted pGFP DNA is capable of producing functional protein 293T cells were transfected with 0.5 pg of extracted pGFP DNA using Lipofectamine™ 2000 Transfection Reagent (Invitrogen).
[00293] 48 hours after transfection cells were harvested and flow cytometry analysis was performed using FACS Celesta and FlowJo software to evaluate GFP expression.
[00294] Results from the transient transfection experiments are presented in Figure 12. The percentage of GFP+ positive cells remained consistent from DO to D 14 (99% ± 1% for eGFP mRNA and 44% ± 9% for pGFP plasmid) as measured using flow cytometry. The mean fluorescence intensities show a decreasing trend from DO to DI 4, suggesting that the total number of pGFP plasmids and eGFP mRNA molecules per cell was decreased over time.
[00295] In vivo stability testing of mRNA formulated in lipid-RNA formulation was carried out as outlined in Figure 13. On Day 0, mice were immunized SC with a mix of E7 and eGFP mRNA formulated in lipid formulation or with lipid formulation containing no RNA (negative control, Empty). Formulations were prepared using Formulation Method A described in Examples 1 or 2 and reconstituted in Montanide® ISA 51 oil diluent. On Days 7, 14 and 21, SOIs were collected and processed for mRNA extraction.
[00296] Total mRNA was purified using RNeasy Mini Kit (Qiagen) and used in RT-PCR to evaluate mRNA integrity and in transient transfections to determine the capacity of the extracted RNA to produce functional protein.
[00297] The complete sequence of the E7 transcript was amplified via RT-PCR. Briefly, extracted RNA was quantified using a Nanodrop and processed for reverse transcription of eluted RNA to cDNA. Template cDNA was then used in PCR to amplify E7 and GAPDH transcripts (positive control; data not shown) using primers listed in Table 6. E7 transcript was amplified using primers specific to the 5’ and 3’ ends of E7 mRNA. Amplifications were performed using the HotStarTaq DNA Polymerase kit (Qiagen) according to the manufacturer’s instructions.
Table 6. Primers for amplification of E7 and GAPDH transcripts
[00298] PCRs were performed in a thermocycler using the following conditions: initial denaturing (95°C) for 15 min, 40 cycles of denaturing (94°C) for 1 min, annealing (57°C) for 30 sec, and elongation (72°C) for 1 min. PCR products were resolved on a 1% agarose gel, visualized by staining with ethidium bromide and photographed.
[00299] The results are shown in Figure 14A. Complete sequence of the E7 transcript was amplified from total RNA extracted from SOIs at SD7 and 14.
[00300] To determine the capacity of eGFP mRNA after formulation and incubation in mice to produce functional protein 5 pg of total RNA extracted from SOIs was used to transfect 293T cells using Lipofectamine™ Messenger MAX™ Transfection Reagent (Invitrogen). 48 hours after transfection cells were harvested and flow cytometry analysis was performed using FACS Celesta and FlowJo software to evaluate GFP expression.
[00301] The results are shown in Figure 14B. The percentage of GFP+ cells was assessed in control group containing no mRNA and was 0.92%. The percentage of GFP+ cells in samples collected from SOIs of mice vaccinated with lipid-RNA formulation containing eGFP mRNA collected at D7 was 35.8%, at D14 was 17.3% and at D21 was 12.2%. This suggests that at least some eGFP mRNA molecules formulated in lipid formulation remain intact and capable to produce functional protein after 21 days inoculation in vivo.
[00302] Together results of integrity test by RT-PCR and functional analysis by transient transfection demonstrate that mRNA is stable in the lipid-RNA formulation for up to 14 days in vivo.
[00303] RNA instability is known to be one of the factors that hinder the application of RNA- based therapeutics. Exogenous RNA tends to be rapidly eliminated from the body due to degradation by RNase, exonuclease, or endonuclease, or via renal or hepatic clearance. The studies described in this Example showed that intact mRNA and plasmid DNA are present in the lipid formulations after 14-day incubation at 37° C in vitro, however the integrity of mRNA and DNA gradually decreases. mRNA is stable in vivo in the lipid formulation for up to 14 days as assessed by RT-PCR and transfection. As a result of these two studies, it can be
concluded that mRNA formulated in the lipid formulation described herein is stable for at least
14 days at 37° C in vitro and in vivo.
[00304] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
[00305] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims
Claims 1. A composition, comprising: a) one or more lipids, b) a negatively charged molecule, c) a carrier comprising a continuous phase of a hydrophobic substance, and d) an ionizable aminoglycoside. 2. The composition of claim 1, wherein the one or more lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof. The composition of claim 2, wherein the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin. 3. The composition of claim 3, wherein the phospholipid comprises dioleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), di oleoyl phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof. 45 The composition of claim 1, wherein the one or more lipids comprise DOPC and cholesterol. 6. The composition of claim 1 or 5, wherein the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, diethylaminoethyl (DEAE)- dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl- D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose-6,6-dibehenate (TDB) with Dimethyldioctadecylammonium (DDA), heptakis(6-deoxy-6-amino)-β-cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof. 7. The composition of claim 6, wherein the ionizable aminoglycoside is chitosan. 8. The composition of claim 6, wherein the ionizable aminoglycoside is chitosan and wherein the chitosan has a molecular weight of about 60 kDa to 150 kDa, about 100 kDa to 120 kDa, or about 100 kDa.
9. The composition of claim 6, wherein the ionizable aminoglycoside is chitosan and wherein the chitosan has a degree of deacetylation (DD) of about 15 - 95%, or about 25%. 10.The composition of claim 6, wherein the ionizable aminoglycoside is chitosan and wherein the chitosan is added in a concentration of about 0.5 mg/mL to about 3 mg/mL, or about 1 mg/mL to about 2 mg/mL. 11. The composition of claim 1, wherein the negatively charged molecule is a polynucleotide. 12. The composition of claim 1, wherein the negatively charged molecule is a ribonucleic acid (RNA), RNA derivative, deoxyribonucleic acid (DNA), or DNA derivative. 13. The composition of claim 12, wherein the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme. 14. The composition of claim 13, wherein the polynucleotide comprises an mRNA. 15. The composition of any one of claims 1-14, wherein the concentration ratio of the lipids and the negatively charged molecule is between about 33000: 1 to about 3300:1, between about 26400:1 to about 6600:1, or about 13200:1. 16. The composition of claim 1 , wherein the carrier comprises an oil or a water-in-oil emulsion. 17. The composition of claim 1, wherein a) the one or more lipids comprise DOPC and cholesterol, b) the negatively charged molecule is a polynucleotide, c) the carrier comprises an oil or a water-in-oil emulsion, and d) the ionizable aminoglycoside is chitosan.
18. The composition of claim 16 or 17, wherein the oil is a natural oil or a synthetic oil, optionally selected from a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, and combinations thereof. 19. The composition of claim 18, wherein the carrier is a mannide oleate in mineral oil solution. 20. The composition of claim 19, wherein the carrier is Montanide® ISA 51. 21. A method for delivering a negatively charged molecule to a target cell, comprising administering the composition of any one of claim 1-20 to said target cell. 22. The method of claim 21, wherein the target cell is an antigen-presenting cell (APC). 23. A method for delivering a negatively charged molecule to a subject, comprising administering the composition of any one of claims 1-20 to said subject. 24. A method for treating or preventing cancer, an infectious disease or an disease and/or disorder ameliorated by humoral and/or cellular immune response in a subject in need thereof, said method comprising administering to the subject an effective amount of the composition of any one of claims 1-20. 25. A method for preparing a composition of any one of claim 1-20. 26. A method for preparing a composition comprising one or more lipids, a negatively charged molecule, a carrier comprising a continuous phase of a hydrophobic substance, and an ionizable aminoglycoside, comprising: a) dissolving the one or more lipids in one or more organic solvents and optionally an aqueous solvent to create a lipid solution, b) adding the negatively charged molecule to the lipid solution formed in step a) and mixing; c) adding the ionizable aminoglycoside to the mixture formed in step b) and mixing; d) optionally, adding additional amount of the organic solvent(s) or aqueous solvent to the mixture formed in step c) thereby the overall Wt/Wt or V/V percentage ratio
of organic: aqueous solvent or aqueous: organic solvent in the mixture is between 20-50%; e) drying the mixture formed in step c) or d) to generate a dried preparation; and f) dissolving the dried preparation in the carrier comprising a continuous phase of a hydrophobic substance, thereby generating said composition. 27. The method of claim 26, wherein in step a) the one or more organic solvents is present in an amount sufficient to prevent the one or more lipids from forming lipid vesicle particles in the lipid solution. 28. The method of claim 26, wherein the one or more organic solvents comprises tert-butanol, ethanol, methanol, chloroform, or a mixture thereof. 29. The method of claim 26, wherein the aqueous solvent is water or a buffer solution. 30. The method of claim 26, wherein drying is performed by freeze-drying, spray freeze- drying, spray drying, or rotary evaporation. 31. The method of claim 26, wherein the one or more lipids comprise one or more of a phospholipid, cholesterol or a cholesterol derivative, or a combination thereof. 32. The method of claim 31, wherein the phospholipid is one or more of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine, phosphoinositol, phosphatidylcholine or lecithin. 33. The method of claim 32, wherein the phospholipid comprises di oleoyl phosphatidylcholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), dioleoyl phosphatidylethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-succinate (DGS), or a combination thereof. 34. The method of claim 26, wherein the one or more lipids comprise DOPC and cholesterol. 35. The method of claim 26 or 34, wherein the ionizable aminoglycoside is one or more of chitosan, cationic alginate, cationic gelatin, cationic dextran, diethylaminoethyl (DEAE)-
dextran hydrochloride, aminated cellulose, aminated sucrose, aminated trehalose, N-acetyl- D-glucosamine, D-(+)-glucosamine hydrochloride, trehalose-6,6-dibehenate (TDB) with Dimethyldioctadecylammonium bromide (DDA), heptakis(6-deoxy-6-amino)-P- cyclodextrin heptahydrochloride, and glycyrrhizic acid ammonium salt, or derivatives thereof. 36. The method of claim 35, wherein the ionizable aminoglycoside is chitosan. 37. The method of claim 35, wherein the ionizable aminoglycoside is chitosan and wherein the chitosan has a molecular weight of about 60 kDa to 150 kDa, about 100 kDa to 120 kDa, or 100 kDa. 38. The method of claim 35, wherein the ionizable aminoglycoside is chitosan and wherein the chitosan has a degree of deacetylation (DD) of about 15 - 95%, or about 25%. 39. The method of claim 35, wherein the ionizable aminoglycoside is chitosan and wherein the chitosan is added in a concentration of about 0.5 mg/mL to about 3 mg/mL, or about 1 mg/mL to about 2 mg/mL. 40. The method of claim 26, wherein the negatively charged molecule is a polynucleotide. 41. The method of claim 40, wherein the negatively charged molecule is a ribonucleic acid (RNA), or RNA derivative, deoxyribonucleic acid (DNA), or DNA derivative. 42. The method of claim 41, wherein the polynucleotide comprises or encodes a messenger RNA (mRNA), an antisense RNA, an interfering RNA, a catalytic RNA, or a ribozyme. 43. The method of claim 42, wherein the polynucleotide comprises an mRNA. 44. The method of any one of claims 26-43, wherein the concentration ratio of the lipids and the negatively charged molecule is between about 33000: 1 to about 3300: 1, between about 26400:1 to about 6600:1, or about 13200:1. 45. The method of claim 26, wherein the carrier comprises an oil or a water-in-oil emulsion.
46. The method of claim 26, wherein a) the one or more lipids comprise DOPC and cholesterol, b) the negatively charged molecule is a polynucleotide, c) the carrier comprises an oil or a water-in-oil emulsion, and d) the ionizable aminoglycoside is chitosan. 47. The method of claim 45 or 46, wherein the oil comprises a natural oil or a synthetic oil, optionally selected from a vegetable oil, mineral oil, a nut oil, soybean oil, peanut oil, and combinations thereof. 48. The method of claim 47, wherein the carrier comprises a mannide oleate in mineral oil solution. 49. The method of claim 48, wherein the carrier comprises Montanide® ISA 51. 50. A kit comprising a composition of any one of claims 1-20, and instructions for using said composition to deliver a negatively charged molecule to a subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063084179P | 2020-09-28 | 2020-09-28 | |
PCT/IB2021/000650 WO2022064274A1 (en) | 2020-09-28 | 2021-09-28 | Lipid compositions comprising polynucleotide antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4216934A1 true EP4216934A1 (en) | 2023-08-02 |
Family
ID=80845036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21871737.9A Pending EP4216934A1 (en) | 2020-09-28 | 2021-09-28 | Lipid compositions comprising polynucleotide antigens |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230355526A1 (en) |
EP (1) | EP4216934A1 (en) |
CA (1) | CA3197163A1 (en) |
WO (1) | WO2022064274A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2588705T3 (en) * | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Use of liposomes in a vehicle comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
WO2010043630A2 (en) * | 2008-10-13 | 2010-04-22 | Sigmoid Pharma Limited | A delivery system for rna |
US20200230057A1 (en) * | 2017-07-10 | 2020-07-23 | Immunovaccine Technologies Inc. | Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof |
-
2021
- 2021-09-28 EP EP21871737.9A patent/EP4216934A1/en active Pending
- 2021-09-28 CA CA3197163A patent/CA3197163A1/en active Pending
- 2021-09-28 US US18/028,617 patent/US20230355526A1/en active Pending
- 2021-09-28 WO PCT/IB2021/000650 patent/WO2022064274A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022064274A1 (en) | 2022-03-31 |
CA3197163A1 (en) | 2022-03-31 |
US20230355526A1 (en) | 2023-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11235069B2 (en) | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo | |
US20240016738A1 (en) | Lipid nanoparticles | |
EP3860656A1 (en) | Rna particles comprising polysarcosine | |
EP4126069A1 (en) | Rna particles comprising polysarcosine | |
US20230414747A1 (en) | Lnp compositions comprising rna and methods for preparing, storing and using the same | |
US20230355526A1 (en) | Lipid compositions comprising polynucleotide antigens | |
WO2022218503A1 (en) | Lnp compositions comprising rna and methods for preparing, storing and using the same | |
Aldosari et al. | Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics 2021, 13, 206 | |
AU2022256732A1 (en) | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same | |
WO2024064886A1 (en) | Using n-terminal degrons to enhance rna t cell vaccine immunogenicity | |
WO2024027910A1 (en) | Rna for preventing or treating tuberculosis | |
WO2023036960A1 (en) | Lipid-based rna formulations suitable for therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230419 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |